


The Research Modernisation Deal

A Strategy to Ending Animal Experiments



PHASELLUS NEC
IN HARC HABITA
TURST. SED EFFI
CULIS TINCIDUNT
ACCOMMODA. VELL
FENGIAT PHASET
PIBUS ERAS. SE
LECTUS. SED SE
ADIN FINIBUS PA
SQUE SEMPER I
TEMPUS ACTUS
PROIN PASUERE
UNUSQUE ORCI N
MTRA ULTRICIES
VELIT. MORBI SE
CORRECTETUR
MAURIS AC LIBE
RECT. NEQUE ET.

© iStock.com/ ClaudioVentrella

S NEC VESTIBULUM LEO. IN HARC HABITA TURST. SED EFFICITUR CUI IN EX IACULIS TINCIDUNT RE ANIS ANTE. PHARETRA. CRAS VEL DAPIBUS E. SED EGET GR. ORA LECTUS. SED SEMPER MAURIS NEC ODIO FINIBUS FACILIS. PELLENTI ETUS VOLUTPAT EGET. PROIN POS. ARE POSUERE COMMOD. VIVAMUS ORCI NULLA. MULPUTATE MTRA ULTRICIES QUIS. BIBEODU IPSUM CONSCTETUR PELLANTESQUE. MAURIS AC LIBERO SAGITTIS. LAOSET. DEUDE ET. DICTUM DIAM.



People for the Ethical Treatment of Animals (PETA) Nederland

People for the Ethical Treatment of Animals (PETA) Nederland is a charity dedicated to establishing and protecting the rights of all animals. Please visit www.peta.nl for more information.

Any mention of PETA Science Consortium International e.V. prior to December 2020 refers to the PETA International Science Consortium Ltd.

PETA encourages the sharing and downloading of the content within this document for personal and non-commercial use. If you wish to use any of the document materials (including text, images, photographs, etc.) for any other purpose, you must obtain our express written consent before doing so by contacting info@peta.nl.

© PETA Nederland

Version 1.31 • last updated 21 December 2021.

Samenvatting

De verbazingwekkende vooruitgang in de technologie zorgt nu al voor een revolutie op het gebied van biomedisch onderzoek en regelgeving, en in de komende jaren wordt nog meer vooruitgang verwacht.

De overgang van onderzoek dat gebaseerd is op het gebruik van dieren om menselijke ziekten te modelleren, of als instrument om menselijke reacties op geneesmiddelen of andere stoffen te voorspellen naar methoden die gebaseerd zijn op de menselijke biologie, verandert het beleid en de praktijk over de hele wereld. Financiers van onderzoek zijn zich er steeds meer van bewust dat falende methodes met dieren die worden gebruikt om zowel de werkzaamheid als het toxicologische risico vast te stellen de ontwikkeling van potentiële geneeswijzen in de weg staan. In het bestaande onderzoeksparadigma gebaseerd op dierproeven duurt het 10 tot 15 jaar om nieuwe geneesmiddelen op de markt te brengen, tegen kosten die kunnen oplopen tot meer dan 1,7 miljard euro, en meer dan 95% van de geneesmiddelen faalt wanneer ze in klinische proeven worden gebruikt. Deze faalpercentages kunnen niet economisch of ethisch worden verantwoord, en inspanningen om de onderzoeksomgeving te veranderen zijn dringend nodig.

Neem de volgende punten in overweging:

- Systematische reviews die zijn gepubliceerd in wetenschappelijke tijdschriften hebben beperkingen blootgelegd in het omzetten van resultaten van onderzoek met behulp van dieren naar behandelingen voor de mens voor tal van ziektegebieden. Minder dan 10% van de veelbelovende basiswetenschappelijke ontdekkingen leidt binnen 20 jaar tot een klinische toepassing.
- Tussen 50% en 89% van het preklinische onderzoek is niet reproduceerbaar, waarbij dierproeven een ernstig probleemgebied vormen.
- Grote wetenschappelijke doorbraken op ziektegebieden zoals diabetes en borstkanker zijn gebaseerd op onderzoek naar ziekten bij patiënten. Met behulp van dierproeven zouden ze niet mogelijk zijn geweest.

Naast het groeiende bewijs dat dierproeven zich niet goed laten vertalen naar behandelingen voor de mens – en de ontwikkeling en implementatie van technologie die het gebruik van dieren in laboratoria overbodig maken – is er in onze samenleving een groeiende morele bezorgdheid over het gebruik van dieren in experimenten ontstaan.

Overheids-, particuliere en liefdadigheidsinstellingen moeten bezuinigen op de budgetten voor dierproeven en de middelen overhevelen naar onderzoeksmethoden zonder dieren. Om een einde te maken aan het gebruik van dieren in experimenten bevelen wij de ontwikkeling van een strategie aan die de volgende noodzakelijke stappen omvat:

- 1. Stop onmiddellijk met het gebruik van dieren in onderzoeksgebieden waarin is aangetoond dat dieren slechte en onbetrouwbare voorspellers zijn voor de mens en vooruitgang hebben belemmerd.**
- 2. Voer kritische systematische reviews uit om overige gebieden te identificeren waarin het gebruik van dieren onmiddellijk kan worden beëindigd.**
- 3. Zorg voor transparante en robuuste prospectieve en retrospectieve evaluaties zoals voorgeschreven door Richtlijn 2010/63/EU betreffende de bescherming van dieren die voor wetenschappelijke doeleinden worden gebruikt.**
- 4. Werk samen met agentschappen en instanties over de hele wereld om de internationale acceptatie van testmethoden zonder dierproeven voor verplichte toxiciteitsproeven te harmoniseren en te bevorderen.**
- 5. Gebruik de huidige financiering voor dierproeven voor het ontwikkelen van methoden zonder het gebruik van dieren.**



Executive Summary

Astonishing advances in research technology are already revolutionising biomedical research and regulatory testing, and even more progress is expected in the coming years.

The transition away from research relying on the use of animals to model human disease or as tools to predict human responses to drugs or other substances and towards human biology-based methods is changing policy and practice around the globe. Research funders are becoming increasingly aware that failing animal methods used to establish both efficacy and toxicology risk are holding back the development of potential cures. In the existing animal research paradigm, novel drugs take 10 to 15 years to reach the market at a cost of over 1.7 billion euros, and over 95 per cent of them fail when they reach clinical trials. These failure rates cannot be supported economically or ethically, and efforts to transform the research environment are urgently needed.

Consider the following key points:

- Systematic reviews published in peer-reviewed journals document limitations in translating results from studies using animals to treatments for humans for numerous disease areas. Fewer than 10 per cent of highly promising basic science discoveries enter routine clinical use within 20 years.
- Between 50 and 89 per cent of preclinical research is not reproducible, with animal experimentation implicated as a serious problem area.
- Major scientific breakthroughs in disease areas such as diabetes and breast cancer have relied on studies of human disease in patients; they would not have been possible using animal research.

Along with growing evidence that experiments on animals do not faithfully translate to treatments for humans – as well as the development and implementation of technology that supplants animal use in laboratories – our society has also witnessed growing moral concern regarding the practice of using animals in experiments.

Public, private, and charitable funding bodies must cut budgets for experiments using animals and redirect funds to non-animal methods. In order to end the use of animals in experiments, we recommend the development of a strategy that includes the following critical steps:

1. Immediately eliminate animal use in areas for which animals have already been shown to be poor and unreliable predictors for humans and have impeded progress.
2. Conduct critical scientific reviews to identify the areas in which the use of animals has failed to advance human health and should therefore be phased out.
3. Implement transparent, robust prospective and retrospective evaluations, as required by Directive 2010/63 EU on the protection of animals used for scientific purposes.
4. Work with agencies and bodies globally to harmonise and promote international acceptance of non-animal testing methods for regulatory toxicity testing requirements.
5. Redirect funds from animal studies to the development of non-animal methods.



Table of Contents

I. Introduction	6
II. Limited Predictive Value of Research Using Animals	7
i. Lack of Validity	7
ii. Lost in Translation	8
III. The Need for a Paradigm Shift	9
IV. Opportunities for Economic Advancement	10
i. The High Cost of Drug Development	10
ii. Employment and Economic Growth in the Technology Sector	12
V. Regulatory Opportunities for Humane Toxicity Assessment	12
VI. Public Opinion and Animal Sentience	13
VII. World Leadership	14
VIII. Plan for Action: Recommendations to Modernise Scientific Research and Assessment	15
1. Immediately eliminate animal use in research areas in which animals have been demonstrated to be poor “models” of humans and their use has impeded scientific progress.	15
2. Conduct critical scientific reviews to identify the areas in which the use of animals can be ended immediately.	15
3. Implement transparent, robust prospective and retrospective evaluations, as required by Directive 2010/63/EU on the protection of animals used for scientific purposes.	15
4. Work to harmonise and promote international acceptance of non-animal testing methods for regulatory toxicity testing requirements.	16
5. Increase funds for non-animal studies and decrease funds for animal studies.	17
References	18
Appendices	21



I. Introduction

“When you read about advances in medicine, it often seems like long-awaited breakthroughs are just around the corner for cancer, Alzheimer’s, stroke, osteoarthritis, and countless less common diseases. But it turns out we live in a world with an awful lot of corners.”¹



The observation expressed above by best-selling science journalist Richard Harris echoes in the hearts and minds of every person suffering or who knows someone suffering from an incurable disease. The US National Institutes of Health (NIH), the world’s largest funder of biomedical research, reports that “failure rates [for novel drugs] occur in about 95 percent of human studies”,² even though these drugs showed success in preclinical experiments using animals.

In the EU, several initiatives exist to address the problem. At member-state level, both the Netherlands³ and the UK⁴ have government-backed strategies in place to reduce and replace the use of animals in experiments, and at EU level, the European Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) is working to replace the use of animals in both biomedical research and toxicological testing. Indeed, EURL ECVAM launched a study to review the use of alternative methods in biomedical research, noting, “Encouraging the uptake of alternative methods is important therefore to tackle such considerable reliance on animal studies for carrying out research,” adding that because “alternative methods offer the promise of recapitulating human physiology more effectively than many animal models, shifting to new animal-free methodologies and research strategies can in fact enhance the understanding of human-specific biology and disease”.⁵

Acceptance of non-animal techniques in one region or country is an open door to international harmonisation and the wider statutory elimination of animal experiments. Over the past two decades in particular, significant progress has been seen in the development, validation, implementation, and regulatory acceptance of non-animal technology for the assessment of human health endpoints such as skin irritation and corrosion, serious eye damage, skin sensitivity, skin absorption, and phototoxicity. We’ve also seen an end to notoriously cruel international test guidelines such as the Organisation for Economic Co-operation and Development (OECD) Test No 401, also known as the LD₅₀ test. Opportunities exist to increase and harmonise the use of validated non-animal test methods for regulatory assessment, and by taking them, we can achieve better protection of human health and the environment within the appropriate legal framework.

Directive 2010/63/EU on the protection of animals used for scientific purposes aims to secure the principles of replacement, reduction, and refinement of animal use (the 3Rs) within the legislative framework and ultimately recognises that the final goal is to replace all scientific procedures using animals for both basic biomedical research and regulatory requirements.⁶

In order to work towards this goal, we present in this report a roadmap for replacing the use of animals in experimentation. We identify a number of strategic priorities and append further information regarding areas of both regulatory (government-required) and non-regulatory research where there are opportunities for the immediate and near-future replacement of animal use. We have also included information outlining areas in which further development, validation, and implementation of non-animal methods are required.



II. Limited Predictive Value of Research Using Animals



A great deal of scholarly research shows that animal studies are flawed and divert both monetary and intellectual resources from methodologies better suited to curing human disease. There are many factors at play in the failure of animal experimentation to predict human outcomes reliably, including reporting and publication bias, poor study design, and inadequate sample size.⁷ Critically, intrinsic biological and genetic differences among species contribute significantly to inescapable problems in extrapolating results from non-human animals to humans, even in the best-controlled and best-executed study designs.

i. Lack of Validity

Problems with internal and external validity contribute to the failure of animal experiments in the translation of biomedical research from bench to bedside. The internal validity of animal experiments is undermined by poor study design, including the failure of animal experimenters to implement processes to prevent bias, such as blinding the individuals conducting the experiments or those analysing the data. Following a meta-analysis of systematic reviews of preclinical animal experiments across a wide variety of disease areas, University of Oxford scientists found that a lack of measures to reduce bias in animal experiments likely results in overestimation of the benefits of the treatment studied.⁸ The authors concluded, “Biased animal research is less likely to provide trustworthy results, is less likely to provide a rationale for research that will benefit humans, and wastes scarce resources.”⁹ They also advised, “Since human studies are often justified based on results from animal studies, our results

suggest that unduly biased animal studies should not be allowed to constitute part of the rationale for human trials.”¹⁰

A 2015 investigation concluded that between 50 and 89 per cent of all preclinical research, a large part of which involves animal testing, could not be reproduced

Poor internal validity means that many experiments on animals cannot be reproduced, a critical aspect of the scientific process that speaks to the potential validity of a finding. It can therefore be of little surprise that a 2015 investigation concluded that between 50 and 89 per cent of all preclinical research, a large part of which involves animal testing, could not be reproduced.¹¹

However, the weaknesses of animal experiments cannot be overcome by simply improving study design, because external

validity, or the “extent to which research findings derived in one setting, population or species can be reliably applied to other settings, populations and species”,¹² can never be achieved. Inherent species differences mean that non-human animals cannot serve as analogues for understanding the specific biological details necessary to develop safe and effective drugs for humans. As Wall and Shani write, even the “extrapolated results from studies using tens of millions of animals fail to accurately predict human responses”.¹³

Therefore, animal experiments lack internal and external validity. In other words, they are usually poorly executed, but even if the experimental methods were improved, the results would not translate to humans.

In a 2018 review in the *Journal of Translational Medicine*, Pandora Pound and Merel Ritskes-Hoitinga discuss species differences as an insurmountable



problem of external validity for preclinical animal models.¹⁴ Attempts to control for or correct species differences result in what the authors refer to as the “extrapolator’s circle”: “[I]f we want to determine whether a mechanism in animals is sufficiently similar to the mechanism in humans to justify extrapolation, we must know how the relevant mechanism in humans operates. But if we already know about the mechanism in humans then the initial animal study is likely to have been redundant.”¹⁵ They also discuss the concerning trend among those involved in animal experimentation to minimise the issue of species differences and the effects on external validity, a problem that is acknowledged by a number of researchers.^{16,17} Pound and Ritskes-Hoitinga go on to state that it is unsurprising that the issue of species differences is downplayed, as not doing so would force experimenters to confront the “possibility that the preclinical animal research paradigm no longer has a great deal to offer”. There is growing scientific consensus that far more is to be gained from human-relevant research methods and technology that are better suited to solving human biomedical and regulatory assessment paradigms than from reliance on animal studies. As a recent UK industry report emphasised, the time has come to humanise drug discovery and toxicology.¹⁸

ii. Lost in Translation

Given the problem of poor validity and reproducibility inherent in studies using animals, it comes as no surprise that their results often fail to translate into clinical relevance for human patients. As mentioned above, NIH reports that novel drugs fail “in about 95 percent of human studies”¹⁹ – even though they appeared safe and effective in preclinical experiments using animals.

To assess whether or not the promises of basic biomedical research were being fulfilled, Stanford Professor of Medicine, Health Research, and Policy John Ioannidis and his colleagues identified 101 articles published in

the most prestigious medical journals in which the authors explicitly stated that their research would lead to a new application with real potential for a clinical breakthrough. The majority of the articles analysed (63 per cent) were for animal experiments. Their investigation of the application of basic science to clinical applications found that fewer than 10 per cent of highly promising basic science discoveries enter routine clinical use within 20 years.²⁰

More recently, a stunning 2014 analysis published in *The BMJ* found that – contrary to public perception – studies using animals have not furthered knowledge in the field of human health or led to the development of treatments for conditions affecting humans.²¹ The authors note, “[I]f research conducted on animals continues to be unable to reasonably predict what can be expected in humans, the public’s continuing endorsement and funding of preclinical animal research seems misplaced.”²²

Fewer than 10 per cent of highly promising basic science discoveries enter routine clinical use within 20 years.

A mouse in a laboratory will not respond to a drug in the same way that a mouse in a field would. One then has to ask, how does this biologically distinct mouse reliably represent the biology of human beings?

The difficulties in applying data derived from animals to human patients are compounded by the confinement and unnatural conditions of laboratory life, which thwart animals’ ability to engage in natural behaviour.²³ This deprivation contributes to their stress and alters their physiology and neurobiology, causing them to exhibit various psychopathologies.^{24,25,26,27,28} Importantly, the fact that animals in laboratories have altered physiology and neurobiology means that they will not be good “models” for their counterparts in the wild. A mouse in a laboratory will not respond to a drug in the same way that a mouse in a field would. One then has to ask, how does this biologically distinct mouse reliably represent the biology of human beings?




Evidence Box 1: Lack of Clinical Success

The failure of basic and applied scientific studies involving animals is perhaps most evident in the stark litany of seemingly promising treatments that have simply not worked in humans. For example, stroke experiments on animals have been an outright failure. Researchers at the Institute for Stroke and Dementia Research in Munich have described the shortcomings:

More than 1000 neuroprotective compounds have been tested in rodent models with the aim to improve stroke outcome. ... Indeed, many agents reduced brain damage (in most cases measured as decreased infarct volume) in rodent models of experimental stroke. Out of these candidates approximately 50 neuroprotective agents were tested in more than 100 clinical stroke trials, but none has improved outcome in clinical stroke patients.²⁹

Oncology drugs, which also undergo animal testing, have a success rate of only 3.4 per cent.³⁰ This theme pervades many human disease areas. There is an abundance of literature documenting the failing of various animal models of neurodegenerative diseases – such as Alzheimer’s, for which the clinical failure rate for new drugs is 99.6 per cent.³¹

III. The Need for a Paradigm Shift



If our finite public funds are to be used responsibly, they must fund research, whether basic or applied, that leads to effective treatment for humans. But the evidence that basic and applied research involving animals is impeding the development of treatment and cures for human ailments has not prompted sufficient reconsideration of research and funding priorities by national and European authorities. Such a paradigm shift is crucial both within and beyond the EU.

Some within the scientific community have begun to advocate for change. In support of using an evidence-based approach to accelerating the delivery of useful drugs to the patients who need them, 15 Vanderbilt University researchers published a 2017 article calling for the elimination of experiments using animals where there is clear evidence that animal “models” are not useful or predictive of human disease:

“The literature is replete with examples of contradictions and discordance between animal and

human effects, including many cases in which promising animal results have failed to translate to clinically significant efficacy in humans. This is particularly true in some therapeutic areas such as neurodegenerative, psychiatric, and central nervous system diseases, as well as sepsis and inflammatory diseases.

These complexities inherent in translational research present an important opportunity for exploring novel approaches that successfully and efficiently yield outcomes as proximal as possible to eventual human benefit. Supported by several illustrative

examples encountered in our drug repurposing program, we propose herein an approach for assessing when it is appropriate to conduct the “last experiment first,” that is, progressing directly to human investigations when animal work would likely fail to provide data appropriate for translation into human applications of interest. This represents a significant – and we suggest, avoidable – barrier to drug introduction.”³²

The shifting consensus away from the use of animals in experimentation can be observed in a number of arenas,



including in publications documenting the limited predictive value of experiments on animals,³³ in the increased awareness of animal cognition and sentience,³⁴ and in the fast-eroding public support for animal studies.³⁵ For example, *The Turkish Journal of Gastroenterology* – the journal of the Turkish Society of Gastroenterology – officially banned the publication of studies involving experiments on animal from its pages. Journal editor Dr Hakan Şentürk wrote that the new policy represents

“growing concern about the lack of applicability of animal research to humans”.³⁶ He further commented, “When we recognize that the reliance on inherently flawed animal models of human disease are largely responsible for clinical failure ... it does not make sense to continue to promote this practice. ... Human-relevant approaches should be more aggressively developed and utilized instead.”

Significantly, a move away from animal-based research will allow

for substantial growth in the science and technology sectors and for faster return on investment in drug research and development.³⁷ An evolution of research funding priorities towards human-relevant methods will get treatments to the patients who need them more safely and likely in less time.³⁸ As public funding for research is limited, reliance on animals is impeding research that is more likely to lead to effective medications and cures.

IV. Opportunities for Economic Advancement



i. The High Cost of Drug Development

By mandating a move away from animal experimentation and towards advanced scientific methods, the EU has the opportunity to expand job growth rapidly in science and technology and reduce health-care costs for the population. As Meigs and colleagues report in their recent review, “Animal Testing and Its Alternatives – the Most Important Omics Is Economics”, “an economy of alternative approaches has developed that is outperforming traditional animal testing”.³⁹

Likewise, the UK funding body Innovate UK has identified non-animal technologies “as one of a series of emerging technologies with the potential to drive future UK economic growth” and, in doing so, proposed that British companies be able to take advantage of these “new commercial opportunities”.⁴⁰

Moving a new drug to market may cost up to US\$2 billion (approximately €1.7 billion, or £1.5 billion) and take as long as 15 years.⁴¹ One factor in the high cost of research and development is the substantial

risk associated with developing a product that fails to result in a marketable drug because it does not succeed in clinical trials.

Ninety-five per cent of drugs that test safe and effective in animals fail in humans⁴² because they are either not safe or not effective. Furthermore, it may be that drugs that could be effective in humans are rejected without clinical trials because they were ineffective in animals. Columbia University scientists Kacey Ronaldson-Bouchard and Gordana Vunjak-Novakovic, in advocating for the use of human

tissues *in vitro* during drug development, also make the following observation:

“Equally damaging is the cautious elimination of potentially curative new drugs because their adverse effects in animals do not necessarily translate into humans. These false-positive and false-negative readouts create an enormous financial burden, resulting in decision-making in which the potential profitability of a drug is leveraged against the potential risks, rather than on the drug’s



potential to improve disease outcomes.”⁴³

Compounding the problem of effectively and efficiently bringing new drugs to market is the lack of reproducibility of preclinical trials. A recent investigation by the UK House of Commons Science and Technology Committee into the scientific integrity of government-funded research highlighted the current “reproducibility crisis” and indicated the continued upward trend in misconduct and mistakes in publishing.⁴⁴ At the most conservative US estimate, the abundant failure to reproduce preclinical research results in approximate annual spending of \$28 billion on misleading experimentation.⁴⁵ Additionally, even in journals that support the “Animal Research: Reporting of In Vivo Experiments” (ARRIVE) guidelines⁴⁶ – which aimed to improve the reporting of research using animals – studies continue to demonstrate low reproducibility, poor value for money, and a waste of animals’ lives.⁴⁷

Through the use of human-relevant technology in place of expensive, time-consuming, and inaccurate animal experiments, the cost of drug discovery has the potential to decrease dramatically. Writing in the official journal of the American Society for Clinical Pharmacology & Therapeutics, Tal Burt and his co-authors made the following comments:

“Increasing costs of drug development and ethical

concerns about the risks of exposing humans and animals to novel chemical entities favor limited exposure clinical trials such as microdosing and other phase 0 trials. An increasing body of research supports the validity of extrapolation from the limited drug exposure of phase 0 approaches to the full, therapeutic exposure. An increasing number of applications and design options

demonstrate the versatility and flexibility these approaches offer to drug developers.”⁴⁸

To achieve the highest standards of rigour, reproducibility, and relevance in the study of human disease, it is critical that considerable financial support be made available for the implementation and further investigation of reliable, humane *in vitro* and *in silico* approaches.

Evidence Box 2: The Dangers of Misleading Results

Many novel drugs don’t simply fail, representing a huge loss in time and investment – they harm humans. In 2016, a Portuguese company developed a drug intended to help with mood, anxiety, and motor problems related to neurodegenerative disease. The drug was administered orally to volunteers as part of the Phase I clinical trial conducted by a French drug evaluation company. Six men, aged 28 to 49, experienced such adverse reactions that they had to be hospitalised. One participant was pronounced brain-dead and later died. A report on this incident reveals that “[n]o ill-effects were noted in the animals, despite doses 400 times stronger than those given to the human volunteers.”⁴⁹

In his 2010 article “TGN1412: From Discovery to Disaster”, Husain Attarwala of Northeastern University in the US recounts the tragic outcome of the 2006 clinical trial for Theralizumab, an immunomodulatory drug. He writes, “After [the] very first infusion of a dose 500 times smaller than that found safe in animal studies, all six human volunteers faced life-threatening conditions involving multiorgan failure for which they were moved to [the] intensive care unit.”⁵⁰ Five of the six participants had to remain hospitalised for three months after the initial dose, while the other was comatose. Even six months later, participants suffered from headaches and memory loss. One had to have toes and fingers amputated as a result of gangrene.⁵¹ Studying this and other trials, Attarwala concluded, “Drugs showing safety and efficacy in preclinical animal models may show very different pharmacological properties when administered to humans.”⁵²

The opposite is also true: therapies that have not worked well in animals have sat useless on the shelf while patients have gone without life-saving treatment. For example, penicillin was first tested in rabbits in 1929, but as it had no apparent effect in this species, it was ignored for more than a decade – costing countless human lives. The first human clinical trials weren’t conducted until the 1940s.⁵³ Researchers later remarked on the good fortune that it was not first tested in guinea pigs, for whom the antibiotic is lethal. Had experimenters seen this result, penicillin may have never been tried in humans.⁵⁴



ii. Employment and Economic Growth in the Technology Sector

The market for human-based *in vitro* technology for biomedical research and testing is growing rapidly. A leading market research company estimates that “[t]he global market for cell-based assays should grow from \$20.1 billion in 2018 to \$32.7 billion by 2023”,⁵⁵ the “global induced pluripotent stem cells (iPSC) market should reach \$3.8 billion by 2024”,⁵⁶ and the 3D cell culture market “should reach \$3.9 billion by 2021”.⁵⁷ The market researchers also projected that the global regenerative medicine market will reach a volume of \$89.5 billion by 2025.⁵⁸

In the US, the Boston-based start-up Emulate, Inc, recently raised an additional \$36 million in financing to expand its organ-on-a-chip technology, which is currently being used by AstraZeneca, Roche, Merck, Johnson & Johnson, and others to predict the safety and efficacy of drug candidates more accurately.⁵⁹

Evidence Box 3: Revisiting Failed Drugs

An April 2018 study published by Emulate and Janssen Pharmaceuticals demonstrated how a blood vessel-on-a-chip was able to predict a human thrombosis caused by an antibody therapy. This therapy had previously been determined to be safe following preclinical animal tests, but clinical trials had to be stopped after humans given the drug developed blood clots, which were not predicted by the animal experiments.⁶⁰

New technology such as that developed by Emulate will streamline drug development, making the process safer, cheaper, and more effective. Developing these techniques allows for the establishment of interdisciplinary research teams that will be fundamental in creating personalised disease models for precision medicine or developing effective and precise systems for toxicological risk assessment.



V. Regulatory Opportunities for Humane Toxicity Assessment

The past quarter-century has seen a revolution in the way in which chemicals are tested – non-animal tests are rapidly replacing animal tests. This is the result of our better understanding of biological processes and the emergence of new technology, which has allowed for the development of testing methods that can look directly at cellular mechanisms rather than at the crude, inscrutable results that come from using animals. It is also the result of public pressure and, as explained below, dissatisfaction among scientists with the results from animal tests. Cellular and genetic information about the potential toxicity of a chemical, such as the potential for receptor binding or gene or pathway activation, is obtained more readily with non-animal tests (using human cells *in vitro*) than with animal tests (*in vivo*).⁶¹

Concurrently, there is growing recognition among regulators and the regulated community that animal-based methods do not adequately protect either human health or the environment and that “the current approach is time-

consuming and costly, resulting in an overburdened system that leaves many chemicals untested, despite potential human exposure to them”.⁶²

In 2007, the US National Academies of Sciences, Engineering, and Medicine

published a landmark report titled “Toxicity Testing in the 21st Century: A Vision and a Strategy”. The report states that advances in toxicogenomics, bioinformatics, systems biology, epigenetics, and computational toxicology could transform



toxicity testing from a system based on whole-animal testing to one founded primarily on *in vitro* methods that evaluate changes in biologic processes using cells, cell lines, or cellular components, preferably of human origin. The proposed changes will generate better data on the potential risks humans face from environmental agents such as pesticides, building a stronger scientific foundation that can improve regulatory decisions to mitigate those risks and reducing the time, money, and number of animals needed for testing.

The report recommends an approach that would take advantage of rapidly evolving scientific understanding of the way genes, proteins, and small molecules interact to maintain normal cell function and how

some of these interactions can be perturbed in ways that could lead to health problems. Specifically, the new testing approach would focus on toxicity pathways – also known as adverse outcome pathways (AOPs). These are cellular pathways that, when sufficiently perturbed, are expected to lead to adverse health effects. The committee recommends the use of high-throughput assays – rapid, automated experiments that can test hundreds or thousands of chemicals over a wide range of concentrations – to evaluate chemicals’ effects on these toxicity pathways. On the basis of data from these and other experiments, researchers could develop models to describe responses in toxicity pathways as well as models to estimate the human exposure

necessary to produce responses in these pathways.⁶³

By eliminating the use of tests on animals for regulatory purposes where full replacements exist and by promoting the acceptance of methods currently in development, we have the opportunity to shift the regulatory testing paradigm further towards innovative non-animal techniques and thus become world leaders in the application of these methods. In the appendices to this report, we elaborate on opportunities to end the use of animals for regulatory testing immediately or within the next two to 10 years. These include acute systemic, genotoxicity, and pyrogenicity testing; vaccine and biologics testing; endocrine disruption; and carcinogenicity.

VI. Public Opinion and Animal Sentience

Public opposition to animal research is a major factor driving policy change. Indeed, the cosmetics testing and marketing bans were included in the EU Cosmetics Regulation following tremendous public and political support across Europe premised on the fundamental belief that the harm caused to animals used in testing cannot be outweighed by the potential benefits of new cosmetics products.⁶⁴ A 2009 YouGov survey conducted in six EU countries found overwhelming opposition to animal experiments – 84 per cent of respondents were in favour of prohibiting all experiments in which animals would be subjected to severe pain and suffering.⁶⁵ Public support for investment in non-animal methods is also high – 74 per cent of respondents to a UK survey backed increased efforts to develop alternatives to animal use.⁶⁶



Given the growing recognition of animal sentience, public opposition to animal experimentation is not surprising. In 2012, a prominent international group of neuroscientists issued *The Cambridge Declaration on*

Consciousness, which definitively stated that “humans are not unique in possessing the neurological substrates that generate consciousness” and that, like humans, “[n]on-human animals have the ... capacity to exhibit intentional behaviours”.⁶⁷

The declaration illustrates that recognition of animal sentience is growing within the scientific community, too. Statistics make clear that animals are not appropriate human surrogates in biomedical research, but when it comes to their ability to suffer,



Statistics make clear that animals are not appropriate human surrogates in biomedical research, but when it comes to their ability to suffer, how much like humans need they be before a critical review of animal-based research is considered mandatory?

how much like humans need they be before a critical review of animal-based research is considered mandatory?

Over 150 academics, intellectuals, and writers have also backed a report by the Oxford Centre for Animal Ethics that condemns experiments on animals as both morally and scientifically indefensible.⁶⁸ “The deliberate and routine abuse of innocent, sentient animals involving harm,

pain, suffering, stressful confinement, manipulation, trade, and death should be unthinkable. Yet animal experimentation is just that: the ‘normalisation of the unthinkable,’” write the report’s authors. They conclude that experimenting on animals contradicts what we now know about animals’ ability to experience not only pain but also shock, fear, foreboding, trauma, anxiety, stress, distress, anticipation, and terror.

VII. World Leadership

There is movement internationally that reflects the growing consensus in the scientific community that using animals in basic biomedical research or for regulatory assessment requirements is neither ethical nor efficacious. In many parts of the world, cruel and deadly cosmetics tests are now illegal or policies are in development to ban such practices. In addition, Israel and India have ended animal testing for household products and their ingredients and the UK Home Office has placed strict limitations on the use of animals for such tests.⁶⁹ The UK Health and Safety Executive has also significantly limited animal testing for plant-protection products.⁷⁰



“The deliberate and routine abuse of innocent, sentient animals involving harm, pain, suffering, stressful confinement, manipulation, trade, and death should be unthinkable. Yet animal experimentation is just that: the ‘normalisation of the unthinkable.’”

– Oxford Centre for Animal Ethics

In 2016, the Dutch government announced its plan to become the world leader in animal-free innovation by 2025. Soon after, the Netherlands National Committee for the Protection of Animals Used for Scientific Purposes (NCad) published an advice report on the country’s transition to animal-free innovation in which it concluded, among other things, that toxicity tests on animals for chemicals, food ingredients, pesticides, veterinary medicines, and

vaccines could be phased out by 2025.⁷¹

Subsequently, the government-led Transition Programme for Innovation without the use of animals (TPI) was established, aiming to bring together stakeholders and offer a platform for developing activities to speed up the transition towards animal-free innovation.⁷²

The US Environmental Protection Agency (EPA) announced in 2019

that it would provide additional funding for the development of non-animal methods and reduce tests on mammals by 30 per cent by 2025, with a view to eliminating these tests completely by 2035.⁷³

Such changes are necessary to improve the quality of biomedical research and regulatory assessment and for Europe to prove itself as a world leader in innovative and superior research and testing methods.



VIII. Plan for Action: Recommendations to Modernise Scientific Research and Assessment



1. Immediately eliminate animal use in research areas in which animals have been demonstrated to be poor “models” of humans and their use has impeded scientific progress.

Multiple reviews have documented the overwhelming failure of animal use to benefit human health in specific areas, including neurodegenerative diseases, neuropsychiatric disorders, cardiovascular disease and stroke, cancer, diabetes and obesity, inflammation and immune responses, HIV/AIDS research, addiction studies, trauma research, and medical training. As such, animal experiments in these research areas should be ended as soon as possible and replaced with more effective and efficient non-animal research methods. Please find appended further elaboration and recommendations on these areas.

2. Conduct critical scientific reviews to identify the areas in which the use of animals can be ended immediately.

For those areas of investigation where there is still some question as to whether the use of animals is beneficial, a thorough systematic review should be conducted to determine the efficacy of using animals. Systematic reviews, which critically analyse multiple research studies, are the first step in assessing the effectiveness of animal research. Some experts recommend that systematic reviews be conducted before animal studies can receive funding, for example, scientists from the SYstematic Review Centre for Laboratory animal Experimentation (SYRCLE) at Radboud University Medical Centre stated the following:

“Making systematic reviews of animal studies a routine is our scientific and societal responsibility, just as with clinical studies in humans. ... Funding agencies should stimulate and fund systematic reviews. ... Systematic reviews disclose inadequacies in methodology of individual studies. This helps improve future study design, and reduce failure rate of animal studies of new drugs. Specifically, funding agencies can mandate systematic reviews of animal experiments as part of a funding. This will make the choice of animal models more evidence-based and provide better protection for human patients.”⁷⁴

Furthermore, Article 58 of Directive 2010/63/EU mandates that the European Commission conduct periodic reviews concerning the use of animals in scientific procedures, thus providing a clear mechanism for advancing the replacement of animals in scientific procedures. To keep pace with scientific innovations, it is vital that this process be focused and timely, and in order to maximise the process’s potential, it is vital that member states and other stakeholders feed into it.

3. Implement transparent, robust prospective and retrospective evaluations, as required by Directive 2010/63/EU on the protection of animals used for scientific purposes.

Directive 2010/63/EU requires that applications to conduct research using animals be evaluated to ensure full use of available alternative techniques and test methods as well as consideration of whether the expected outcome of the research can justify the level of pain, distress, and suffering likely to be experienced by animals.⁷⁵ While these project evaluations are generally conducted through government bodies, they at least provide a means by which ethical evaluations can take place. However, a recent retrospective analysis by



Pandora Pound and Christine J Nicol concluded that “[t]he regulatory systems in place ... failed to safeguard animals from severe suffering or to ensure that only beneficial, scientifically rigorous research was conducted”.⁷⁶ They compared the harms experienced by animals in preclinical studies for six treatment interventions to the benefits the studies offered to humans, concluding that fewer than 7 per cent of studies should have been permitted and that all the studies were of poor quality.

Likewise, in order to improve the robustness of the regulatory system, the UK government’s Animals in Science Committee has recommended that the prospective harm-benefit analysis should be improved and that societal concerns about animal research should be explored and addressed. Furthermore, the committee recommended that methods to avoid those procedures predicted to cause severe pain, distress, and lasting harm should be explored – the ultimate goal being the elimination of these types of procedures in their entirety.

In addition to mandatory prospective project evaluations, Article 39 of Directive 2010/63/EU also requires retrospective reviews of procedures classified as “severe” and those involving non-human primates (other than procedures classified as “mild” or “non-recovery”) in order to assess severity retrospectively and to judge “whether the objectives of the project were achieved”.⁷⁷ The requirement, in place since 2013, has yet to be fully tested, but for retrospective project evaluation to be used as intended, it must be treated as more than a tick-box exercise. It is hoped that comparing the objectives of the experiment with those judged to have been achieved will prove useful in future decision-making, and as such, the retrospective evaluations must be publicly accessible and feed into the thematic reviews required under Article 58 of Directive 2010/63/EU.

Therefore, to increase scientific scrutiny of research proposals and to identify failing “animal models”, we recommend that member states develop and implement a robust schedule of prospective and retrospective evaluations in line with the requirements of Directive 2010/63/EU. To increase the transparency and accountability of the regulatory process further, project licence applications should be made available for a public commenting period, and associated retrospective evaluations should be published and linked to the original application. Such changes will help ensure the accuracy of the harm-benefit analysis process and its relevance to human clinical outcomes.

4. Work to harmonise and promote international acceptance of non-animal testing methods for regulatory toxicity testing requirements.

As described above, the regulatory acceptance of non-animal techniques in one region or country is an open door to international harmonisation and the wider statutory elimination of animal testing methods. Therefore, we advocate that national and international regulatory bodies and standards organisations liaise with industry, research agencies, and relevant NGOs worldwide to establish and promote clear paths to the validation and harmonisation of non-animal techniques for regulatory testing requirements.

To implement the vision of a more sophisticated approach to toxicity testing that will more adequately provide safety information on all chemicals in commerce, we further recommend that regulatory and government agencies enforce the current EU legal requirement that a scientifically satisfactory method or testing strategy not entailing the use of live animals be used instead of a procedure involving animals wherever possible.⁷⁸ In addition, we recommend that the establishment of a public-private centre for predictive animal-free toxicology be coordinated through the European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM). Such a centre would help transform the science of safety assessment, with new tools to guide industry, government, consumers, and international trade partners to adopt best practices.



5. Increase funds for non-animal studies and decrease funds for animal studies.

Poor predictivity of preclinical experiments on animals for toxicity and efficacy in humans has led to high attrition rates in the development of new therapies and is likely the cause of poor investment in the life sciences. As the EU focuses on making the transition from Horizon 2020 to Horizon Europe, member states should focus on driving future national economic growth by developing inventive, intelligent technology and encouraging outside investment in the life sciences. As described above, non-animal techniques are one of the emerging fields with growing economic potential, and investment in them could increase returns and, in turn, encourage new investors.

Not only does the national development of this field make financial and scientific sense, EU member states are also legally bound to act by Article 47 of Directive 2010/63/EU, which mandates contribution to the development and validation of non-animal methods, the encouragement of further research in this field, and the promotion and dissemination of information about non-animal approaches.

National and international institutes must now take the next step and end the funding of crude experiments that have failed to provide effective treatments and cures. With greater investment in exciting and innovative non-animal methods and bold policy initiatives, far more promising cures and treatments for humans can be developed. This will also alleviate the almost unimaginable suffering of millions of animals.



References

- ¹Harris R. Rigor Mortis: How Sloppy Science Creates Worthless Cures, Crushes Hope, and Wastes Billions. New York: Basic Books; 2017.
- ²National Center for Advancing Translational Sciences (NCATS). About NCATS. <https://ncats.nih.gov/about>. Updated 3 July 2018. Accessed 3 July 2018.
- ³Transition Programme for Innovation without the use of animals (TPI). <https://www.transitieproefdiervrijinnovatie.nl/english>. Accessed 15 December 2021.
- ⁴Home Office; Department for Business, Innovation & Skills; Department of Health. Working to reduce the use of animals in scientific research. Delivery report. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/417441/Delivery_Report_2015.pdf. Published March 2015. Accessed 15 November 2018.
- ⁵EURL ECVAM. Reviewing the use of alternative methods in biomedical research. <https://ec.europa.eu/jrc/en/science-update/alternative-methods-biomedical-research>. Published 18 April 2018. Accessed 15 November 2018.
- ⁶Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes, Recital 10. <https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32010L0063>. Published 22 September 2010. Accessed 31 May 2018.
- ⁷MacLeod MR, McLean AL, Kyriakopoulou A, *et al*. Risk of bias in reports of *in vivo* research: A focus for improvement. *PLoS Biol*. 2015;13(10):e1002273.
- ⁸Hirst JA, Howick J, Aronson JK, *et al*. The need for randomization in animal trials: An overview of systematic reviews. *PLoS One*. 2014;9(6):e98856.
- ⁹Ibid.
- ¹⁰Ibid.
- ¹¹Freedman LP, Cockburn IM, Simcoe TS. The economics of reproducibility in preclinical research. *PLoS Biol*. 2015;13(6):e1002165.
- ¹²Pound P, Ritskes-Hoitinga M. Is it possible to overcome issues of external validity in preclinical animal research? Why most animal models are bound to fail. *J Transl Med*. 2018;16(1):304.
- ¹³Wall RJ, Shani M. Are animal models as good as we think? *Theriogenology*. 2008;69(1);2-9.
- ¹⁴Pound, Ritskes-Hoitinga.
- ¹⁵Ibid.
- ¹⁶van der Worp HB, Howells DW, Sena ES, *et al*. Can animal models of disease reliably inform human studies? *PLoS Med*. 2010;7(3):e1000245.
- ¹⁷Bailoo JD, Reichlin TS, Würbel H. Refinement of experimental design and conduct in laboratory animal research. *ILAR J*. 2014;55(3):383-391.
- ¹⁸BioIndustry Association, Medicines Discovery Catapult. State of the discovery nation 2018 and the role of the Medicines Discovery Catapult. <https://md.catapult.org.uk/FlipBuilder/mobile/index.html>. Published January 2018. Accessed 12 November 2018.
- ¹⁹NCATS.
- ²⁰Contopoulos-Ioannidis DG, Ntzani E, Ioannidis JP. Translation of highly promising basic science research into clinical applications. *Am J Med*. 2003;114(6):477-484.
- ²¹Pound P, Bracken MB. Is animal research sufficiently evidence based to be a cornerstone of biomedical research? *BMJ*. 2014;348:g3387.
- ²²Ibid.
- ²³Lahvis GP. Unbridle biomedical research from the laboratory cage. *Elife*. 2017;6:e27438; Latham N, Mason G. From house mouse to mouse house: The behavioural biology of free-living *Mus musculus* and its implications in the laboratory. *Appl Anim Behav Sci*. 2004;86(3-4):261-289.
- ²⁴Garner JP. Stereotypies and other abnormal repetitive behaviors: Potential impact on validity, reliability, and replicability of scientific outcomes. *ILAR J*. 2005;46(2):106-117.
- ²⁵Bayne K, Würbel H. The impact of environmental enrichment on the outcome variability and scientific validity of laboratory animal studies. *Rev Sci Tech*. 2014;33(1):273-280.
- ²⁶Wolfer DP, Litvin O, Morf S, Nitsch RM, Lipp HP, Würbel H. Laboratory animal welfare: Cage enrichment and mouse behaviour. *Nature*. 2004;432(7019):821-822.
- ²⁷Gross AN, Richter SH, Engel AK, Würbel H. Cage-induced stereotypies, perseveration and the effects of environmental enrichment in laboratory mice. *Behav Brain Res*. 2012;234(1):61-68.
- ²⁸Balcombe JP. Laboratory environments and rodents' behavioural needs: A review. *Lab Anim*. 2006;40(3):217-235.
- ²⁹Roth S, Liesz A. Stroke research at the crossroads – where are we heading? *Swiss Med Wkly*. 2016;146:w14329.



- ³⁰Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. *Biostatistics*. 2018;kxx069.
- ³¹Cummings JL, Morstorf T, Zhong K. Alzheimer's disease drug-development pipeline: Few candidates, frequent failures. *Alzheimer's Res. Ther.* 2014;6(4):1-7.
- ³²Pulley JM, Jerome RN, Zaleski NM, *et al.* When enough is enough: Decision criteria for moving a known drug into clinical testing for a new indication in the absence of preclinical efficacy data. *Assay Drug Dev Technol.* 2017;15(8):354-361.
- ³³Pound, Bracken.
- ³⁴Low P. *The Cambridge Declaration on Consciousness*. <http://fcmconference.org/img/CambridgeDeclarationOnConsciousness.pdf>. Published 7 July 2012. Accessed 16 July 2018.
- ³⁵Ipsos MORI. Attitudes to animal research in 2016. <https://www.ipsos.com/ipsos-mori/en-uk/attitudes-animal-research-2016>. Published 15 September 2016. Accessed 31 May 2018.
- ³⁶Şentürk H. Moving beyond animal models. *Turk J Gastroenterol.* 2015;26:A-IX.
- ³⁷Meigs L, Smirnova L, Rovida C, Leist M, Hartung T. Animal testing and its alternatives – the most important omics is economics. *ALTEX*. 2018;35(3):275-305.
- ³⁸Kramer LA, Greek R. Human stakeholders and the use of animals in drug development. *Business and Society Review*. 2018;123(1):3-58; Piesing M. How tech could spell the end of animals in drugs testing. *The Guardian*. <https://www.theguardian.com/science/2014/aug/23/tech-end-animals-drugs-testing>. Published 23 August 2014. Accessed 2 August 2018.
- ³⁹Meigs *et al.*
- ⁴⁰Innovate UK. New kids on the emerging block. <https://innovateuk.blog.gov.uk/2016/03/23/new-kids-on-the-emerging-block/>. Published 23 March 2016.
- ⁴¹NCATS.
- ⁴²*Ibid.*
- ⁴³Ronaldson-Bouchard K, Vunjak-Novakovic G. Organs-on-a-chip: A fast track for engineered human tissues in drug development. *Cell Stem Cell*. 2018;22(3):310-324.
- ⁴⁴House of Commons Science and Technology Committee. Research integrity: Sixth report of session 2017–19. <https://publications.parliament.uk/pa/cm201719/cmselect/cmsctech/350/350.pdf>. Published 26 June 2018. Accessed 13 March 2019.
- ⁴⁵Freedman *et al.*
- ⁴⁶Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. *PLoS Biol.* 2010;8(6):e1000412.
- ⁴⁷Leung V, Rousseau-Blass F, Beauchamp G, Pang DSJ. ARRIVE has not ARRIVED: Support for the ARRIVE (Animal Research: Reporting of in vivo Experiments) guidelines does not improve the reporting quality of papers in animal welfare, analgesia or anesthesia. *PLoS One*. 2018;13(5):e0197882.
- ⁴⁸Burt T, Yoshida K, Lappin G, *et al.* Microdosing and other phase 0 clinical trials: Facilitating translation in drug development. *Clin Transl Sci*. 2016;9(2):74-88.
- ⁴⁹AFP in Paris. Man who died in French drug trial had “unprecedented” reaction, say experts. *The Guardian*. <https://www.theguardian.com/science/2016/mar/07/french-drug-trial-man-dead-expert-report-unprecedented-reaction>. Published 7 March 2016. Accessed 20 September 2018.
- ⁵⁰Attarwala H. TGN1412: From discovery to disaster. *J Young Pharm.* 2010;2(3):332-336.
- ⁵¹Ferguson PR. The TGN1412 drug disaster. *American Bar Association*. 2009;5(4):12-13.
- ⁵²Attarwala.
- ⁵³Fleming A. On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of *B. influenzae*. *Br J Exp Pathol*. 1929;10(3):226-236; Greek R, Hansen LA. The strengths and limits of animal models as illustrated by the discovery and development of antibacterials. *Biol Syst*. 2013;2(2):109.
- ⁵⁴Florey H. The advance of chemotherapy by animal experiment. *Conquest*. 1953;41:12; Koppanyi T, Avery MA. Species differences and the clinical trial of new drugs: A review. *Clin Pharmacol Ther.* 1966;7:250-270.
- ⁵⁵BCC Research. Cell-based Assays: Technologies and Global Markets. <https://www.bccresearch.com/marketresearch/biotechnology/cell-basedassays-technologies-markets-report.html>. Published December 2018. Accessed 24 April 2020.
- ⁵⁶BCC Research. Induced Pluripotent Stem Cells: Global Markets. <https://www.bccresearch.com/market-research/biotechnology/induced-pluripotent-stem-cells-report.html>. Published February 2020. Accessed 24 April 2020.
- ⁵⁷BCC Research. 3D Cell Cultures: Technologies and Global Markets. <https://www.bccresearch.com/market-research/biotechnology/3d-cell-culture-technologies-markets-report.html>. Published May 2017. Accessed 24 April 2020.



⁵⁸BCC Research. Global Regenerative Medicine Market.

<https://www.bccresearch.com/partners/verified-market-research/global-regenerative-medicine-market.html>. Published December 2018. Accessed 24 April 2020.

⁵⁹Emulate adds \$36M to expand “organ chip” drug research technology. *Xconomy*. <https://xconomy.com/boston/2018/06/19/emulate-adds-36m-to-expand-organ-chip-drug-research-technology>. Published 19 June 2018. Accessed 5 July 2018.

⁶⁰Barrile R, van der Meer AD, Park H, et al. Organ-on-chip recapitulates thrombosis induced by an anti-CD154 monoclonal antibody: Translation potential of advanced microengineered systems. *Clin Pharmacol Ther*. 2018;104(6):1240-1248.

⁶¹Hartung T, FitzGerald RE, Jennings P, et al. Systems toxicology: Real world applications and opportunities. *Chem Res Toxicol*. 2017;30(4):870-882.

⁶²Frueh S, Morocco S. Report calls for new directions, innovative approaches in testing chemicals for toxicity to humans. National Academies of Sciences, Engineering, and Medicine.

⁶³National Research Council. Toxicity testing in the 21st century: A vision and a strategy. Washington: National Academies of Sciences, Engineering, and Medicine; 2007.

⁶⁴European Commission. Commission staff working document: Impact assessment on the animal testing provisions in Regulation (EC) 1223/2009 on cosmetics. COM(2013) 135 final. <http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52013SC0066&from=EN>. Published 11 March 2013. Accessed 13 March 2013.

⁶⁵Statista. Einstellung der Bevölkerung ausgewählter europäischer Länder zu Tierversuchen. <https://de.statista.com/statistik/daten/studie/252053/umfrage/investitionen-von-kosmetikherstellern-fuer-tierversuchsfreie-forschung/>. Accessed 15 November 2018.

⁶⁶Ipsos MORI.

⁶⁷Low.

⁶⁸Linzey A, Linzey C. Normalising the unthinkable: The ethics of using animals in research. Executive summary. Oxford: Working Group of the Oxford Centre for Animal Ethics; 2015. <https://www.crueltyfreeinternational.org/sites/default/files/Oxford%20summary%20final.pdf>. Accessed 13 March 2019.

⁶⁹Home Office. Ban will end testing of household products on animals. <https://www.gov.uk/government/news/ban-will-end-testing-of-household-products-on-animals>. Published 12 March 2015. Accessed 15 November 2018.

⁷⁰Health and Safety Executive. Vertebrate testing. <http://www.hse.gov.uk/pesticides/topics/pesticide-approvals/pesticides-registration/applicant-guide/vertebrate-testing.htm>. Accessed 22 July 2018.

⁷¹NCad. Transition to non-animal research: On opportunities for the phasing out of animal procedures and the stimulation of innovation without laboratory animals. <https://www.ncadierproevenbeleid.nl/documenten/rapport/2016/12/15/ncad-opinion-transition-to-non-animal-research>. Published December 2016. Accessed 15 November 2018.

⁷²TPI.

⁷³News Releases from Headquarters. Chemical Safety and Pollution Prevention (OCSPP). Administrator Wheeler Signs Memo to Reduce Animal Testing, Awards \$4.25 Million to Advance Research on Alternative Methods to Animal Testing. *US Environmental Protection Agency*. <https://www.epa.gov/newsreleases/administrator-wheeler-signs-memo-reduce-animal-testing-awards-425-million-advance>. Published 9 October 2019. Accessed 24 January 2020.

⁷⁴Hooijmans CR, Ritskes-Hoitinga M. Progress in using systematic reviews of animal studies to improve translational research. *PLoS Med*. 2013;10(7):e1001482.

⁷⁵Directive 2010/63/EU, Article 38.

⁷⁶Pound P, Nicol CJ. Retrospective harm benefit analysis of pre-clinical animal research for six treatment interventions. *PLoS One*. 2018;13(3):e0193758.

⁷⁷Directive 2010/63/EU, Article 39.

⁷⁸Directive 2010/63/EU, Article 4.



Appendices

Please find below further detail on opportunities to replace animals in the following areas of biomedical research and training, forensic sciences, toxicity assessment, and laboratory production methods. Also included is information regarding the expertise of the scientists who work for PETA entities.

Table of Contents

Glossary	22	Toxicity Assessment	44
Basic and Applied Biomedical Research	23	Exposure-Based Assessment	44
Cancer	23	Skin Irritation/Corrosion	44
Cardiovascular Disease	24	Eye Irritation/Corrosion	45
Diabetes	25	Skin Sensitisation	46
HIV/AIDS	27	Pyrogenicity	47
Inflammation and Immunology	28	Tobacco and E-Cigarette Testing	48
Nerve Regeneration	29	Genotoxicity	49
Neurodegenerative Diseases	31	Acute Systemic Toxicity	50
Neuropsychiatric Disorders	33	Acute Oral Toxicity	50
Sepsis	34	Acute Dermal Toxicity	50
Stroke	36	Acute Inhalation Toxicity	51
Substance Abuse	38	Carcinogenicity	51
Trauma	39	Endocrine Disruption	52
Training and Forensic Enquiries	41	Repeat Dose, Reproductive, and Developmental Toxicity	53
Forensic Sciences	41	Aquatic Toxicity Testing	53
Medical Training	42	Laboratory Production Methods	55
Microsurgery Training	42	Biologic Drugs	55
Trauma Training	42	Antibody Production	56
		Foetal Bovine Serum	57
		Scientific Advisory Capabilities of PETA Entities	59
		References (Appendices)	60



Glossary

3Rs	replacement, reduction, and refinement (of animal use)	ISO	International Organization for Standardization
AD	Alzheimer's disease	JaCVAM	Japanese Center for the Validation of Alternative Methods
ADHD	attention deficit hyperactivity disorder	LAL	Limulus amoebocyte lysate test
AIDS	acquired immune deficiency syndrome	MAT	monocyte activation test
AOP	adverse outcome pathway	MND	motor neurone disease
ATLS	Advanced Trauma Life Support	NICEATM	NTP Interagency Center for the Evaluation of Alternative Toxicological Methods
BCOP	bovine corneal opacity and permeability	NIH	National Institutes of Health
CTA	cell transformation assay	NOS	nitric oxide synthase
DPRA	direct peptide reactivity assay	NRU	neutral red uptake
ECHA	European Chemicals Agency	NTP	National Toxicology Program
EDQM	European Directorate for the Quality of Medicines & HealthCare	OECD	Organisation for Economic Co-operation and Development
EDSP	Endocrine Disruptor Screening Program	PD	Parkinson's disease
EMA	European Medicines Agency	PDAC	pancreatic ductal adenocarcinoma
EPA	Environmental Protection Agency	Ph Eur	European Pharmacopoeia
EURL	European Union Reference Laboratory	REACH	Registration, Evaluation, Authorisation and Restriction of Chemicals
ECVAM	for Alternatives to Animal Testing	RhCE	reconstructed human cornea-like epithelium
FBS	foetal bovine serum	RHE	reconstructed human epidermis
GEMM	genetically engineered mouse model	RPT	rabbit pyrogen test
GHS	Globally Harmonized System of Classification and Labelling	SA	structural alert
h-CLAT	human cell line activation test	SCCS	Scientific Committee on Consumer Safety
HD	Huntington's disease	SCI	spinal cord injury
HIV	human immunodeficiency virus	SCHEER	European Commission Scientific Committee on Health, Environmental and Emerging Risks
hPL	human platelet lysate	SIV	simian immunodeficiency virus
IATA	integrated approach to testing and assessment	STAIR	Stroke Therapy Academic Industry Roundtable
ICCVAM	Interagency Coordinating Committee on the Validation of Alternative Methods	STE	short time exposure
IET	Institution of Engineering and Technology	T2DM	type 2 diabetes mellitus
IFV	influenza	TER	transcutaneous electrical resistance
		TZD	thiazolidinedione
		WoE	weight of evidence



Basic and Applied Biomedical Research

Detailed below are opportunities to end the non-regulatory use of animals immediately in a number of specific areas of biomedical research.

Cancer

Recommendation: End the use of animals immediately

Oncology drugs have the lowest “likelihood of approval” among all disease categories. A survey of 4,451 drugs made by 835 companies between 2003 and 2011 found that only 6.7 per cent of cancer drugs were approved after entering the first phase of clinical trials, even though they were all successful in preclinical testing. A 2018 analysis of data collected between 2000 and 2015 shows that the success rate for oncology drugs dropped to 3.4 per cent,¹ suggesting that the problem is getting worse. The authors admit that the “current animal models (e.g., xenograft tumour models in mice) can be poor predictors of clinical outcomes in humans”.² Even though study design and other logistical issues can be problematic, cancer physicians at McMaster University in Ontario state the following:

[M]ost futilities in fact originate from molecular mechanisms of the drug(s) tested...
Crucial genetic, molecular, immunologic and cellular differences between humans and mice prevent animal models from serving as effective means to seek for a cancer cure.³

Following an analysis of 1,110 mouse xenograft tumour models, which involve the transplantation of human tumour cells into mice, scientists and physicians from Harvard University, Massachusetts Institute of Technology, the Dana-Farber Cancer Institute, and other respected institutions reached a conclusion that challenged the ability of xenograft models to predict patients’ response to therapy. They found that transplanting human cancer cells into these mice altered the genetic composition of those cells in ways that would be unlikely to happen in humans. That, in turn, altered the responses that the cells had to chemotherapy drugs,⁴ invalidating one of the foundational animal models for human cancer research.

There are numerous examples of the ways in which rodent models have misled cancer researchers. For brevity, we will present three cases. Scientists now know that endogenous bile acids, if dysregulated, can induce DNA damage and several forms of cancer, such as colon cancer, in humans. However, previous experiments on rats show that bile acids are not carcinogenic on their own. The profiles of bile acids, metabolism of bile acids (by the liver and gut microbiome), and colon epithelial cell accumulated turnover rate (adjusted by age) are all different between rodents and humans, contributing to the discrepancy.⁵

Another example of the disconnect between human cancer and rodent cancer research is the formerly proposed link between soya and breast cancer. It is now recognised that isoflavones in soya may be protective against several types of cancer, such as breast and prostate cancers,⁶ particularly if people are exposed to it early in life.⁷ However, it was observed that genistein, a major isoflavone in soya, induces oestrogen-sensitive tumours in some animals used in studies, including rodents. The inconsistency was later explained to be due to differences in phase II metabolism of genistein in rodents, whose level of unconjugated, and hence active, genistein is about 20 to 150 times higher than that of humans (depending on the strain). Additionally, rodent models had low endogenous oestrogen levels and different metabolic profiles compared to humans, and high experimental levels of isoflavones were used in those initial studies.⁸



Rodents are not suitable for radiation-induced carcinogenesis research, including for thyroid cancer. The nuclear architecture and spatial positioning of genes involved in radiation-induced injury are drastically different between rodent and human thyroid cells.⁹ Similarly, rodents are not suitable for research into pancreatic ductal adenocarcinoma (PDAC). As some scientists have pointed out, “Although it may seem obvious that there are important differences between men and mice, this is often overlooked by those modelling human disease. ... The potential for species differences to be relevant is greatest in models that use nonhuman PDACs, such as genetically engineered mouse models (GEMMs) and syngeneic xenografts.”¹⁰

Given the many shortcomings described above as well as the astonishingly low translational success rate of cancer research, despite the popularity of using rodents in such research, it is clear that they are not good models for any type of human cancer experimentation. Therefore, it is wise to move away from rodent models and focus on human-relevant methods.

The prestigious Institution of Engineering and Technology (IET) global Harvey Engineering Research Prize was recently awarded to Portuguese scientist Rui L Reis for his work using tissue engineering to create reliable 3-dimensional (3-D) engineered functional cancer disease models. According to IET, his innovative research will “help to predict the efficacy of novel cancer drugs and potential therapies, avoiding a range of unnecessary animal tests, and preclinical and clinical trials of doomed to fail new drugs”.¹¹

Other recent, human-relevant cancer research includes the development of a human blood vessel-on-a-chip to aid in the advancement of new cancer therapies that may inhibit new blood vessel formation to slow tumour growth,¹² the study of patient-derived human brain organoids to develop personalised therapies for deadly glioblastomas,¹³ the use of a tumour microenvironment-on-a-chip to create precision medicine tailored to individual patients and specific cancer types,¹⁴ and the application of 3-D printing to producing precise replicas of tumours using patients’ own cells in the bioink.¹⁵ In addition, by sequencing DNA and RNA in human skin cells, researchers at the University of California–San Francisco have analysed which signalling pathways are disrupted in the evolution of melanoma.¹⁶

Former National Cancer Institute Director Dr Richard Klausner stated the following:

The history of cancer research has been a history of curing cancer in the mouse. We have cured mice of cancer for decades – and it simply didn’t work in humans.¹⁷

Cancer is a highly variable, individualised disease that will require individualised treatment to overcome.¹⁸ Scientists using non-animal methods for cancer research are faced with a smaller translational hurdle, since they are able to use patients’ own cancer cells and because all human-relevant methods are grounded in human – instead of rodent – biology.

Cardiovascular Disease

Recommendation: End the use of animals immediately

Cardiotoxicity is a primary reason that drugs fail in clinical trials. Experts point out the “lack of concordance between the effects of compounds in animals (or animal-derived tissues) and those in humans”,¹⁹ that “substantial differences in drug responsiveness between species can limit the effectiveness of predicting clinical outcome from animal toxicity testing”,²⁰ and the many known species-related differences in cardiac contractile function and calcium handling.²¹ In a co-authored review, scientists from Stanford University, the US Food and Drug Administration, and the biopharmaceutical company AbbVie refer to testing cardiotoxicity in animal models as a “black box” approach.²²



The properties of calcium-handling proteins and their composition differ in the hearts of rats, mice, rabbits, dogs, and humans, and rodents and humans do not have the same profiles or functions of contractile proteins.²³ This makes the profile of ventricular repolarisation and susceptibility of arrhythmia different, leading to varied drug responses. A meta-analysis evaluating 11 measured functional parameters of the heart, comparing rodents with humans, concluded that only one (systolic pressure) was within an acceptable range for comparison between the two species.²⁴ Rodents are also resistant to atherosclerosis, a major cause of many cardiovascular diseases, owing to their lack of cholesteryl ester transfer protein.²⁵

For heart failure research, “insights gleaned from animal-based research efforts have shown poor translation in terms of deciphering human heart failure and developing effective therapies”, and “lack of concordance between animal models and human disease state has been acknowledged as a major contributing factor [to this translational failure]”.²⁶ It is clear that human-relevant *in vitro* and *in silico* methods are much more suitable for cardiotoxicity testing and cardiovascular research in general.

The global stem cell biotechnology company Novoheart is using a platform called MyHeart™ composed of engineered human cardiac tissues, which has been able to “detect the devastating arrhythmogenic hazards of certain ‘anti-arrhythmic’ drugs that had previously caused fatalities in human patients despite passing through the flawed process of animal testing for FDA approval”.²⁷ Scientists in Singapore and New York are using organ-on-a-chip models of blood vessels and beating heart tissue, respectively, to model human atherosclerosis and test human reactions to various drug compounds.^{28,29} Worcester Polytechnic Institute’s Marsha Rolle, a tissue engineer, has created functional blood vessels from human cells to “replicate what happens when [human blood vessels are] diseased”.³⁰ In a news release, she noted that the 10-year average for developing new medications is “exacerbated by the fact that animal testing, which is the way most new drugs are tested, is not always an accurate indicator of how human blood vessels will respond to the same drugs”.³¹

Other recent advancements in human tissue engineering for cardiovascular research include the ability of scientists to control the electrical pace of lab-grown heart cells using light,³² the use of plant-derived cellulose framework as scaffolding to build networks of human veins,³³ and the development of an *in vitro* 3-D model of human early heart development that “could serve as an embryotoxicity screening assay in drug discovery, regulation, and prescription for healthy fetal development”.³⁴ This 3-D “organogenesis-in-a-dish” model could provide a way to determine drug safety in pregnant women.

Computer modelling is also rapidly advancing human cardiovascular research. Recently, Clemson University Assistant Professor Ethan Kung was given a prestigious National Science Foundation grant for his work “aimed at reducing human and animal testing and addressing concerns that the skyrocketing cost of developing new devices and surgeries is unsustainable”. His research merges numerical computer models with experimental data to create modern cardiovascular biochemical models.³⁵ University of Oxford researchers have demonstrated that *in silico* methods are more accurate than animal models at predicting the cardiotoxicity of certain drugs.³⁶

Diabetes

Recommendation: End the use of animals immediately

From 1984 to 2014, more than 50 papers were published per month describing experiments on rodent models of type 2 diabetes mellitus (T2DM).³⁷ Considering these numbers, we now know a great deal about diabetes, or metabolic disturbances that look like diabetes, in rodents, but “many details of human T2DM pathogenesis remain unclear, and means of preventing disease progression remain elusive”.³⁸ Rodent studies were used to identify thiazolidinedione (TZD) drugs as possible therapeutics for humans with T2DM or insulin dysfunction.



Unfortunately, the studies did not predict that TZDs would increase the risk of cardiovascular death in these patients by 64 per cent; in fact, they provided contradictory evidence.³⁹

T2DM is a disease of glucose misregulation that leads to broad physiological effects. Rodents differ from humans on every tier of glucose regulation, from the level of nucleic acids to differences in proteins, pathways, cells, tissues, and organs. The two species also differ in terms of disease progression at the organism level and, dramatically, in environmental exposure and autonomy of lifestyle.^{40,41} “Because mice rely principally on the liver for glucose homeostasis, while humans rely on skeletal muscle where transport mechanisms and biochemical pathways differ, mice may not be expected to be analogous to [T2DM] patients in regards to mechanisms of glucose metabolism or its dysfunction.”⁴² Despite these clear discrepancies, diabetes research in animals continues while more relevant, human-based methods are often ignored.

Many genetic models of T2DM are based on leptin or leptin-receptor deficiency, even though neither of these represent an important contributor to T2DM in humans.⁴³ Mice who have been genetically modified to lack select insulin-signalling genes are also poor models. For example, mice with a complete deletion of the insulin receptor die within a few days of birth, while humans with this rare condition can survive until age 2.⁴⁴ Overall, observed phenotypes in these and similar animal models of diabetes are only “secondary to genetic mutations that do not reflect disease etiology in humans”.⁴⁵

Human-relevant alternatives to the use of animals in diabetes research include human imaging, *in vitro* technology using human heterologous cell lines, human induced pluripotent stem cells, organotypic 3-D cell culture, the use of human organs *ex vivo*, post-mortem human tissue, non-invasive human imaging, epidemiological and human genetic studies – including nutrigenomics and nutrigenetics – as well as *in silico* modelling.^{46,47} For example, scientists at Glasgow Caledonian University recently used human cells from a tissue bank to generate wound-healing models for diabetic patients, who have difficulty with wound healing and controlling skin infections.⁴⁸ Additionally, the US Food and Drug Administration has approved a closed-loop insulin pump developed using *in silico* modelling as a substitute for animal testing, providing just one example of how “[r]ealistic computer simulation is capable of providing invaluable information about the safety and the limitations of closed-loop control algorithms, guiding clinical studies, and out-ruling ineffective control scenarios in a cost-effective manner”.⁴⁹

In their recent publication, Ali, Chandrasekera, and Pippin discuss a wealth of relevant methods for studying diabetes, stressing the need to focus on human biology for human diabetes research:

As we continue to uncover major species differences in factors affecting glucose biology – such as cell division, stimulus-secretion coupling and autocrine–paracrine interactions ... it is now becoming unquestionable that **new information should be derived solely from human primary cells, tissues and organs**, obtained from nonpatient controls and patients in the various progressive stages of T2DM. ... If the ultimate goal of the diabetes research community is to understand disease mechanisms that will lead to better T2DM prevention and therapeutic outcomes for patients, then the best way to achieve that goal is by prioritising human-centred research [emphasis added].⁵⁰



HIV/AIDS

Recommendation: End the use of animals immediately

The failures of animal experiments to translate into useful human application of HIV/AIDS vaccines were recognised more than 20 years ago when, in 1995, the US National Institutes of Health (NIH) instituted a moratorium on the breeding of chimpanzees, the most commonly used animal in HIV/AIDS research at the time, acknowledging the failure of studies using the species to produce clinically useful data in this field. Following NIH's acknowledgement that chimpanzees aren't human-relevant surrogates for this research, experimenters began to use other non-human primate species, notably macaques.

Because macaques are unreceptive to HIV, experimenters who wanted to use them shifted their focus to studying simian immunodeficiency virus (SIV), even though it is known that SIV isn't related to the most widespread HIV virus, HIV-1, but rather is a relative of the rarer and less pathogenic HIV-2.⁵¹ The genetic homology between HIV and SIV is only 55 per cent, and SIV is less genetically diverse than HIV.^{52,53} Owing to differences in surface proteins and other molecular markers, antibodies that neutralise SIV have no effect on HIV, and vice versa,⁵⁴ making them useless in HIV research. Importantly, the dose of SIV administered to non-human primates in experiments is much higher than the typical amount of HIV-1 to which a human is exposed during sexual transmission.⁵⁵ AIDS researcher Mark Girard has stressed, "Extrapolating from vaccine protection results in non-human primate [SIV/SHIV] studies to efficacy in man may be misleading."⁵⁶

Immune system and genetic variances between humans and non-human primates weaken non-human primate HIV/AIDS research. Here are some examples:

- Non-human primates have more leukocyte antigen genes and therefore wider variety in antigen recognition than do humans.⁵⁷
- Non-human primate T cells contain molecules called siglecs, which act as "brakes" on the immune system, preventing hyper-responsiveness. The absence of siglecs in human T cells dramatically affects how humans respond to infection and treatment.⁵⁸
- The primate TRIM5 α gene codes for a restriction factor that affects responsiveness to retroviruses such as SIV, giving some non-human primates greater resistance to infection, a function mostly lost in human TRIM5 α .⁵⁹
- Even in chimpanzees, humans' closest non-human relatives, transcript expression in the liver differs by 40 per cent,⁶⁰ a species difference that becomes more pronounced following the varying translation of these transcripts into proteins.

For these reasons and more, HIV/AIDS vaccine research involving non-human primates has been called "[one of the most notable failures in animal experimentation translation](#)".⁶¹

Because of broad failures in non-human primate HIV/AIDS research, experimenters have recently shifted some focus to a species even more genetically removed from humans: the mouse. The "humanised" mouse model for HIV/AIDS research is a mouse who has been partially repopulated by human immune cells, allowing the animals to be infected with HIV-1. However, humanised mice are limited in their longevity with the disease and retain murine major histocompatibility complex antigens, "complicating immune response interpretations".⁶² Not surprisingly, the use of "humanised" mice has also failed to generate useful results for clinical HIV/AIDS treatment.

Considering the differences between an animal laboratory environment and human society, it is clear that animal experiments will never capture the complexity of this human disease. Animals used in experiments are kept in mostly pathogen-free conditions, and cofactors that may be present in human patients, such as other



microbial infections, are absent, significantly altering the acquisition and course of the virus.⁶³ Additionally, researchers at Emory University in Atlanta state, “HIV persistence is a very complex virological and immunological phenomenon, with infection of several cell types in a wide array of anatomic tissues that are all regulated differently,”⁶⁴ and recognise that human *in vitro* models are needed to replicate this human disease and develop treatment. Thinking progressively about non-animal methods, UK scientists have said, “Existing animal models predicting clinical translations are simplistic, highly reductionist and, therefore, not fit for purpose,” and that clinical attrition data “focusses the attention back on to early target selection/lead generation, but it also questions the suitability of current animal models with respect to congruency with and extrapolation of findings for human hosts”.⁶⁵

Scientists admit that even after costly and unreliable animal experiments, human data is still needed to determine whether a drug is fit for the clinical setting. Rao and Alving of the US Military HIV Research Program state that “human clinical trials still appear to be the only reliable way to determine whether an HIV vaccine candidate will have activity or efficacy in humans”.⁶⁶ In a comprehensive review of preclinical and clinical data, Jarrod Bailey reported that of 85 candidate vaccines that were tested in 197 clinical trials, zero were successful; some drugs even increased the risk of HIV infections compared to the placebo.⁶⁷ A current search of ClinicalTrials.gov will return more than 700 AIDS vaccine trials, and still, none has been successful.

Recently, scientists from Australia, France, Italy, and the UK have been studying the immune cells of individuals called “HIV controllers”, who can become infected with HIV but are able to control the virus’s spread without any intervening therapy.⁶⁸ The hope is that immune cells from HIV controllers can be transferred to HIV-infected patients to help them fight the virus. This promising research is human-specific and requires human-specific testing methods. As Nobel laureate Sydney Brenner declared, “We don’t have to look for model organisms anymore because we are the model organism.”⁶⁹ Similarly, in 2007, the associate editor of *The BMJ* stated, “When it comes to testing HIV vaccines, only humans will do.”⁷⁰

Inflammation and Immunology

Recommendation: End the use of animals (particularly mice) immediately

Because of the development of tools allowing for manipulation of the mouse genome, the mouse is the most commonly used research subject worldwide. However, it should be no surprise that with this rampant use comes substantial evidence that mice are not the same as humans and that there are certain fields, in particular, in which the dramatic differences in physiology between the two species disqualify the use of mice as research subjects. One of the most noted fields in this category is immunology.

In 2004, a compelling review was published in *The Journal of Immunology* outlining the many differences between mouse and human immune systems, including in the anatomy of lymphoid tissue, ratios of white blood cell types, antimicrobial peptide profiles, cytokine profiles and functions, mechanisms for crosstalk between the adaptive and innate immune systems, antibody subtypes, development and regulation of lymphocytes, and activation of clotting factors.⁷¹ Since then, several other analyses have been published detailing the many differences between human and mouse immunology.

A 2014 study found fundamental differences between the species in the innate immune response, stating, “[W]hile in human blood mechanisms of immune resistance are highly prevailed, tolerance mechanisms dominate for the defense against pathogenic microorganisms in mouse blood.”⁷² Logically, these differences make sense: we humans “do not live with our heads a half-inch off the ground”,⁷³ and we have considerably longer lifespans and a larger body size than do mice.^{74,75} As concisely stated by Leist and Hartung, “[H]umans are definitely no 70-kg mice.”⁷⁶ Despite the glaring contrast, mice continue to be used for immunological research.



The use of mice as a model of influenza (IFV) infection has been heavily criticised: “There are ... a number of drawbacks of the [mouse] model that make it unsuitable for addressing certain virological questions and can render data obtained in mice difficult to translate to the human situation.”⁷⁷ Viral infection is species-specific, and mice cannot naturally catch human IFV. To bypass this problem, experimenters have altered both the strain of mice and the viruses used. The BALB/c mouse, for example, is an inbred strain and is highly susceptible to viral infection because of the lack of MX1 gene, which codes for Mx1 protein that can selectively inhibit IFV replication.⁷⁸ The lethal dose of a deadly IFV strain (H5N1) is about 100 times lower in BALB/c mice compared to their cousins in the wild.⁷⁹ BALB/c mice do not possess genetic heterogeneity nor proper immune function for virology research.

The viruses used in animal studies are often adapted through serial passage in target hosts (mice, in this case) for easy infection.⁸⁰ This is because human IFV receptors (α 2,6-linked sialic acids) are not abundant in the upper airways of mice, who have a different receptor (α 2,3-linked sialic acids).⁸¹ Through serial passage, the virus can adapt to the new host and become distinct from the kind that affects humans predominantly.

There are many more differences between mice and humans in terms of IFV disease progression. For example, mice get hypothermia rather than fever following infection.⁸² They do not cough or sneeze.⁸³ Moreover, the virus does not transmit between mice.⁸⁴ Additionally, we now know that gut microbiota are intimately linked to the immune system,⁸⁵ and studies have demonstrated drastic differences between the microbiomes of humans and mice. For example, 85 per cent of bacterial species in mice don't exist in humans.⁸⁶ The aforementioned evidence supports the inapplicability of mouse immunity to human immunity.

Considering the obvious failure of mice as surrogates in the study of human immune systems, investment in human-relevant *in vitro* and *in silico* models is needed. Advances in data collection and computer analyses have allowed for the development of human-relevant multiscale models that “can consistently integrate immunological data generated at several scales, and can be used to describe and optimize therapeutic treatments of complex immune diseases”.⁸⁷

Vanderbilt University researchers have used a dual-chamber blood-brain barrier microfluidic device called the NeuroVascular Unit to study the human blood-brain barrier's response to neuroinflammation.⁸⁸ German scientists developed a computer model that gives them the capability to assess, for the first time, the electrophysiological consequence of the acidosis in human immune cells accompanying most forms of inflammation.⁸⁹ Additionally, a University of Tennessee mathematician, along with surgical and immunological specialists at the University of Pittsburgh, used a mechanistic mathematical model to characterise human immune responses during organ transplantation.⁹⁰

A review summarising the progress of immune-competent human skin disease models recognises the failures of animal studies to translate into effective treatments for diseases such as fibrosis, psoriasis, cancer, contact allergy, and autoimmune diseases, due, in part, to the immunological nature of these conditions. The authors go on to describe how co-culture, 3-D organotype systems and organ-on-a-chip technology will “enable human models of well-controlled complexity, yielding detailed, reliable data; thus providing a fitting solution for the drug development process”.⁹¹

Nerve Regeneration

Recommendation: End the use of animals immediately

Many neuroprotective agents have been developed that are successful in treating spinal cord injury (SCI) in animal models, but clinical trials have been disappointing. Neurologist Aysha Akhtar has described three major reasons for this failure: “differences in injury type between laboratory-induced SCI and clinical SCI, difficulties



in interpreting functional outcome in animals, and inter-species and interstrain differences in pathophysiology of SCI".⁹² In their systematic review of the use of animal models to study nerve regeneration in tissue-engineered scaffolds, Angius and colleagues noted, "The large majority of biomaterials used in animal models have not progressed for approval to be tested in clinical trials in spite of the almost uniform benefit described in the experimental papers."⁹³ The authors lamented the low quality of described animal experiments, in that necessary detail and rationale had been omitted, making it difficult to compare data.

For example, methylprednisolone, a routinely used treatment for acute SCI, has generated inconsistent results in animal models. A systematic review examining 62 studies of the drug on a wide variety of species, from rodents to monkeys, found that 34 per cent of the studies reported beneficial results, 58 per cent no effect, and 8 per cent mixed findings.⁹⁴ The results were inconsistent both among and within species, even within strains. Furthermore, the variability in results remained even when many of the study design and procedure variables were controlled. The authors pointed out numerous intrinsic differences between, and limitations of, each species/model and suggested that as a result of these immutable inter- and intra-species differences, no human-relevant animal model can be developed. They concluded that the "research emphasis should be on the development and use of validated human-based methods".⁹⁵

Among species, rats are particularly unsuitable for nerve repair or regeneration research. Experts have pointed out three major problems with rat models in this field:

- (1) The majority of nerve regeneration data is now being generated in the rat, which is likely to skew treatment outcomes and lead to inappropriate evaluation of risks and benefits.
- (2) The rat is a particularly poor model for the repair of human critical gap defects due to both its small size and its species-specific neurobiological regenerative profile.
- (3) Translation from rat to human has proven unreliable for nerve regeneration, as for many other applications.⁹⁶

More specifically, the inconsistencies between animal models and the clinical situation include the following:

- (1) healthy animals versus sick patients;
- (2) short versus long gap lengths (the clinical need for *large* gap repairs, while 90% of *in vivo* studies are in rats and rabbits where gap lengths are usually ≤ 3 cm);
- (3) animal models that almost always employ *mixed sensory-motor* autografts for repairing mixed defects, versus clinical repairs that almost always involve *sensory* autografts (usually sural nerve) for repairing mixed defects;
- (4) protected anatomical sites in animal models, versus repairs that must often cross articulating joints in humans; and
- (5) inbred, highly homogeneous animal strains and ages, versus diverse patient populations and ages: It is well recognized that animal models fail to mimic the human condition in terms of the *uniformity* of animal subjects used.⁹⁷

University of Florida biomedical engineers Mobini and colleagues add, "We are incapable of truly mimicking human neural injuries in animal models because of the extensive anatomical, functional, molecular, immunological, and pathological differences between humans and frequently studied animals."⁹⁸ Human-relevant methods such as human stem cells and clinical research can bypass these limitations and should be the focus.

Human-relevant methods for studying nerve injury and regeneration have been reviewed by a number of research groups and include human organoids, microfluidics, engineered human tissue scaffold moulds, bioprinting, and other *in vitro* uses of human cells. *Ex vivo* models, such as those that use 3-D engineered scaffolds, bioreactors, neurospheres, and organoids, allow for more controlled studies on specific parameters



than do animal experiments.⁹⁹ Bioprinting can use bioinks containing human cells and materials to construct heterogeneous tissue models in a single step and with great consistency,¹⁰⁰ an aspect of nerve regeneration research that has been particularly lacking in animal models.¹⁰¹

Shrirao and colleagues at Rutgers University recommend microfluidic devices, which are “adaptable for modeling a wide range of injuries” and provide advantages over traditional *in vivo* and *in vitro* experiments by “allowing researchers to (1) examine the effect of injury on specific neural components, (2) fluidically isolate neuronal regions to examine specific effects on subcellular components, and (3) reproducibly create a variety of injuries to model TBI and SCI”.¹⁰² Mobini and colleagues note that microfluidics, or lab-on-a-chip devices, offer advantages in precision, scalability, and cost-effectiveness when compared to traditional cell culture or animal experiments and that these are currently on the market and available for neural regenerative medicine research.¹⁰³

Neurodegenerative Diseases

Recommendation: End the use of animals immediately

There is sufficient literature documenting the failings of various animal models of neurodegenerative diseases, including Alzheimer’s (AD), Parkinson’s (PD), Huntington’s (HD), and motor neurone disease (MND), to write a lengthy appendix for each disease. However, since many of the same limitations of animal models prohibit translation across these conditions, they will be discussed briefly as a whole. For one, all these diseases are human-specific, meaning that none of them occurs naturally in other animals. No animal model has been developed that recapitulates all aspects of a particular neurodegenerative disease.¹⁰⁴ For AD research, the clinical failure rate for new drugs is 99.6 per cent.^{105,106} This includes the recent failure of AstraZeneca and Eli Lilly’s lanabecestat, which was hailed as extremely promising, due to futility.¹⁰⁷ There have been no new discoveries that slow the progression of AD for 18 years.¹⁰⁸

In a bioinformatic analysis comparing transcriptional signatures of human AD, PD, HD, and MND with mouse models of these diseases, Stanford scientists made the following findings:

[M]ost available mouse models of neurodegenerative disease fail to recapitulate the salient transcriptional alterations of human neurodegeneration and ... even the best available models show significant and reproducible differences compared to human neurodegeneration. Although the reasons for the poor transcriptional performance of mouse models varied, the unifying theme was the failure of mouse models to exhibit the variety and severity of diverse defects observed in human neurodegeneration.¹⁰⁹

These molecular discrepancies underscore the artificial ways in which such models are created. Physical and chemical lesioning and systemic administration of toxins are often used. These are acute stressors, not long-term degenerative processes, and as such, they initiate events in animal models that are not present in human patients. The acute and immediate nature of particular disease models, such as the 6-OHDA and MPTP models of PD and the 3-NP model of HD, fail to capture the progressive nature of the disorders that they aim to mimic. In addition, it is commonplace for scientists to use young animals, both rodents and primates, to “model” diseases associated with ageing,¹¹⁰ further reducing the likelihood that their observations will be of use to humans.

Genetically modified mouse models of neurodegenerative disease exhibit an inconsistent range of pathological and behavioural phenotypes, in part because of the transgenes used, inconsistencies in transgene insertion and expression, and mouse background strains.¹¹¹ The most commonly used genetic mouse model of MND, the



SOD1 model, is based on a gene that accounts for only 3 per cent of MND cases in the human population.¹¹² Literature reviews have concluded that findings from this model have not translated into any effective human therapy for MND, that “a biased estimation of treatment efficacy in animals may lead to unnecessary (and possibly harmful) clinical trials in humans”,¹¹³ and that “animal models are not an ideal system for studying [amyotrophic lateral sclerosis (MND)] or for developing drug therapies”.¹¹⁴ In PD, even non-human primate studies do not “constitute a valid scientific modality for the complete understanding of PD and for the development of future neuromodulation therapeutic strategies”.¹¹⁵

As in much of biomedical research, animal subjects suffer greatly when they are used to mimic neurodegenerative disease. In an analysis of published studies on animal models of HD, 51 studies referenced experiments “in which animals were expected to develop motor deficits so severe that they would have difficulty eating and drinking normally”;¹¹⁶ however, only three out of 51 reported making adaptations to the animals’ housing to facilitate food and water intake. The authors of this analysis concluded that experimenters are not following the 3Rs principle (replacement, reduction, and refinement of animal use) and, in their failure to do so, are compromising not only animal welfare but also the relevance of their studies to HD.¹¹⁷

As animal studies fall short, scientists and policymakers are realising that research strategies should be more human-relevant. Following a review of AD research, an interdisciplinary panel recommended that funding be allocated away from animal studies and towards more promising techniques involving patient-derived induced pluripotent stem cell models, “omic” technology (genomics, proteomics, etc.), *in silico* models, neuroimaging, and epidemiological studies.¹¹⁸ For advancements in human blood-brain barrier research, which will greatly benefit scientific progress in developing treatments for human neurodegenerative disease, please see the section on [Stroke](#).

The following are highlights in cutting-edge, human-relevant AD research:

- Scientists at the University of Texas Southwestern Medical Center have discovered a “Big Bang” of AD, identifying the genesis of tau pathology in the disease, not by experimenting on animals but by extracting proteins from human brains and isolating single molecules.¹¹⁹
- Thanks to developments in human brain imaging, scientists at the University of Cambridge were able to trace tau protein in human brains.¹²⁰ Chemists there also used mathematical modelling to understand the role of cholesterol in the aggregation of amyloid proteins.¹²¹
- Patient-derived stem cells were used by Hungarian and Danish scientists to compare neurons from the brains of patients with sporadic AD to those with the familial form of the disease, discovering key similarities and differences between the two pathologies and concluding that stem cell technology is suitable for modelling both forms of the disease.¹²²
- At the Karolinska Institute in Sweden, researchers identified a molecular fingerprint for dementia present in the synapses of brains collected post mortem from patients and subject to proteomic analyses.¹²³

Biological engineering is also transforming MND research. A team of researchers in the Hickman Hybrid Systems Lab at the University of Central Florida have developed a human neuromuscular junction-on-a-chip, the first of its kind, which can be used for toxicity testing of drugs designed to treat neuromuscular diseases, such as MND and spinal muscular atrophy.¹²⁴ When the researchers tested three known drugs on this model, the results matched live human data. Scientists at Harvard University and Lawrence Livermore National Library are also using brain-on-a-chip technology to study how neurons communicate and how exposure to certain chemicals may affect the human brain over time.^{125,126}

For many years, animal experimenters have tormented monkeys, mice, dogs, and other animals in an effort to create drugs to treat these devastating diseases; however, since other animals don’t get these human diseases, experimenters have manipulated their genomes in order to force certain symptoms. The results, after decades



of tests, include more than 100 failed drugs, an untold number of animal deaths, and the continued suffering of human victims of the disease. For these patients, a switch to human-relevant methods is long overdue.

Neuropsychiatric Disorders

Recommendation: End the use of animals immediately

Animal models of neuropsychiatric disorders such as depression, schizophrenia, bipolar disorder, anxiety, and attention deficit spectrum disorders lack two critical aspects of model validity: (1) construct validity, meaning that the mechanistic underpinnings creating the observed symptoms in animals are different from those that lead to the disorder in humans, and (2) face validity, meaning that animals lack the ability to “recapitulate important anatomical, biochemical, neuropathological, or behavioural features of a human disease.”¹²⁷ No single animal model is able to replicate all aspects of a particular condition, and features of human behaviour representing hallmarks of these disorders cannot be produced or properly assessed in animals.

Human depression, for example, is characterised, in part, by a generalised feeling of sadness, hopelessness, and despair. In an effort to measure “despair” in rodents, the most commonly used behavioural test is the forced swim test, in which a rat or mouse is placed in a container of water with no way to escape and no place to rest out of the water. Naturally, the rodent will spend some time swimming and trying to find a way out of the stressful situation but will eventually become immobile and float. The time spent swimming may be extended by giving the animal some forms of human antidepressant drugs, a finding that led some scientists to assert that less time spent immobile was a sign that animals were less “depressed” and that more time spent immobile meant they were more “depressed,” as if they had “given up” and were in despair.

However, as Molendijk and de Kloet discuss, immobility in the forced swim test is simply animals’ adaptation to their situation and should not be used to determine their mood.¹²⁸ Individual animals who are quicker to float also save their energy and are less likely to sink, meaning that those who pick up on this sooner and spend less time struggling are simply learning this adaptive behaviour more readily. Furthermore, the immobility response occurs after treatment with drugs that do not have antidepressant effects at all, such as caffeine and other miscellaneous drugs,^{129,130} and is sometimes not observed after treatment with drugs that do.¹³¹ Time spent swimming versus floating is also influenced by an animal’s strain as well as experimental variances, such as water depth and temperature.^{132,133,134} Nevertheless, thousands of published papers ignore these warnings and use the forced swim test to make erroneous conclusions about an animal’s mood.¹³⁵

Experiments on neuropsychiatric conditions in animals are of poor quality. In a survey of 121 animal studies claiming to investigate attention deficit hyperactivity disorder (ADHD), only five were found to be in any way relevant to the hypotheses of the human medical papers in which they were cited. The authors of the survey concluded that “animal research has contributed very little to contemporary understanding of ADHD”.¹³⁶ A similar failure of animal studies to translate into a clinical setting has been noted with bipolar depression research,¹³⁷ and animal studies have been cited as the primary source of attrition (failure of drugs) in neurobehavioral clinical trials.¹³⁸ Significant differences in physiology between humans and other animals likely account for a large percentage of failed translation. For example, the gene encoding tyrosine hydroxylase, the enzyme involved in the formation of dopamine, was found to be regulated in an entirely different manner in humans from the way it is in mice.¹³⁹ Misregulation of tyrosine hydroxylase has been implicated in several psychiatric illnesses, such as bipolar disorder and schizophrenia.

To quote Dutch animal behaviourists van der Staay, Arndt, and Nordquist, “If evidence accumulates that the intended goal/purpose cannot be reached, then one should consider abandoning further development of the model.”¹⁴⁰ This group also points out that in all cases, “benefits must outweigh the ethical costs of the animals. These costs include pain and suffering, distress and death”.¹⁴¹ Funds should be allocated to more relevant,



human-based experimental models, such as computational modelling using already well-defined biomarkers¹⁴² and the use of patient-specific stem cells for personalised medicine, which “affords the ability to generate neuronal cell-based models that recapitulate key aspects of human disease”¹⁴³ and can be used in drug discovery. Complex diseases like schizophrenia are ideal disorders “to model through stem cell approaches due to ... heterogeneous, complex genetics that are hard to recapitulate in animal models”.¹⁴⁴

Recent developments in the field of human neuropsychiatric research include the following examples:

- A research group at the University of Michigan used induced pluripotent stem cells from bipolar and nonbipolar individuals to grow patient-specific neurons and glial cells. They found that cells from bipolar people were genetically and behaviourally distinct from those from non-bipolar people and that they responded differently to a commonly used therapeutic. The group is now further characterising these cells and testing other treatments.¹⁴⁵
- German neuroscientists are using virtual reality to simulate anxiety-causing events in humans.¹⁴⁶
- In Australia, researchers performed gene expression studies in post-mortem human brains, and their analyses indicated that schizophrenia may be related to the developmental complexity of the human brain.¹⁴⁷
- Scientists at the Albert Einstein College of Medicine used neurons derived from human induced pluripotent stem cells, along with the gene-editing tool CRISPR-Cas9, to identify misregulated genes following the knock-out of a gene implicated in autism and other disorders.¹⁴⁸
- A team at the Salk Institute for Biological Studies used a human cellular model of bipolar disorder to pinpoint key features of the disease, such as hyperexcitability of bipolar neurons and differences in responsiveness to lithium.¹⁴⁹
- At the University of São Paulo, induced pluripotent stem cells were derived from samples collected from three patients with autism spectrum disorder. By generating mixed cell cultures, researchers were able to study the interplay between neurons and astrocytes and pinpoint interleukin-6 as a potential mediator of autism-specific neural defects.¹⁵⁰

In addition to the lack of applicability of animal neuropsychiatric models to the human condition, animals used in this research suffer immensely. To induce “depression”, experimenters subject them to uncontrollable pain through electric shocks or chronic stressors such as restraining them for extended periods of time, starving them or denying them water, tilting their cages, forcing them to live in wet bedding, shaking them, or disrupting their circadian rhythms. Animals are often made to live in complete isolation from members of their species, bullied and physically assaulted by other animals, deprived of parental care, and subjected to genetic or surgical manipulations in an effort to induce a depressed or altered mental state. Owing to the psychological distress inherent in animals provoked to display neuropsychiatric disease tendencies and the inapplicability of the results to humans, we recommend that the use of animals in such studies be ended immediately.

Sepsis

Recommendation: End the use of animals immediately

Sepsis is estimated to affect more than 30 million people worldwide each year. Although the incident rate varies by country, the incidence of severe sepsis to the point of organ dysfunction in the European Union has been estimated at 90.4 cases per 100,000 population, as opposed to 58 per 100,000 for breast cancer.¹⁵¹ Mice are the animals most commonly used in sepsis research – not because they make good models of human sepsis but because they’re cheap, plentiful, small, and docile.¹⁵² The difficulty in reliably translating results from mice to humans is believed to be the primary cause of the failure of practically all human trials of sepsis therapies.



In 2013, *Proceedings of the National Academy of Sciences of the United States of America (PNAS)* published a landmark study that had been 10 years in the making and involved the collaboration of 39 researchers from institutions across North America, including Stanford University and Harvard Medical School. Dr Junhee Seok and his colleagues compared data obtained from hundreds of human clinical patients with results from experiments on animals to demonstrate that when it comes to serious inflammatory conditions such as sepsis, burns, and trauma, humans and mice are not similar in their genetic responses.¹⁵³

NIH Director Dr Francis Collins authored an article about these results, lamenting the time and resources spent developing 150 drugs that had successfully treated sepsis in mice but failed in human clinical trials. He called this disaster “a heartbreaking loss of decades of research and billions of dollars”.¹⁵⁴ The *PNAS* paper reveals that in humans, many of the same genes are involved in recovery from sepsis, burns, and trauma but that it was “close to random” which mouse genes might match these profiles. Collins explains it as follows:

Mice, however, apparently use distinct sets of genes to tackle trauma, burns, and bacterial toxins – when the authors compared the activity of the human sepsis-trauma-burn genes with that of the equivalent mouse genes, there was very little overlap. No wonder drugs designed for the mice failed in humans: they were, in fact, treating different conditions!¹⁵⁵

Even before this landmark study, the criticism of mouse models had been documented in more than 20 peer-reviewed scientific papers. The mice used in sepsis experiments are young, inbred, and of the same age and weight, and they live in mostly germ-free settings; in contrast, it is mostly infant and elderly humans, who live in a variety of unsterilised, unpredictable environments, who develop sepsis.^{156,157} When experimenters induce the condition in mice, the onset of symptoms occurs within hours to days, whereas it takes place within days to weeks in humans. Mice are not typically provided with the supportive therapy that human patients receive, such as fluids, vasopressors, and ventilators.¹⁵⁸ Unlike humans, mice are rarely given pain relief,¹⁵⁹ another difference that undermines data of already questionable value, as pain affects other physiological processes.

The “gold standard” method of inducing sepsis in mice is through caecal ligation and puncture. However, mice’s responses to this procedure vary depending on age, sex, strain, laboratory, the size of needle used, and the size of the incision, which makes results incomparable between laboratories.¹⁶⁰ In addition, the procedure causes the formation of an abscess, whose effects may disguise or be disguised by the effects of the sepsis itself.¹⁶¹ This means that an intervention that appears to be beneficial for sepsis may actually be beneficial only because of its effects on the abscess.

Rats, dogs, cats, pigs, sheep, rabbits, horses, and non-human primates, including baboons and macaques, have also been used in sepsis experimentation. None of these species reproduces all the physiologic features of human sepsis. The pulmonary artery pressure responses of pigs and sheep differ from those of humans, so this aspect of sepsis cannot be compared between these species.¹⁶² Furthermore, baboons and mice are less sensitive to a species of bacteria commonly used to induce sepsis in experimental settings.¹⁶³

Fortunately, researchers do not have to use animals to study and find treatments for sepsis in humans. In 2015, an expert working group consisting of veterinarians, animal technologists, and scientists issued a report on the implementation of the 3Rs in sepsis research.¹⁶⁴ The group noted several methods that could be used instead of animal models, such as *in vitro* cell culture models for studying sepsis mechanisms, systems and computation biology for laying out the inflammatory processes occurring during sepsis, 3-D cell culture models for exploring human disease progression and infectious disease mechanisms, synthetic human models to recreate human disease-related cell types and tissues, and human genomic information to discover how sepsis affects individuals differently and which groups may be more at risk. The authors state that genomic information “will complement or even replace the need for mouse models in disease discovery and drug development”.¹⁶⁵



The following are examples of recent developments in human-relevant sepsis research:

- Scientists at Emory University and the Georgia Institute of Technology have engineered a microfluidic vascularised bleeding model that allows them to test the effects of therapies on clot and plug formation in human blood.¹⁶⁶
- Because the clinical trajectory of sepsis can be drastically different for every individual, University of Chicago researchers propose that human genetic algorithms “can serve as a guide on the path towards true ‘precision control’ of sepsis”.¹⁶⁷
- Physicians from Cincinnati Children’s Hospital support using microfluidic devices to study sepsis in infants, whose cells could be captured from a very small amount of blood.¹⁶⁸
- Researchers from the Harvard TH Chan School of Public Health, Brigham and Women’s Hospital, and the University of Sheffield compared public datasets of the blood transcriptome profiles of adults and children with sepsis, populations that have different mortality rates from the disease. This led them to identify 10 candidate drugs that had never been linked to sepsis before.^{169,170}
- By analysing blood from patients with sepsis, a German group identified a specific microRNA as an independent risk factor for mortality and a biomarker for discriminating between sepsis and infection.¹⁷¹

In fact, there may have already been a breakthrough in sepsis research. Physicians have recently had impressive results by treating sepsis patients with an intravenous vitamin C combination.¹⁷² One patient whose chance of dying from sepsis was nearly 100 per cent was well enough to leave the intensive care unit within seven days of receiving this treatment.¹⁷³ An estimated 10 to 20 per cent of intensive care specialists around the world have already started using this therapy, and studies involving 13 hospitals are underway to confirm its efficacy.¹⁷⁴ Importantly, these successes have been achieved using only human patients, not mice or other animals, and many patients were helped tremendously in the process.

Stroke

Recommendation: End the use of animals immediately

According to researchers at the Institute for Stroke and Dementia Research in Munich, “More than 1000 neuroprotective compounds have been tested in rodent models with the aim to improve stroke outcome. ... Indeed, many agents reduced brain damage (in most cases measured as decreased infarct volume) in rodent models of experimental stroke. Out of these candidates approximately 50 neuroprotective agents were tested in more than 100 clinical stroke trials, but none has improved outcome in clinical stroke patients.”¹⁷⁵

Many factors contribute to this failure, such as flaws in experimental designs, publication bias, disease-management inconsistencies between animal models and clinical populations, and physiological differences between species. Experts in the field admit that “animal models of stroke mimic at best less than 25 percent of all strokes”.¹⁷⁶ The Stroke Therapy Academic Industry Roundtable (STAIR) published its first recommendations in 1999, but the success rate of clinical trials has not improved. One drug, NXY-059, which fulfilled the STAIR criteria, failed in clinical trials.¹⁷⁷ This illustrates the need to shift away from animal models and focus on human-centred methods.

In a 2017 review,¹⁷⁸ Clemens Sommer, MD, of the University Medical Center at Johannes Gutenberg University Mainz, details the following aspects of animal experimentation that limit the translatability of animal-based stroke research to the clinical setting:



- Most animals studied in stroke research have lissencephalic, or smooth, brains, unlike the gyrencephalic brains of humans.
- The expression of certain signalling molecules differs between rodents and humans in three types of brain cell – neurons, astrocytes, and microglia – both at baseline and in response to oxygen deprivation.
- In humans, ischaemic damage to the white matter of the brain is important in the prognosis of stroke, but white matter content in humans is much higher than in other animals. “While in humans the percentage of white matter accounts for 60%, it decreases to about 35% in dogs, 20% in rabbits, 15% in rats and is as low as 10% in mice,”¹⁷⁹ meaning that a major factor in stroke outcomes for humans cannot be accurately compared in animal models.
- Blood vessels in the brain have a different anatomy in humans compared to other animals; even strains of rodents differ in their vascular framework. These “functional differences may have deeper implications concerning the pathophysiology of the ischemic cascade”.¹⁸⁰
- In humans, the gene for the neurotransmitter nitric oxide synthase 2 (NOS2) is regulated differently than it is in mice. NOS is important, since nitric oxide may be an essential gas-signalling molecule during stroke.¹⁸¹
- As discussed elsewhere in this report, immune system differences between humans and other species are drastic. Sommer describes this as follows:

[T]he percentage of neutrophils in mice and rats is about 10–20% compared to 50–70% in humans, while the opposite situation is seen for lymphocytes, which comprise about 50–100% in rodents compared to 20–40% in humans, respectively. Moreover, there is only a minimal intersection of whole-genome mRNA and microRNA expression in leukocytes from rodents versus humans at both baseline and after stroke, raising the question whether rodents are acceptable models at all for the human immune system after stroke.¹⁸²

- The RNA profile of a mouse brain is more similar to that of other tissues in a mouse’s body, such as the lungs, liver, and heart, than it is to that of a human brain.¹⁸³
- Ischaemic stroke typically occurs in heterogeneous elderly patients with comorbid conditions, whereas animal stroke experiments are predominantly carried out in young, healthy, male, inbred animals.

Kaya and colleagues made the following observation:

In animal studies, prolonged survival and neurological improvement rates are not documented realistically. Histopathological findings and treatment effects are rarely adequate to reveal the mechanisms in behavioral and functional improvement. There is great difference between animal experiments and clinical practice in terms of outcome evaluation. The cerebral infarct area is used in animal experiments while neurological function and quality of life are more important in humans.¹⁸⁴

On the other hand, human-based models of stroke do not suffer from these deficiencies. Instead, they allow for high-throughput analyses and are “increasingly important” for “testing novel potentially neuroprotective pharmaceuticals”.¹⁸⁵ Scientists from the Department of Molecular and Cellular Physiology at Louisiana State University have written that a “key benefit of *in vitro* systems is the opportunity to work with human cells, as such Werth *et al.*, utilized the brain slice method in human cortical slices to provide the first direct evidence of glutamate receptor involvement in ischemic injury in the human brain”.¹⁸⁶

Thanks to technological advances, including accurate 3-D representations of multiple neuronal cell types and structures of the human brain, researchers are able to overcome some of the previously limiting factors of human *in vitro* brain research. As part of a \$70 million NIH programme, an interdisciplinary team of researchers at Vanderbilt University have engineered a blood-brain barrier-on-a-chip, which they are using to study human brain inflammation induced by various compounds.¹⁸⁷ Similarly, the Seattle-based biotechnology company Nortis was recently awarded a federal grant to develop its predictive preclinical living model of the blood-brain



barrier as an alternative “to traditional pharmaceutical drug development testing on laboratory animals”, which will “reduce costs and minimize clinical trial failures”.¹⁸⁸ Disruption of the blood-brain barrier following a stroke¹⁸⁹ is a critical factor to consider in attempting to move a potential therapeutic compound from a patient’s bloodstream to the brain. Scientists at the University of California–Irvine opine that “[blood-brain barrier]-on-a-chip models offer tremendous potential for recreating microvasculature in the laboratory that will allow controlled study of the mechanics of [blood-brain barrier] permeability and immune infiltration as they relate to the process of stroke”,¹⁹⁰ particularly those that employ human cells, such as human induced pluripotent stem cells, which “can be used to create clinically relevant models for [central nervous system] disease”.¹⁹¹

A report authored by 42 scientists following a US National Institute of Neurological Disorders and Stroke workshop on translational stroke research concluded, “With increased availability of human cell lines/tissues, organoids, and inducible pluripotent stem cell technologies and high-throughput assays, *in vitro* strategies, in combination with data from animal models, may hold increasing prominence in future drug development strategies.”¹⁹² Animal models will never be able to recapitulate the nature of human stroke nor the human-specific inflammatory response that follows. Considering that in the US, someone suffers a stroke every 40 seconds and that someone dies of one every four minutes,¹⁹³ we cannot afford to spend our limited resources on substandard animal-based research.

Substance Abuse

Recommendation: End the use of animals immediately

Fundamental aspects of non-human animals make them inappropriate for the study of human addiction. First, the use of and addiction to drugs of abuse in humans is a vastly complex experience, one that has been impossible to mimic using animals in a laboratory setting.¹⁹⁴ It has been argued that attempts to model human disorders such as addiction in non-human animals, especially rodents, are “overambitious” and that the “‘validity’ of such models is often limited to superficial similarities, referred to as ‘face validity’ that reflect quite different underlying phenomena and biological processes from the clinical situation.”¹⁹⁵

Second, the pharmacokinetic actions of drugs are different among species. For example, “the rate of metabolism of MDMA [street name: Ecstasy, E, or Molly] and its major metabolites is slower in humans than rats or monkeys, potentially allowing endogenous neuroprotective mechanisms to function in a species specific manner”.¹⁹⁶ Pharmacokinetic differences between humans and “model” animals likely explain why the neurotoxicity seen in rodents after MDMA administration has not been observed in the clinical setting.¹⁹⁷ Since MDMA is being explored because of not only its illegal use as a recreational drug but also its potential use as a therapeutic, accurate knowledge regarding its safety in humans is paramount.

Third, serious flaws in experimental design of addiction experiments greatly skew interpretation of their results. In the human experience with drugs, the user chooses to consume the addictive substance. They choose it over other substances or activities that they may find rewarding. Animals in laboratories are typically not given this option. When they are, the vast majority of them will choose an alternative reward, such as sugar, over the drug of abuse.¹⁹⁸ This holds true for primates as well as mice and rats.¹⁹⁹ Even in animals with very heavy previous drug use, only about 10 per cent would continue to give themselves a drug when they had the option to make another rewarding choice.²⁰⁰ In a review on the “validation crisis” in animal models of drug addiction, French neuroscientist and addiction researcher Serge Ahmed asserts that the lack of choice offered to animals in these experiments elicits “serious doubt” about “the interpretation of drug use in experimental animals”.²⁰¹



The non-human animal has been called a “most reluctant collaborator” in studying alcohol addiction and noted to have a “determined sobriety” that the experimenter must fight against in order to overcome “their consistent failure to replicate the volitional consumption of ethanol to the point of physical dependency”.²⁰² National Institute of Mental Health researchers reason that “it is difficult to argue that [drug self-administration by rodents] truly models compulsion, when the alternative to self-administration is solitude in a shoebox cage”.²⁰³

Despite the prevalence of addiction research conducted on animals, “drugs that effectively curb opioid or psychostimulant addiction by promoting abstinence and preventing relapse have yet to be developed” and “very little clinical development is currently ongoing”.²⁰⁴ The data from animal studies was promising in certain drug classes, but these have either failed to be effective in human trials or not been tolerated well by humans, a negative outcome that was not predicted by animal trials.²⁰⁵

Non-invasive human research methods can provide us with answers to the questions that non-human animals, in their distaste for drugs of abuse, are fundamentally unable to answer. Rutgers University Robert Wood Johnson Medical School researchers recently authored a review article describing how the use of human induced pluripotent stem cells can provide a “unique opportunity to model neuropsychiatric disorders like [alcohol use disorders] in a manner that ... maintains fidelity with complex human genetic contexts. Patient-specific neuronal cells derived from [induced pluripotent stem] cells can then be used for drug discovery and precision medicine”.²⁰⁶

Human-relevant, non-animal research on alcohol use disorder is being carried out by scientists at the University of Connecticut, who recently used stem cells donated by alcoholic and non-alcoholic subjects to study the effects of alcohol on a specific receptor in the brain that is targeted by alcohol. Their results were at odds with some of the findings from animal experiments.²⁰⁷ At Rutgers, scientists used patient-derived cells to generate neural cell types specific to individuals in which they could study alcohol’s effects on various aspects of cell physiology. Their results demonstrated a role for neuronal inflammation in the pathophysiology of alcohol use disorder.²⁰⁸ Others are using human induced pluripotent stem cells to study the effects of alcohol on the human liver.²⁰⁹

In addition, the funds used to support ineffective and wasteful animal substance-abuse studies could instead be used to aid effective and directly human-relevant drug prevention, rehabilitation, and mental health-care programmes.

Trauma

Recommendation: End the use of animals immediately

After rodents, pigs are the species most commonly used in trauma experimentation. However, notable species-specific differences between pigs and humans render results from this research unintelligible. For example, pigs’ coagulation activity differs from that of humans, making it difficult to achieve a state of coagulopathy, or the inability to clot, in pigs. In instances of human trauma, coagulopathy represents part of the “lethal triad” for patients and is a great concern for researchers and physicians.²¹⁰ In addition, there are differences in the administration of mechanical ventilation and drugs such as vasopressin and heparin in research.^{211,212} Importantly, as with mice and humans, immune responses are different between pigs and humans.

Trauma is extremely heterogeneous: patients differ in age, gender, ethnicity, medical history, alcohol and drug use, and the presence of other injuries, making the production of an appropriate animal model difficult,²¹³ if not impossible. In studies of traumatic brain injury, all promising therapeutics identified in animals have failed



in human clinical trials.²¹⁴ There is a significant amount of discussion regarding the limitations of animal models of trauma and haemorrhagic shock, which is summarised in this excerpt from a review by Combes:

Scientific problems with the animal models include the use of crude, uncontrolled and non-standardised methods for traumatising, an inability to model all key trauma mechanisms, and complex modulating effects of general anaesthesia on target organ physiology. Such effects depend on the anaesthetic and influence the cardiovascular system, respiration, breathing, cerebral haemodynamics, neuroprotection, and the integrity of the blood-brain barrier. Some anaesthetics also bind to the NMDA brain receptor with possible differential consequences in control and anaesthetised animals. There is also some evidence for gender-specific effects. Despite the fact that these issues are widely known, there is little published information on their potential, at best, to complicate data interpretation and, at worst, to invalidate animal models. There is also a paucity of detail on the anaesthesiology used in studies, and this can hinder correct data evaluation.²¹⁵

Fortunately, it has been shown that computer simulation can accurately replicate real-life trauma and predict patient outcomes.²¹⁶ For example, scientists at the University of Pittsburgh used a computer model to examine the relationship between spinal cord injury and pressure ulcers in human patients and found that a certain treatment was effective at reducing inflammation and tissue damage.²¹⁷ This Pittsburgh group also used data-driven and mechanistic modelling to discover that the inflammatory response of patients who survive traumatic brain injury is different from that of individuals who do not survive, information that “may point to both novel mechanistic insights and clinically translational applications”.²¹⁸

In addition to the already-mentioned human-relevant methods that can be used to study molecular aspects of the side effects of and comorbidities related to trauma, clinical research remains invaluable in this field and informs mathematical and computer modelling. German researchers conducted a study of 35,232 patients over the course of 12 years and revealed a reduction in intubation rates, ventilation, and systemic complications such as sepsis.²¹⁹ A study conducted at the US Army Institute of Surgical Research used data from more than 250 human experiments to model mechanistically the physiology that underlies blood loss and shock in humans suffering from haemorrhage. The authors describe the study as follows:

Unlike an animal model, we introduce the utilization of lower body negative pressure as a noninvasive model that allows for the study of progressive reductions in central blood volume similar to those reported during actual hemorrhage in conscious humans to the onset of hemodynamic decompensation (i.e. early phase of decompensatory shock), and is repeatable in the same subject. Understanding the fundamental underlying physiology of human hemorrhage helps to test paradigms of critical care medicine, and identify and develop novel clinical practices and technologies for advanced diagnostics and therapeutics in patients with life-threatening blood loss.²²⁰

As a result of the heterogeneity of the causes and outcomes of trauma, and because of physiological and immunological differences among species, only human-relevant research methods are suitable for informing human trauma research.



Training and Forensic Enquiries

Detailed below are opportunities to end the use of animals immediately in forensic research and biomedical education.

Forensic Sciences

Recommendation: End the use of animals immediately

Forensic science is a unique research area and deserves serious ethical scrutiny, as its goal is to understand crime-related issues, rather than improving human health or life conditions, and the experimental methods are often horrific and conducted without anaesthesia. Italian scientists Cattaneo and colleagues explain that there is a “moral obligation to pursue and respect this [responsibility to take care of other animal species], especially where mankind’s actual survival is not at risk”.²²¹

The use of animals in forensic research was heavily criticised as early as 1992, when Bernard Knight asserted that “painful, sometimes mutilating experiments on conscious animals” in order to obtain “tenuous potential benefit to some medico-legal problem” cannot be condoned, particularly when one considers that such works “are not regularly used in routine forensic practice” and just “gather dust in university libraries”.²²² He also observed that “a vast amount of published material using animal experimentation seems to have little practical relevance, other than to expand the curriculum vitae and the career prospects of the researcher”.²²³

In 2015, Cattaneo and colleagues published a meta-analysis and review examining 404 forensic science articles and found that 69.1 per cent “concerned studies involving animals sacrificed exclusively for the sake of the experiment” and that “killing still frequently includes painful methods such as blunt trauma, electrocution, mechanical asphyxia, hypothermia, and even exsanguination; of all these animals, apparently only 60.8% were anesthetized”.²²⁴ In 2018, another meta-analysis was conducted by South African researchers Calvin Gerald Mole and Marise Heyns, who examined 204 original forensic science studies, using 5,050 animals, which were conducted between 2012 and 2018.²²⁵ In these, animals, including rats, pigs, mice, rabbits, sheep, and cows, were drowned, electrocuted, cut, beaten, and made to ingest acid, among other cruel procedures. Mole and Heyns conclude that not enough is being done in forensic science research to uphold basic ethical principles of research and to adhere to the 3Rs.

Cruelty aside, Cattaneo and colleagues stress, “[T]he history of forensic sciences has provided us with much evidence of the inapplicability of data obtained from studies performed on animal models,”²²⁶ given the anatomical, physiological, and genetic differences between species. Mole and Heyns suggest that “much of the reported animal tissue use in the traumatic research articles in the current study could be minimized using human tissue obtained at medico-legal autopsy” and that “[m]edico-legal autopsies may be an underutilized resource for scientific research specimens”.²²⁷

In addition, there are a plethora of alternative methods, such as manikins, simulators, artificial materials, and *in vitro* technology, and “applying alternative methods rather than using animals has provided, in the forensic field, important and reproducible results”.²²⁸ Taken together, the ethical problems and scientific and practical issues associated with animal experimentation as well as the abundant and readily available alternative methods signify that forensic research is a prime area for animal use to end immediately.



Medical Training

Recommendation: End the use of animals immediately

Animals have traditionally been used in biomedical education to teach human physiology and pharmaceutical principles, study human anatomical form and function, and practise human surgical procedures. Yet the following recent developments have contributed to a paradigm shift in this field: improvements in human-patient simulation and computer-assisted learning technology that teaches biomedical education as well as or better than animal dissection and experimentation,²²⁹ rising public opposition to animal use in laboratories,²³⁰ increasing animal laboratory cost burdens,²³¹ and a renewed focus by the medical community on improving patient safety and reducing clinical errors through simulation-based training.²³²

Medical experts have recommended a transition from an animal-based pedagogy to “a robust curriculum composed of didactics, task trainers, virtual reality, cadavers, computer software, high-fidelity patient simulators, and supervised clinical work”.²³³ Unlike animal-based laboratories, these non-animal training methods accurately model human anatomy, physiology, and pharmaceutical intervention and can effectively prepare students for the workplace. Further benefits include allowing students to repeat medical procedures until proficiency is achieved, improving provider confidence and transference of learned skills to clinical practice, and allowing educators to receive real-time objective performance feedback.²³⁴

Microsurgery Training

There now exists an array of low- and high-fidelity non-animal methods that researchers have developed for the effective teaching of a wide variety of basic and advanced microsurgical skills to novice and expert physicians and that have been endorsed as replacements for live-animal use. These include task trainers and perfused human cadavers that can teach procedures such as anastomoses, resection of artificial tumours, bypasses, and aneurysm creation, dissection, and clipping.

For example, a study from the University of Toronto comparing the microsurgical anastomosis skills of surgical residents trained on live rats versus those trained on a silicone model found that, following identical initial training on inanimate models, the latter group was as proficient at performing single-layer, microsurgical anastomoses as those trained on live animals. The authors concluded, “[T]raining with low-fidelity bench models is as effective as training with high-fidelity, live animal models for the acquisition of technical skill among surgical trainees.”²³⁵

A systematic review of microsurgical training methods supported these findings:

It would appear from the best available evidence that simulated microsurgery training on low fidelity models can be as effective as on high fidelity models. ... In the UK and elsewhere, the mainstay of microsurgical simulated training has historically been exposure to an in vivo rat microsurgery course, but generally this at a far too early stage in training where the bridge with clinical hands-on exposure to relevant cases cannot be made, and without repetition.²³⁶

Trauma Training

A study published by a US Air Force team compared the self-efficacy reported by military trainees taught emergency procedures on human simulators versus those taught using live animals and found equivalent results in both groups, concluding that “the belief in the superiority of animal training may just be a bias” and that “if the goal for trainers is to produce individuals with high self-efficacy, artificial simulation is an adequate modality compared with the historical standard of live animal models”.²³⁷ The lead author published a separate letter in the same medical journal stating, “We have entered into an age where artificial simulator models are



at least equivalent to, if not superior to, animal models. ... [T]he military should make the move away from all animal simulation when effective equivalent artificial simulators exist for a specific task. For emergency procedures, this day has arrived.”²³⁸

Non-animal methods are used exclusively instead of animals for military trauma training by nearly 80 per cent of NATO member states,²³⁹ and the US Coast Guard has become the first branch of the US Armed Forces to end the use of animals for this practice.²⁴⁰ These developments confirm that animal use for trauma training is neither necessary nor justified.

Efforts to replace animals with human simulators in military trauma training have gained many prominent supporters, including, recently, The New York Times Editorial Board²⁴¹ as well as numerous medical and veterans organisations representing more than 255,000 physicians and doctors-in-training, which have former US Surgeons General among their leadership.²⁴²

In the civilian sector, the American College of Surgeons has affirmed that human simulators can replace the use of animals in Advanced Trauma Life Support (ATLS) training, and national ATLS programmes in numerous countries have made this transition and ended animal use for this purpose.²⁴³

Given the non-animal training methods already available, we recommend that the use of animals for military and civilian trauma training and microsurgery training be ended immediately.



Toxicity Assessment

Detailed below are opportunities to end or significantly reduce the use of animals for the toxicity assessment of substances in the context of regulatory toxicity requirements. Also described are areas in which greater support is required to develop innovative methods that are relevant for the assessment of human health endpoints.

Please note that where tests are required for regulatory purposes, the OECD website (www.OECD.org) should be consulted for the most recent versions of test guidelines and guidance documents.

Exposure-Based Assessment

Recommendation: Immediately promote the use of exposure-based waiving as an opportunity to reduce the use of animals dramatically

Exposure-based waiving will reduce animal testing by shifting the focus of regulatory decision-making from a hazard-based to an exposure-based approach. This strategy employs “fit-for-concern” assessments rather than simple “box-ticking” by exploring safety based on real concerns and avoiding characterising hazards not relevant to human safety. The pesticide industry is actively seeking ways to promote exposure-based waiving for the assessment of their products.

Further work and collaboration by all involved stakeholders will be necessary to determine whether exposure-based waiving can be accepted and approved by regulatory authorities and the public.

Skin Irritation/Corrosion

Recommendation: Immediately eliminate the use of animals for skin irritation/corrosion testing

Skin irritation and corrosion tests for chemicals are required or recommended by multiple regulatory agencies. In these tests, rabbits are shaved, test substances are applied to their exposed skin, and they are observed for up to 14 days to assess the degree of skin damage. The tests can cause permanent skin damage, ulcers, bleeding, bloody scabs, and scarring. There is no requirement that animals be provided with pain-relieving drugs during this prolonged process.

Despite years of use, animal-based skin irritation studies have never been properly validated. Evidence exists that they are highly variable, of limited reliability, and generally poor predictors of human skin reactions. For example, a comparison of data from rabbit tests and four-hour human skin patch tests for 65 substances found that 45 per cent of classifications of chemical irritation potential based on animal tests were incorrect.²⁴⁴

The Organisation for Economic Co-operation and Development (OECD) has developed an integrated approach to testing and assessment (IATA) for skin irritation using *in vitro* skin irritation and corrosion methods that avoids or minimises animal use.²⁴⁵



- **OECD Test No 439: *In Vitro* Skin Irritation: Reconstructed Human Epidermis (RHE) Test Method:** May be used for the hazard identification of irritant chemicals (substances and mixtures), in accordance with the UN Globally Harmonized System of Classification and Labelling (GHS), as category 2, category 3, or non-classified chemicals. May be used as a stand-alone test or in a tiered testing strategy.
- **OECD Test No 430: *In Vitro* Skin Corrosion: Transcutaneous Electrical Resistance (TER) Test Method:** May be used for the identification of non-corrosive and corrosive test chemicals in accordance with the GHS.
- **OECD Test No 431: *In Vitro* Skin Corrosion: RHE Test Method:** May be used for the identification of corrosive chemical substances and mixtures. May also distinguish between severe and less severe skin corrosives.
- **OECD Test No 435: *In Vitro* Membrane Barrier Test Method for Skin Corrosion:** Allows for the subcategorisation of corrosive chemicals into the three GHS subcategories of corrosivity.

Recently, OECD TG 439 was validated for use in assessing the ability of medical device extracts to cause skin irritation, and the ISO 10993 guidance is currently being updated to include this test.^{246,247} A number of the above methods are currently undergoing evaluation in a joint effort by the US Environmental Protection Agency (EPA), industry, and the US NTP Interagency Centre for the Evaluation of Alternative Toxicological Methods (NICEATM) for use with pesticide products. This evaluation consists of side-by-side comparison and analysis of existing *in vitro* and *in vivo* data generated by pesticide companies for their products. Depending on the outcome of these efforts, additional work may be needed to validate the use of these methods with certain classes of chemicals that were not covered during OECD validation efforts.

Additionally, there are opportunities available to waive these tests based on criteria described in the OECD guidance document on considerations for the waiving or bridging of mammalian acute toxicity tests.²⁴⁸

Eye Irritation/Corrosion

Recommendation: Immediately eliminate the use of animals for eye irritation/corrosion testing

To assess eye irritation and corrosion using the Draize eye irritancy test, a chemical substance is applied to rabbits' eyes and the degree of damage is monitored over a 14-day period. Rabbits may endure eye swelling, discharge, ulceration, haemorrhaging, cloudiness, or blindness. The Draize test was developed 75 years ago, and advanced replacements have since been developed and validated. Furthermore, an analysis of 491 chemicals with at least two rabbit eye tests showed that there was a 73 per cent (for category 1), 32.9 per cent (for category 2A), 15.5 per cent (for category 2B), and 93.9 per cent (for no category) probability of obtaining the same GHS classification more than once.²⁴⁹ Importantly, these results showed that there was a 10.4 per cent chance that a chemical once identified as category 1 would later be identified as no category. The majority of category 2A and 2B chemicals were classified differently in repeat testing: 59.4 per cent of category 2A chemicals and 80.2 per cent of category 2B chemicals were classified as no category in a second test.

While no single *in vitro* test can predict the full range of serious eye damage/irritation categories, it is possible to categorise a test substance using only one method. A top-down approach is used when chemicals are expected, based on existing information, to have a high irritancy potential or induce serious eye damage. Conversely, a bottom-up approach may be used when chemicals are expected, based on existing information, not to cause sufficient eye irritation to require a classification. An OECD guidance document on an IATA of serious eye damage and irritation was published in 2017.²⁵⁰



- **OECD Test No 491: Short Time Exposure (STE) *In Vitro* Test Method.** May be used to identify chemicals causing serious eye damage (GHS category 1) or not requiring classification (GHS no category). May also allow the classification of irritants as minimal, moderate, or severe.
- **OECD Test No 492: Reconstructed human Cornea-like Epithelium (RhCE) Test Method (EpiOcular™, MatTek).** May be used to identify chemicals not classified for eye irritation or causing serious eye damage (GHS no category).
- **OECD Test No 460: Fluorescein Leakage Test Method.** May be used to identify chemicals causing serious eye damage (GHS category 1) or not requiring classification (GHS no category). Recommended as an initial step within a top-down approach to identifying ocular corrosives or severe irritants.
- **OECD Test No 437: Bovine Corneal Opacity and Permeability (BCOP) Test Method.** May be used to identify chemicals causing serious eye damage (GHS category 1) or not requiring classification. Validated by the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM), the European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM), and the Japanese Center for the Validation of Alternative Methods (JaCVAM).
- **OECD Test No 438: Isolated Chicken Eye Test Method.** May be used to identify chemicals causing serious eye damage (GHS category 1) or not requiring classification. Validated by ICCVAM, EURL ECVAM, and JaCVAM. Recommended as the first step within a top-down or bottom-up testing strategy.

These methods are generally validated for use with cosmetics and industrial chemicals that fall under the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) regulation, and there may be limitations for some methods with certain types of chemicals (e.g. surfactants, solids, etc.). None of the current OECD-approved assays is recommended for directly determining category 2 eye irritants in a regulatory setting, but category 2 can be inferred if a substance is demonstrated not to be category 1 (severe eye damage) or no category. There is a vital need for validation of a non-animal method that can directly predict category 2 (irritant) substances for use in a regulatory setting.

The EPA currently accepts the use of *in vitro* methods for the determination of eye irritation and corrosion when classifying antimicrobial cleaning products and other pesticide products on a case-by-case basis, and it has published a guidance document describing the testing framework that industry can use for this endpoint.²⁵¹ Also, the agency, in collaboration with the PETA Science Consortium International e.V. (the Science Consortium), NICEATM, and industry members, is currently engaged in evaluating these methods for use with agrochemical formulations.

India, as per the modifications in the Drugs and Cosmetics (Amendment) Act, 2017 accepts the OECD-validated *in vitro* methods for eye irritation for all the products under its mandate.

Additionally, there are opportunities available to waive these tests based on criteria described in the OECD guidance document on considerations for waiving or bridging of mammalian acute toxicity tests.²⁵²

Skin Sensitisation

Recommendation: Immediately eliminate the use of animals for skin sensitisation testing

The assessment of skin sensitisation involves measuring the likelihood that a substance will cause an allergic reaction if applied to the skin. In animals, such assessments have previously been based on applying a test substance to the shaved skin of guinea pigs or to the ears of mice, who are later killed. Fortunately, for industrial chemicals and drugs, the regulatory requirement to test for skin sensitisation can be fully replaced with a combination of *in vitro* and *in chemico* assays that each address a different key event in the adverse outcome pathway (AOP) for this endpoint.²⁵³ The methods distinguish between sensitisers and non-sensitisers and are recommended to be used in an IATA.



- **OECD Test No 442C: In Chemico Skin Sensitisation: Direct Peptide Reactivity Assay (DPRA).** The DPRA addresses the molecular initiating event of the skin sensitisation AOP.
- **OECD Test No 442D: In Vitro Skin Sensitisation Assays Addressing the AOP Key Event on Keratinocyte Activation.** This test guideline addresses the second key event of the skin sensitisation AOP.
- **OECD Test No 442E: In Vitro Skin Sensitisation Assays Addressing the Key Event on Activation of Dendritic Cells on the Adverse Outcome Pathway for Skin Sensitisation.** This method addresses the third key event of the skin sensitisation AOP.

A recent study showed that non-animal approaches to predicting skin sensitisation are as good as or better than the mouse test when compared to human data.^{254,255} While none of the methods is endorsed for potency determination, several approaches – for instance, the human cell line activation test (h-CLAT) – show promise in this regard.²⁵⁶ Further efforts are underway to explore this potential.

The OECD has published a guidance document on the reporting of defined approaches to be used within IATA for skin sensitisation.²⁵⁷ In general, the methods can be used to test cosmetics and industrial chemicals. The EPA accepts the use of non-animal approaches to testing single chemicals and is conducting a validation study with a goal of expanding this policy to formulations in the near-term future.²⁵⁸ Likewise, the UK accepts *in vitro* methods for addressing the potential of pesticides to cause skin sensitisation for plant-protection products.²⁵⁹ Additionally, there is an effort underway to validate non-animal skin sensitisation methods to replace the ISO 10993–required guinea pig skin sensitisation test for assessing medical device biocompatibility.²⁶⁰ There are opportunities to waive these tests based on criteria described in the OECD guidance document on considerations for waiving or bridging of mammalian acute toxicity tests.²⁶¹

Pyrogenicity

Recommendation: Immediately eliminate the use of animals for pyrogenicity assessment

Before drugs and medical devices can be marketed, regulators require testing to demonstrate that they are not contaminated with substances that trigger a fever response. These substances, collectively termed pyrogens, are chemically and structurally diverse but incite fever in humans through a common mechanism: peripheral blood monocytes and macrophages detect pyrogens and release pro-inflammatory cytokines that induce a rise in body temperature.

The rabbit pyrogen test (RPT) requires that rabbits be injected with a test substance and subsequently restrained for three hours, during which changes in their body temperature are monitored rectally. In Europe alone, more than 100,000 rabbits are used each year in the RPT,²⁶² even though it has never been formally validated for its relevance to humans and its results can vary depending on the animal's stress level. There are also differences in pyrogen sensitivity among species, and the test is incompatible with certain drug classes.²⁶³

The Limulus amoebocyte lysate test (LAL), also called the bacterial endotoxins test, detects only bacterial endotoxins and no other pyrogens. It requires the use of haemolymph from captured horseshoe crabs. After the biomedical bleeding process, up to 30 per cent of the crabs die. Those who live are less likely to survive in the wild.²⁶⁴ A synthetic version of the LAL, in which the haemolymph is replaced by a recombinant reagent (the recombinant factor C assay), is available, but sensitivity is still limited to bacterial endotoxins.

Since 2010, the monocyte activation test (MAT) has been validated and included in the *European Pharmacopoeia (Ph Eur)* as a test for assessing pyrogen contamination.²⁶⁵ It mimics the innate human fever response *in vitro*, exposing human whole blood or isolated human monocytes to test articles followed by tests to detect pro-inflammatory cytokines released during exposure, and it is compatible with drugs and medical devices.²⁶⁶ It avoids the aforementioned problems with the RPT and LAL tests, and case studies document



instances in which the MAT detected pyrogen contamination in products that had passed the RPT and LAL but caused fever in human patients.²⁶⁷

Regulators in the EU, India, and the US accept the MAT, and the pharmacopoeias used in these regions all allow its use following product-specific validation. Nevertheless, animal tests are still used, despite their well-documented limitations.²⁶⁸ To eliminate the use of animals in pyrogen tests, regulatory authorities and standards organisations must make increased effort to integrate and harmonise a preference for the MAT in international testing requirements and to encourage drug and device manufacturers to use and submit data from the MAT in their product dossiers. In September 2018, participants at a workshop organised by the PETA Science Consortium International and NICEATM discussed non-animal approaches to medical device pyrogen testing. Publication of the resulting report is forthcoming.²⁶⁹

Following a survey of pyrogen test users, the European Directorate for the Quality of Medicines & HealthCare (EDQM) revised the *Ph Eur* general chapter on the MAT to improve the method's usability and to emphasise that it is considered a replacement for animal-based pyrogen tests.^{270,271} This endorsement is repeated in statements from the European Medicines Agency.²⁷² The International Organization for Standardization (ISO) is revising its guidance to allow use of the MAT when evaluating medical device pyrogen contamination, but the revision process has moved slowly.²⁷³ In the 8th edition of *Indian Pharmacopoeia*, the Indian Pharmacopoeia Commission revised the pyrogen testing general chapter, introduced the monograph on MAT, and replaced the RPT with the LAL.²⁷⁴ Drug and device manufacturers report discomfort with regulatory ambiguity about the applicability of the MAT as a stand-alone pyrogen test, and the RPT and LAL will continue to be used until this is resolved.

Tobacco and E-Cigarette Testing

Recommendation: Immediately eliminate the use of animals for developing and testing tobacco and e-cigarette products

Around the world, animals are used to test existing tobacco products and for the development of new ones, such as e-cigarettes. In such tests, rats may be squeezed into narrow tubes, immobilised, and forced to inhale toxic substances for up to six hours each day for several years.

The European Commission Scientific Committee on Health, Environmental and Emerging Risks (SCHEER) appropriately states that, in light of the European Union (EU) policy banning animal studies for chemicals to be used in voluntary products such as cosmetics, animal studies are not endorsed to assess the safety of tobacco additives.²⁷⁵ In addition, Belgium, Estonia, Germany, Slovakia, and the United Kingdom already prohibit animal tests for tobacco products because of ethical concerns.^{276,277,278,279,280}

The hazard assessment of tobacco products increasingly employs innovative non-animal methods, including the exposure of cell and tissue cultures to whole cigarette smoke or e-cigarette vapour at the air–liquid interface, cell transformation assays (CTAs), and genomic analyses.^{281,282,283,284} These techniques have been used to investigate cytotoxicity, genotoxicity, inflammation, and gene expression. They are more relevant to actual human exposure than are animal tests that have historically under-predicted the hazards of tobacco.



Genotoxicity

Recommendation: In light of existing non-animal methods and WoE approaches, the use of animals in genotoxicity testing can be dramatically reduced

Currently, the assessment of genotoxicity typically follows a step-wise approach, beginning with a core battery of *in vitro* tests that may be followed up by *in vivo* studies if the *in vitro* results are positive. The major endpoints that must be evaluated are gene mutation, structural chromosomal aberrations, and numerical chromosomal aberrations. In its “Strategy to Avoid and Reduce Animal Use in Genotoxicity Testing”, EURL ECVAM recommends the Ames test to identify gene mutations, combined with the *in vitro* micronucleus test to identify both structural and numerical chromosomal aberrations.²⁸⁵ If a substance produces negative results in both tests, it can be categorised as having no genotoxic potential and no further testing is indicated. If a substance produces positive results in either test, certain regulatory applications currently specify *in vivo* tests as the next step. This is because while *in vitro* tests are highly sensitive, producing false negative results at a low rate, they are less specific, producing false positive results at a higher rate. The number of false positive results can be reduced by using p53-competent human cells, evaluating cytotoxicity based on cell proliferation, and testing at reduced maximum concentrations.²⁸⁶ These considerations have been incorporated into recent revisions of OECD test guidelines.

- **OECD Test No 490: *In Vitro* Mammalian Cell Gene Mutation Tests Using the Thymidine Kinase Gene.** Two distinct assays can be used to detect gene mutations induced by chemical substances.
- **OECD Test No 487: *In Vitro* Micronucleus Test.** This test can be used to detect micronuclei in the cytoplasm of interphase cells that have undergone cell division during or after exposure to the test substance.
- **OECD Test No 471: Bacterial Reverse Mutation Test.** This test uses amino acid–requiring *Salmonella typhimurium* and *Escherichia coli* to detect point mutations by base substitutions or frameshifts.
- **OECD Test No 473: *In Vitro* Mammalian Chromosomal Aberration Test.** This test identifies chemical substances that cause structural chromosomal aberrations in cultured mammalian somatic cells.
- **OECD Test No 476: *In Vitro* Mammalian Cell Gene Mutation Test Using *Hrpt* and *xrpt* Genes.** These tests can detect gene mutations induced by chemicals.

To undertake a better assessment of the genotoxic potential of substances that produce positive results in the core battery, additional *in vitro* tests can be used in place of *in vivo* tests. In its “Notes of Guidance for the Testing of Cosmetic Ingredients and Their Safety Evaluation”, the European Commission’s Scientific Committee on Consumer Safety (SCCS) recommends using a micronucleus test on 3-dimensional (3-D) reconstructed human skin or a comet assay either in mammalian cells or on 3-D reconstructed human skin.²⁸⁷ However, negative results produced in these alternative tests do not necessarily rule out genotoxic potential. In such cases, expert judgement as well as mechanistic investigations may be helpful in evaluating the WoE. For example, *in vitro* toxicogenomics-based tests can provide information on the mode of action of potential genotoxicants by identifying global gene expression changes.

Validation studies of the micronucleus test and comet assay on 3-D reconstructed human skin are currently being conducted and thus providing further opportunities for phasing out the use of animals for genotoxicity testing.²⁸⁸



Acute Systemic Toxicity

Recommendation: In light of existing non-animal methods and weight-of-evidence (WoE) approaches, the use of animals for acute systemic toxicity testing can be dramatically reduced

To determine the danger of acute exposure to a product or chemical, a substance is administered to animals in extremely high doses through force-feeding (oral), skin contact (dermal), and/or forced inhalation. In this test, the dose at which half the animals would be killed – called the lethal dose 50 (LD₅₀), or lethal concentration 50 (LC₅₀) for inhalation testing – is calculated. Animals may endure severe abdominal pain, diarrhoea, convulsions, seizures, paralysis, or bleeding from the nose, mouth, or genitals before they ultimately die or are killed. The LD₅₀ and its adaptations have never been scientifically validated, and their accuracy in predicting chemical effects in humans remains questioned. One analysis of the variability of the acute oral toxicity animal test showed that there is 78 or 74 per cent accuracy in obtaining the same EPA or GHS classification, respectively, if the same chemical is tested more than once.²⁸⁹

Regulatory authorities may issue waivers for acute toxicity testing in animals if certain criteria are met. The OECD has published guidance for waiving or bridging acute toxicity testing,²⁹⁰ and the EPA has published similar guidance for pesticides and pesticide products.²⁹¹ This includes the use of existing data for read-across and the consideration of the physicochemical properties of the test substance.

Acute Oral Toxicity

NICEATM and ICCVAM organised a project to develop predictive models for acute oral systemic toxicity.²⁹² The outcome was consensus quantitative structure-activity relationship (QSAR) models for the prediction of acute oral toxicity to meet various regulatory needs, which were presented at an April 2018 workshop.²⁹³ The models are being optimised and will be posted on the NICEATM and EPA websites.

EURL ECVAM's strategy to replace, reduce, and refine the use of animals in the assessment of acute mammalian systemic toxicity focuses on the *in vitro* 3T3 neutral red uptake (NRU) cytotoxicity assay, which can be used in a WoE approach to support the identification of non-classified substances.²⁹⁴ *In vitro* tests such as the 3T3 NRU and normal human keratinocyte assays that measure basal cytotoxicity can also be useful in determining starting doses in animal tests. EURL ECVAM is currently working to improve confidence in the 3T3 NRU through the use of QSARs and by accounting for target organ information and the lack of metabolism in 3T3 cells.^{295,296,297} In addition, it has proposed an approach to identifying non-classified substances using information from 28-day repeated dose toxicity studies, thereby avoiding acute systemic toxicity testing.²⁹⁸

In its "Guidance on Information Requirements and Chemical Safety Assessment", the European Chemicals Agency (ECHA) advises that an *in vivo* acute oral toxicity study can potentially be avoided if a registrant has relevant data, which are used in a WoE approach.²⁹⁹ In cases in which the WoE adaptation leads to the assumption of low/no expected acute oral toxicity (>2000 mg/kg bw/d), the registrant can avoid unnecessary animal testing pursuant to REACH Articles 13(1) and 25(1).³⁰⁰

Acute Dermal Toxicity

Testing by the dermal route of exposure can be waived if data on oral toxicity are available. The EPA and NICEATM analysed the relative contributions of data from acute oral and dermal toxicity tests to pesticide hazard classification and labelling. Finding that the dermal data provided little to no added value in regulatory decision-making, the EPA published guidance allowing registrants to submit waiver requests.³⁰¹ In addition, dermal studies can be waived for substances that are non-classified by the oral route and not absorbed dermally. The European Commission recently amended REACH Annex VIII so that substances that are non-classified by the oral route do not require dermal data.



Acute Inhalation Toxicity

Testing by the inhalation route of exposure can be waived if substances demonstrate low volatility and are not aerosolised or otherwise made respirable under conditions of use. In addition, promising research efforts are underway to develop non-animal methods for acute inhalation toxicity.^{302,303} A recent series of webinars (ThePSCI.eu/inhalation-webinars) and a workshop hosted by the PETA Science Consortium International and NICEATM presented several approaches that could eventually replace animal testing for this endpoint.^{304,305}

Carcinogenicity

Recommendation: In light of existing non-animal methods and WoE approaches, the use of animals in carcinogenicity testing can be dramatically reduced

The carcinogenicity study currently requires that testing be conducted on rats (or other species when justified) for the majority of their life (up to two years for rodents). The test requires the use of 50 animals of each sex per dose, and a minimum of three doses and control for each study, which equates to a minimum total of 400 rats or mice per chemical. Some chemical regulation requires carcinogenicity tests on both rats and mice (OECD Test No 451 and No 453), meaning approximately 1,000 animals are used to meet toxicity testing requirements for one chemical.

While carcinogenicity studies are still routinely conducted, the test has been under scientific scrutiny since the early 1970s for its lack of reproducibility³⁰⁶ and its inability to predict human outcomes.³⁰⁷ Several reviews have been conducted over the past three decades to highlight the overall lack of reliability in the rodent cancer bioassays.³⁰⁸⁻³²⁵ There are two assumptions that underlay these bioassays: (1) rodent carcinogens are human carcinogens, and (2) high-dose chemical exposure in rodents is indicative of an environmentally relevant dose. Both have been proved incorrect by 50 years' worth of carcinogenicity data.³²⁶

In an assessment of 202 pesticide evaluations from the EU review programme, it has been demonstrated that the mouse carcinogenicity study contributed little or nothing to either derivation of an acceptable daily intake for assessment of chronic risk to humans or hazard classification for labelling purposes.³²⁷ In terms of pesticide approvals, the authors showed that the mouse study did not influence a single outcome. An additional study reported that data collected from 182 pharmaceutical chemicals show that little value is gained from the carcinogenicity study when compounds lack certain histopathologic risk factors, hormonal perturbation, and positive genetic toxicity results.³²⁸ This study highlights the opportunity to use a WoE approach to determine whether the carcinogenicity study can be waived for chemicals that meet certain criteria.^{329,330}

Additionally, *in vitro* CTAs recapitulate a multistage process that closely models *in vivo* carcinogenesis, and they have the potential to detect both genotoxic and non-genotoxic carcinogens. In its recommendation on the CTA based on the Bhas 42 cell line, EURL ECVAM notes that information on the transforming potential of substances generated by CTAs may be sufficient for decision-making.³³¹ In a validation study, the Bhas 42 CTA was tested with 98 substances, including carcinogens and non-carcinogens; for predicting carcinogenicity, its performance was equivalent or superior to conventional genotoxicity assays.^{332,333} As the protocols were transferable and reproducible between laboratories, they are recommended for routine use. In addition, because the Bhas 42 CTA is based on a cell line rather than primary cells, no animals are required.

In its guidance document on the Bhas 42 CTA, the OECD recommends that it be used as part of a testing strategy rather than as a stand-alone assay. When combined with other information, such as genotoxicity data, structure-activity analysis, and toxicokinetic information, CTAs in general – and the Bhas 42 CTA specifically – can contribute to the assessment of carcinogenic potential and may provide an alternative to the use of *in vivo* testing.^{334,335}



The structural alerts (SAs) rule base has recently been expanded with a large number of new SAs for non-genotoxic carcinogenicity and has been incorporated into the OECD QSAR Toolbox version 4.4.1.³³⁶ Additionally, the EPA has published a computer model, OncoLogic™, to evaluate chemicals for carcinogenic potential,³³⁷ and commercial options are also available, such as the Lhasa Carcinogenicity Database, MultiCASE, UL Cheminformatics, and Leadscape. Ultimately, the identification of DNA-reactive chemicals with the Ames test or genotoxic SAs can potentially be combined with the identification of non-genotoxic carcinogens using non-genotoxic SAs, leaving CTAs to model most of what is left unexplained in a WoE approach. There is an expert group at the OECD working to generate an IATA for non-genotoxic carcinogens.³³⁸

Endocrine Disruption

Recommendation: In light of existing non-animal methods and WoE approaches, the use of animals in endocrine testing can be dramatically reduced

In the 1990s, the EPA's Endocrine Disruptor Screening Program (EDSP) was established to screen approximately 10,000 chemicals for their effects on the human body's hormone systems and on wildlife. The programme has the potential to use millions of animals in testing. In order to reduce the number of animals used and rapidly and effectively screen such a high volume of chemicals, the agency has turned to several non-animal methods.

Its Toxicity Forecaster (ToxCast) ranks and prioritises chemicals using more than 700 high-throughput screening assays, which cover a variety of high-level cell responses and approximately 300 signalling pathways, as well as computational toxicology approaches. Data have already been generated on thousands of chemicals of interest to the EPA.

ToxCast is being used successfully for these purposes. After a comparative study of ToxCast oestrogen pathway assay results and uterotrophic assay results,³³⁹ the EPA announced that it will accept ToxCast data as an alternative to at least one animal test – the uterotrophic assay – that screens for effects on the oestrogen pathway.³⁴⁰ The agency is working to finalise the use of ToxCast data as an alternative to the rat Hershberger assay, which screens for effects on the androgen pathway.

The thyroid pathway has more complexity than either the oestrogen or the androgen pathways. Although ToxCast is showing promising results, more research is required in this area, and use of this system to replace tests on animals is still several years away. There are complementary efforts at the international level. An OECD scoping document for *in vitro* approaches to the thyroid signalling pathway was published in 2014.³⁴¹ The OECD Molecular Screening Group's *in vitro* Thyroid Subgroup is working to bring relevant *in vitro* thyroid assays to the attention of OECD member countries and provide recommendations for their development and use. More research and development is needed to obtain non-animal approaches to screening for thyroid disruption potential in humans and wildlife populations.



Repeat Dose, Reproductive, and Developmental Toxicity

Recommendation: Immediately fund and support the development of innovative non-animal methods for assessing repeat dose, reproductive, and developmental toxicity

In repeat dose toxicity studies, animals are exposed repeatedly to substances for one to three months in order to measure the effects of multiple chemical exposures. Chemicals are usually administered to animals using an oral gavage.

Reproductive toxicity studies measure a chemical's effects on reproductive organs and fertility, while developmental toxicity studies measure a chemical's effect on developing offspring during pregnancy.

While the assessment of repeat dose toxicity is a standard requirement in human safety evaluation, no non-animal methods are currently accepted for regulatory purposes. The European Commission's Detection of Endpoints and Biomarkers of Repeated Dose Toxicity Using *In Vitro* Systems (DETECTIVE) project was one of the six research projects funded under the Safety Evaluation Ultimately Replacing Animal Testing (SEURAT-1) cluster umbrella. The aim of the project was to set up a screening pipeline of high-content, high-throughput, and "-omics" technology to identify and investigate human biomarkers in cellular models for repeat dose *in vitro* testing. In addition, the EU-ToxRisk project integrates advancements in cell biology, -omics technology, systems biology, and computational modelling to define the complex chains of events that link chemical exposure to toxic outcome. The project focuses on repeat dose systemic toxicity and developmental and reproductive toxicity.

None of the *in vivo* methods used for testing reproductive and developmental toxicity have been validated for their relevance to humans.³⁴² There are considerable limitations surrounding the *in vivo* methods, with a predictivity of only around 60 per cent and large interspecies variations.^{343,344}

EURL ECVAM has investigated the validation of *in vitro* reproductive toxicity test methods and is leading the development of an AOP for an aspect of reproductive toxicity, i.e. PPAR γ activation leading to impaired fertility.^{345,346} The EU FP6 project, ReProTect, has also investigated possible strategies to cover the entire mammalian reproductive cycle, resulting in a series of published works.³⁴⁷ Furthermore, the ChemScreen FP7 project has been designed to generate a rapid screening system that is relatively simple and cost-effective.³⁴⁸

The EPA's National Center for Computational Toxicology is also exploring the potential for chemicals to disrupt prenatal development through the use of its virtual embryo model, v-Embryo™, which integrates *in vitro* and *in silico* modelling approaches.³⁴⁹ While the field is gradually moving towards IATA strategies in order to cover the majority of possible mechanisms, much more research is required.

Aquatic Toxicity Testing

Recommendation: In light of existing non-animal methods and WoE approaches, the use of animals in aquatic toxicity testing can be substantially reduced

Aquatic toxicity tests are conducted to measure the effects of chemicals on the environment and wildlife. In 2011, nearly 180,000 fish were used for toxicological and other safety assessments in the EU.³⁵⁰ As assessment of aquatic toxicity is required in various regulatory frameworks, strategies to replace testing using aquatic animals are urgently needed.



Several non-animal alternatives to the use of live animals are available now. In 2018, two OECD test guidelines for *in vitro* intrinsic clearance using cryopreserved rainbow trout hepatocytes³⁵¹ and rainbow trout liver S9 subcellular fraction³⁵² and an associated guidance document³⁵³ were adopted. Liver intrinsic clearance values can be used either for physiologically based toxicokinetic models for fish bioaccumulation or for extrapolation to an *in vivo* biotransformation rate. The latter can be used with *in silico* models for prediction of bioconcentration factors. Thus, although these test guidelines require the use of fish to obtain primary cells, they can contribute to replacing the use of fish in OECD Test No 305 on bioaccumulation in fish.³⁵⁴

To reduce the number of juvenile and adult fish used in acute aquatic toxicity testing, ECHA will accept data from the Fish Embryo Acute Toxicity Test³⁵⁵ in a WoE approach³⁵⁶ on a case-by-case basis.

A promising cytotoxicity assay using the RTgill-W1 cell line has been developed for the determination of acute aquatic toxicity testing.³⁵⁷ This *in vitro* assay has the potential to reduce or even replace the use of fish in the acute fish toxicity test.³⁵⁸ A ring trial on transferability and both intra- and inter-laboratory reproducibility of the assay organised by the Swiss Federal Institute of Aquatic Science and Technology has been completed,³⁵⁹ and a Standard Operating Procedure has been adopted by the ISO.³⁶⁰ A project to develop an OECD test guideline on the fish cell line acute toxicity test using the RTgill-W1 cell line assay has been included in the work plan of the OECD Test Guideline Programme in 2019. Adoption of the test guideline is planned for April 2020.



Laboratory Production Methods

Detailed below are opportunities to end the use of animal-derived products for scientific or medical purposes and to reduce significantly the use of animals for the production of drugs and vaccines.

Biologic Drugs

Recommendation: In light of existing non-animal methods and WoE approaches, the use of animals can be dramatically reduced in the production and evaluation of biologic drugs

Many vaccines and other biologic drugs are produced or tested for quality, identity, safety, and efficacy in experiments that require the use of large numbers of animals. These procedures often cause severe suffering before the animals die or are killed. New technology has enabled the production and testing of biologics without animals, but experience has shown that validation and regulatory acceptance of these methods have not guaranteed their use.^{361,362,363,364} Activities intended to phase out the use of animals in this context must ensure that regulatory authorities and industry commit to (1) making the transition to non-animal biologic production platforms, (2) ensuring that available non-animal methods are consistently used in place of animal-based tests, and (3) developing non-animal replacements for quality, identity, safety, and efficacy tests for all biologics.

Production platforms are available that replace animal-derived substances with recombinant, cell-based equivalents. Antitoxins, for example, have been produced historically by hyper-immunising horses and other large mammals and isolating the resulting immunoglobulins from animals' blood. These animal-derived immunoglobulins can be replaced with recombinant human antitoxin expressed in cell culture. Several recombinant antitoxins have been licensed for marketing, and more are in development.³⁶⁵ With adequate funding and support from regulators, all biologics of animal origin, including antibodies (described above), can and should be replaced in a similar fashion in order to resolve issues inherent in using antibodies derived from animals.

Non-animal quality tests are available, but no formal mechanism exists to ensure that barriers to their implementation are resolved in a timely manner.³⁶⁶ In some instances, manufacturers report difficulty meeting the technical criteria for using validated non-animal methods (as with the *in vitro* *Leptospira* vaccine potency tests).³⁶⁷ In other instances, international regulators have yet to agree on technical criteria for using non-animal methods (as with the *in vitro* rabies vaccine potency test).³⁶⁸ In the absence of formal oversight of the implementation process, these barriers are left to be resolved informally through workshops and decentralised problem-solving by consortia of interested parties. For companies seeking to use validated non-animal methods, this approach is prohibitively expensive and slow. As a consequence, industry adoption of non-animal methods remains limited, despite the documented reduction in animal use when they are implemented successfully.³⁶⁹ Additional barriers to the implementation of currently available alternative tests have been discussed at length in the literature for erysipelas, clostridial, and tetanus vaccines and for recombinant therapeutic hormones.³⁷⁰ Accelerating and standardising processes that facilitate the use of these existing replacement methods is crucial.

Regulatory leadership will ensure international regulatory and industrial coordination on best practices to remove these barriers. Regulatory authorities must establish harmonised manufacturing consistency



requirements, as tightly controlled manufacturing consistency policies are the foundation of many animal-replacement strategies.^{371,372}

Antibody Production

Recommendation: Immediately eliminate the use of animal-derived antibodies in scientific applications

Affinity reagents such as antibodies are essential tools used in research to bind to a molecule to identify it or influence its activity. Every year, tens of thousands of animals are injected with viruses, bacteria, or other foreign substances and then killed for the antibodies that their bodies produce in response. Animals used in antibody production are subjected to a number of invasive and painful procedures, including antigen injection and repeated blood or ascites collection, before being killed. In the ascites method of antibody production, animals have been reported to be unable to eat, walk, or breathe properly. A number of countries, such as Australia, Canada, Germany, the Netherlands, Switzerland, and the United Kingdom, have restricted or banned the production of antibodies via the ascites method because of animal-welfare concerns.³⁷³

Growing concern about the lack of quality and reproducibility of animal-derived antibodies, which often show poor specificity or fail to recognise their targets, is also evident in the literature. In a February 2015 *Nature* commentary, 109 academic and industry scientists joined Andrew Bradbury of the Los Alamos National Laboratory in the US and Andreas Plückthun, head of the Department of Biochemistry at the University of Zurich, to call for an international shift to the use of recombinant antibodies for reasons that include increased reliability and reduced lot-to-lot variability in affinity reagents.³⁷⁴ Bradbury and Plückthun note that they believe that poorly characterised antibodies were in large part to blame in a study in which the scientific results of only six out of 53 landmark preclinical studies could be replicated. In addition, a May 2015 *Nature* news feature reports that antibodies may be the laboratory tool most commonly contributing to the “reproducibility crisis”.³⁷⁵ Furthermore, a systematic analysis of 185 commercially available hybridoma monoclonal antibodies found that one-third were not reliably monospecific, and the authors recommended replacing the use of animal-derived monoclonal antibodies with sequence-defined recombinant antibodies as a straightforward and cost-effective solution to this serious problem.³⁷⁶ This issue is not limited to monoclonal antibodies. Because only 0.5 to 5 per cent of the antibodies in a polyclonal reagent bind to their intended target, and polyclonal reagents have significant batch-to-batch variation, in 2015, 111 academic and industry scientists called for polyclonal antibodies to be phased out of research completely.³⁷⁷

In addition to the lack of scientific reliability and the animal-welfare concerns, there are significant economic issues related to using animal-derived antibodies. It is estimated that \$800 million is wasted annually worldwide on unreliable antibodies.³⁷⁸ Thus, there are potential cost savings associated with the more reproducible research that would result from using higher-quality affinity reagents.

Non-animal affinity reagents, such as recombinant antibodies and aptamers, can be used in all applications in which traditional antibodies are used, including in basic research, regulatory testing, and clinical applications. They are commercially available and, with appropriate resources, can be developed by researchers in their own laboratories.^{379,380} The numerous scientific advantages of non-animal affinity reagents over animal-derived antibodies include high affinity and specificity, shorter generation time, reduced immunogenicity, the ability to control selection conditions, and the ability to be generated against unstable, toxic, immunosuppressant, and non-immunogenic antigens.³⁸¹

International efforts have highlighted the importance of a large-scale transition from animal-derived antibodies to animal-free affinity reagents. In December 2018, a working group of the Scientific Advisory Committee of EURL ECVAM reviewed the scientific validity and benefits of using animal-free technology to produce affinity



reagents, concluding that the use of animal-free affinity reagents would improve scientific reproducibility and that scientists should work towards the replacement of animal-derived antibodies.³⁸² In the U.S., experts and organizations, including NICEATM and the PETA Science Consortium International, are working to increase access to animal-free affinity reagents. In December 2019, NICEATM and the Science Consortium convened a meeting to outline a pathway to improve the quality and reproducibility of research and testing by accelerating their production and use. Steps to overcome hurdles to a comprehensive shift from animal-derived to animal-free, sequence-defined affinity reagents that were identified at the meeting are described in the article “Increasing the use of animal-free recombinant antibodies”.³⁸³ More information on sources of animal-free affinity reagents, webinars, publications, and the scientific, economic, and ethical advantages of replacing animal-derived antibodies with animal-free options is available at ThePSCI.eu/our-work/antibodies/.

An EU-wide ban on the *in vivo* production of monoclonal antibodies using the ascites method should be introduced, in line with the one that has been in place in the Netherlands for more than 20 years, and the EU should further move to eliminate the import of animal-derived monoclonal antibodies and the use of animals in the hybridoma method.³⁸⁴ In order to expedite such a ban, we recommend that member states and research funding bodies provide grant opportunities for the generation and implementation of non-animal affinity reagents.

Foetal Bovine Serum

Recommendation: Immediately eliminate the use of foetal bovine serum in scientific applications

Foetal bovine serum (FBS) is a supplement for cell culture media that provides an undefined mixture of macromolecules that function to maintain cell viability and facilitate cell metabolism, growth, proliferation, and spreading in culture. When pregnant cows are slaughtered, a large-gauge needle is used to draw the blood from the beating heart of the foetus. Because the unborn calves are not anaesthetised at the time of blood collection, they likely experience pain. It has been estimated that 600,000 litres of FBS are produced globally each year, which translates to the use of up to 1.8 million bovine foetuses for this purpose.³⁸⁵

Additionally, a number of scientific concerns are associated with the use of FBS, including batch variation leading to reproducibility issues for *in vitro* studies using FBS, the unknown composition of the serum, and the risk of contamination by animal proteins or pathogens, which is especially problematic in the manufacture of biologics for human therapies. Dutch organisations hosted workshops in 2003 and 2009 that called for the transition from FBS to non-animal serum supplements in cell culture.^{386,387} A third workshop on FBS and alternatives was held in 2016, organised by the SET Foundation and the Deutscher Tierschutzbund (German Animal Welfare Federation).³⁸⁸ The workshop report recommends increased funding and continued development of serum-free culture models and the use of serum-free media when establishing new cell lines. Because a universal chemically defined serum-free culture medium is not yet available and there is high demand for different cell types, the report recommends the use of human platelet lysate (hPL) as a replacement for FBS when a serum-free medium is not available.

Animal component-free and chemically defined serum-free media are available for some cell types. For others, researchers still need to optimise the concentration of each supplement to replace FBS. For these cell types, hPL, which is obtained from donated human platelets, contains growth factors essential for cell growth and proliferation and is a superior alternative to FBS for culturing cells.

Listings of commercially available products and FBS-free media recipes published in scientific literature are available on the Science Consortium’s website (ThePSCI.eu/fbs) and in the Fetal Calf Serum-Free Database



(<https://fcs-free.org/>). Expert presentations on replacing FBS in cell culture media while maintaining robust cell growth and cellular functions are also available at ThePSCI.eu/fbs.

Government and regulatory agencies should move expediently to restrict the production and use of FBS when non-animal media or supplements are available. They should also provide funding for the development and optimisation of non-animal, serum-free medium. For cell types in which non-animal supplement concentrations have not yet been optimised and hPL cannot be used, they should require exemptions to be obtained before FBS can be produced or used. To obtain exemptions, measures should be taken to seek non-animal alternatives, and a plan to make the transition to non-animal media or supplements should be implemented.



Scientific Advisory Capabilities of PETA Entities

The Netherlands National Committee for the Protection of Animals Used for Scientific Purposes (NCad) consulted with PETA scientists before publishing its advice report on the transition towards animal-free innovation for the Dutch government. PETA entities stand ready to offer our assistance in whatever capacity might be required.

PETA Science Consortium International e.V. promotes and funds non-animal research methods and coordinates the scientific and regulatory expertise of its members, PETA entities around the world. With an eye towards championing the best non-animal methods and reducing animal testing, the Science Consortium and its members are actively involved in the development, validation, global implementation, and harmonisation of non-animal test methods. The Science Consortium is an accredited ECHA stakeholder and a member of the EURL ECVAM Stakeholder Forum, the European Food Safety Authority, and the UK Chemicals Stakeholder Forum and regularly comments on OECD test guidelines as a member of the International Council on Animal Protection in OECD Programs (ICAPO).

The scientists who work for PETA entities have a proven track record of productively assisting many Fortune 100 corporations as well as regulatory and government agencies. This assistance includes providing expert opinions, regulatory advice, and technical support in a broad range of fields. Given the breadth and depth of our expertise, we believe that we can make a valuable contribution to developing and implementing a strategic plan for the future of biomedical research and regulatory testing.



References (Appendices)

- ¹Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. *Biostatistics*. 2018;kxx069.
- ²Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. *Nat Biotechnol*. 2014;32(1):40-51.
- ³Mak IW, Evaniew N, Ghert M. Lost in translation: Animal models and clinical trials in cancer treatment. *Am J Transl Res*. 2014;6(2):114-118.
- ⁴Ben-David U, Ha G, Tseng YY, *et al*. Patient-derived xenografts undergo mouse-specific tumor evolution. *Nat Genet*. 2017;49(11):1567-1575.
- ⁵Bernstein H, Bernstein C, Payne CM, Dvorakova K, Garewal H. Bile acids as carcinogens in human gastrointestinal cancers. *Mutat Res*. 2005;589(1):47-65.
- ⁶Setchell KD, Brown NM, Zhao X, *et al*. Soy isoflavone phase II metabolism differs between rodents and humans: Implications for the effect on breast cancer risk. *Am J Clin Nutr*. 2011;94(5):1284-1294.
- ⁷Messina M, Wu AH. Perspectives on the soy-breast cancer relation. *Am J Clin Nutr*. 2009;89(5):1673S-1679S.
- ⁸Setchell *et al*.
- ⁹Gandhi M, Nikiforov YE. Suitability of animal models for studying radiation-induced thyroid cancer in humans: Evidence from nuclear architecture. *Thyroid*. 2011;21(12):1331-1337.
- ¹⁰Logsdon CD, Arumugam T, Ramachandran V. Animal models of gastrointestinal and liver diseases. The difficulty of animal modeling of pancreatic cancer for preclinical evaluation of therapeutics. *Am J Physiol Gastrointest Liver Physiol*. 2015;309(5):G283-G291.
- ¹¹The Institution of Engineering and Technology (IET). Press release from 29 November 2017. <https://www.theiet.org/media/press-releases/press-releases-2017/29-november-2017-350-000-prize-for-portuguese-scientist-s-tissue-engineering-research-to-predict-efficacy-of-cancer-drugs/>. Published 29 November 2017. Accessed 07 May 2020.
- ¹²Pauty J, Usuba R, Cheng IG, *et al*. A vascular endothelial growth factor-dependent sprouting angiogenesis assay based on an *in vitro* human blood vessel model for the study of anti-angiogenic drugs. *EBioMedicine*. 2018;27:225-236.
- ¹³Begley S. Brain organoids get cancer, too, opening a new frontier in personalized medicine. *STAT*. <https://www.statnews.com/2017/12/01/brain-organoids-glioblastoma/>. Published 1 December 2017. Accessed 10 July 2018.
- ¹⁴Ozcelikkale A, Shin K, Noe-Kim V, *et al*. Differential response to doxorubicin in breast cancer subtypes simulated by a microfluidic tumor model. *J Control Release*. 2017;266:129-139.
- ¹⁵CELLINK. CELLINK featured in Business Insider: Sweden's hottest biotech startup is now 3D printing tumors to help cure cancer. <https://cellink.com/cellink-featured-business-insider-swedens-hottest-biotech-startup-now-3d-printing-tumors-help-cure-cancer/>. Published 10 January 2018. Accessed 20 May 2019.
- ¹⁶Shain AH, Joseph NM, Yu R, *et al*. Genomic and transcriptomic analysis reveals incremental disruption of key signaling pathways during melanoma evolution. *Cancer Cell*. 2018;34(1):45-55.
- ¹⁷Cimons M, Getlin J, Maugh II TH. Cancer drugs face long road from mice to men. *Los Angeles Times*. <http://articles.latimes.com/1998/may/06/news/mn-46795>. Published 6 May 1998. Accessed 11 July 2018.
- ¹⁸Verma M. Personalized medicine and cancer. *J Pers Med*. 2012;2(1):1-14.
- ¹⁹Gintant G, Sager PT, Stockbridge N. Evolution of strategies to improve preclinical cardiac safety testing. *Nat Rev Drug Discov*. 2016;15(7):457-471.
- ²⁰del Álamo JC, Lemons D, Serrano R, *et al*. High throughput physiological screening of iPSC-derived cardiomyocytes for drug development. *Biochim Biophys Acta*. 2016;1836(7B):1717-1727.
- ²¹*Ibid*.
- ²²Gintant *et al*.
- ²³Milani-Nejad N, Janssen PM. Small and large animal models in cardiac contraction research: Advantages and disadvantages. *Pharmacol Ther*. 2014;141(3):235-249.
- ²⁴*Ibid*.
- ²⁵Barter P, Rye KA. Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now? *Trends Pharmacol Sci*. 2011;32(12):694-699.
- ²⁶Chandrasekera PC, Pippin JJ. The human subject: An integrative animal model for 21st century heart failure research. *Am J Transl Res*. 2015;7(9):1636-1647.
- ²⁷Novoheart Holdings Inc. Novoheart strengthens North American presence opening new R&D location at the world-class Cove Facility, UC Irvine, California. Marketwired.com. <http://www.marketwired.com/press-release/novoheart-strengthens-north-american-presence-opening-new-r-d-location-world-class-cove-tsx-venture-nvh-2238284.htm>. Published 25 October 2017. Accessed 11 July 2018.
- ²⁸Menon NV, Tay HM, Pang KT, *et al*. A tunable microfluidic 3D stenosis model to study leukocyte-endothelial interactions in atherosclerosis. *APL Bioengineering*. 2018;2:016103.



- ²⁹Schiller B. This human heart-on-a-chip lets us test drugs on actual human tissue – not animals. FastCompany.com. <https://www.fastcompany.com/40518390/this-human-heart-on-a-chip-lets-us-test-drugs-on-actual-human-tissue-not-animals>. Published 22 January 2018. Accessed 11 July 2018.
- ³⁰Gaudin S. Engineering diseased blood vessels to more accurately test new medications. Worcester Polytechnic Institute. <https://www.wpi.edu/news/engineering-diseased-blood-vessels-more-accurately-test-new-medications>. Published 7 June 2018. Accessed 11 July 2018.
- ³¹Ibid.
- ³²Savchenko A, Cherkas V, Liu C, et al. Graphene biointerfaces for optical stimulation of cells. *Sci Adv*. 2018;4(5):eaat0351.
- ³³Gershlak JR, Hernandez S, Fontana G, et al. Crossing kingdoms: Using decellularized plants as perfusable tissue engineering scaffolds. *Biomaterials*. 2017;125:13-22.
- ³⁴Hoang P, Wang J, Conklin BR, Healy KE, Ma Z. Generation of spatial-patterned early-developing cardiac organoids using human pluripotent stem cells. *Nat Protoc*. 2018;13(4):723-737.
- ³⁵Alongi P. Cardiovascular treatments could reach patients faster with new Clemson University research. The Newsstand, Clemson University. <http://newsstand.clemson.edu/mediarelations/cardiovascular-treatments-could-reach-patients-faster-with-new-clemson-university-research/>. Published 30 April 2018. Accessed 11 July 2018.
- ³⁶Passini E, Britton OJ, Lu HR, et al. Human *in silico* drug trials demonstrate higher accuracy than animal models in predicting clinical pro-arrhythmic cardiotoxicity. *Front Physiol*. 2017;8:668.
- ³⁷Chandrasekera PC, Pippin JJ. Of rodents and men: Species-specific glucose regulation and type 2 diabetes research. *ALTEX*. 2014;31(2):157-176.
- ³⁸Ibid.
- ³⁹Bunner AE, Chandrasekera PC, Barnard ND. Knockout mouse models of insulin signaling: Relevance past and future. *World J Diabetes*. 2014;5(2):146-159.
- ⁴⁰Chandrasekera, Pippin 2014.
- ⁴¹Bunner et al.
- ⁴²Ibid.
- ⁴³Wang B, Chandrasekera PC, Pippin JJ. Leptin- and leptin receptor-deficient rodent models: Relevance for human type 2 diabetes. *Curr Diabetes Rev*. 2014;10(2):131-145.
- ⁴⁴Bunner et al.
- ⁴⁵Wang et al.
- ⁴⁶Chandrasekera, Pippin 2014.
- ⁴⁷Ali Z, Chandrasekera PC, Pippin JJ. Animal research for type 2 diabetes mellitus, its limited translation for clinical benefit, and the way forward. *Altern Lab Anim*. 2018;46(1):1-10.
- ⁴⁸Physicians Committee for Responsible Medicine. Using skin cells to model diabetes in humans. <https://www.pcrm.org/news/ethical-science/using-skin-cells-model-diabetes-humans>. Published 20 November 2017. 20 November 2018.
- ⁴⁹Kovatchev BP, Breton M, Man CD, Cobelli C. *In silico* preclinical trials: A proof of concept in closed-loop control of type 1 diabetes. *J Diabetes Sci Technol*. 2009;3(1):44-55.
- ⁵⁰Ali et al.
- ⁵¹Haigwood NL. Update on animal models for HIV research. *Eur J Immunol*. 2009;39(8):1994-1999.
- ⁵²Antony JM, MacDonald KS. A critical analysis of the cynomolgus macaque, *Macaca fascicularis*, as a model to test HIV-1/SIV vaccine efficacy. *Vaccine*. 2015;33(27):3073-3083.
- ⁵³Centlivre M, Combadière B. New challenges in modern vaccinology. *BMC Immunol*. 2015;16:18.
- ⁵⁴Haigwood.
- ⁵⁵Jülg B, Barouch DH. Novel immunological strategies for HIV-1 eradication. *J Virus Erad*. 2015;1(4):232-236.
- ⁵⁶Girard M, Habel A, Chanel C. New prospects for the development of a vaccine against human immunodeficiency virus type 1. An overview. *C R Acad Sci III*. 1999;322(11):959-966.
- ⁵⁷Kumar N, Chahroudi A, Silvestri G. Animal models to achieve an HIV cure. *Curr Opin HIV AIDS*. 2016;11(4):432-441.
- ⁵⁸Nguyen DH, Hurtado-Ziola N, Gagneux P, Varki A. Loss of Siglec expression on T lymphocytes during human evolution. *Proc Natl Acad Sci U S A*. 2006;103(20):7765-7770.
- ⁵⁹Song B, Javanbakht H, Perron M, Park DH, Stremlau M, Sodroski J. Retrovirus restriction by TRIM5alpha variants from Old World and New World primates. *J Virol*. 2005;79(7):3930-3937.
- ⁶⁰Gilad Y, Oshlack A, Smyth GK, Speed TP, White KP. Expression profiling in primates reveals a rapid evolution of human transcription factors. *Nature*. 2006;440(7081):242-245.
- ⁶¹Akhtar A. The flaws and human harms of animal experimentation. *Camb Q Healthc Ethics*. 2015;24(4):407-419.
- ⁶²Haigwood.
- ⁶³Antony, MacDonald.
- ⁶⁴Kumar et al.
- ⁶⁵Matthews H, Hanison J, Nirmalan N. "Omics"-informed drug and biomarker discovery: Opportunities, challenges and future perspectives. *Proteomes*. 2016;4(3):28.
- ⁶⁶Rao M, Alving CR. Adjuvants for HIV vaccines. *Curr Opin HIV AIDS*. 2016;11(6):585-592.
- ⁶⁷Bailey J. An assessment of the role of chimpanzees in AIDS vaccine research. *Altern Lab Anim*. 2008;36(4):381-428.
- ⁶⁸Galperin M, Farenc C, Mukhopadhyay M, et al. CD4+ T cell-mediated HLA class II cross-restriction in HIV controllers. *Sci Immunol*. 2018;3(24):eaat0687.
- ⁶⁹Ledford H. Translational research: The full cycle. *Nature*. 2008;453(7197):843-845.



- ⁷⁰Tonks A. Quest for the AIDS vaccine. *BMJ*. 2007;334:1346-1348.
- ⁷¹Mestas J, Hughes CCW. Of mice and not men: Differences between mouse and human immunology. *J Immunol*. 2004;172(5):2731-2738.
- ⁷²Zschaler J, Schlorke D, Arhhold J. Difference in innate immune response between man and mouse. *Crit Rev Immunol*. 2014;34(5):433-454.
- ⁷³Mestas, Hughes.
- ⁷⁴Ibid.
- ⁷⁵Zschaler *et al*.
- ⁷⁶Leist M, Hartung T. Inflammatory findings on species extrapolations: Humans are definitely no 70-kg mice. *Arch Toxicol*. 2013;87(4):563-567.
- ⁷⁷Bouvier NM, Lowen AC. Animal models for influenza virus pathogenesis and transmission. *Viruses*. 2010;2(8):1530-1563.
- ⁷⁸Staeheli P, Grob R, Meier E, Sutcliffe JG, Haller O. Influenza virus-susceptible mice carry Mx genes with a large deletion or a nonsense mutation. *Mol Cell Biol*. 1988;8(10):4518-4523.
- ⁷⁹Tumpey TM, Szretter KJ, Van Hoeven N, *et al*. The Mx1 gene protects mice against the pandemic 1918 and highly lethal human H5N1 influenza viruses. *J Virol*. 2007;81(19):10818-10821.
- ⁸⁰Bouvier NM, Lowen AC. Animal models for influenza virus pathogenesis and transmission. *Viruses*. 2010;2(8):1530-1563.
- ⁸¹Ibricevic A, Pekosz A, Walter MJ, *et al*. Influenza virus receptor specificity and cell tropism in mouse and human airway epithelial cells. *J Virol*. 2006;80(15):7469-7480.
- ⁸²Majde JA, Bohnet SG, Ellis GA, *et al*. Detection of mouse-adapted human influenza virus in the olfactory bulbs of mice within hours after intranasal infection. *J Neurovirol*. 2007;13(5):399-409.
- ⁸³Bouvier, Lowen.
- ⁸⁴Lowen AC, Mubareka S, Tumpey TM, García-Sastre A, Palese P. The guinea pig as a transmission model for human influenza viruses. *Proc Natl Acad Sci U S A*. 2006;103(26):9988-9992.
- ⁸⁵Wu HJ, Wu E. The role of gut microbiota in immune homeostasis and autoimmunity. *Gut Microbes*. 2012;3(1):4-14.
- ⁸⁶Nguyen TLA, Vieira-Silva S, Liston A, Raes J. How informative is the mouse for human gut microbiota research? *Dis Model Mech*. 2015;8(1):1-16.
- ⁸⁷Cappuccio A, Tieri P, Castiglione F. Multiscale modeling in immunology: A review. *Brief Bioinform*. 2016;17(3):408-418.
- ⁸⁸Brown JA, Codreanu SG, Shi M, *et al*. Metabolic consequences of inflammatory disruption of the blood-brain barrier in an organ-on-chip model of the human neurovascular unit. *J Neuroinflammation*. 2016;13(1):306.
- ⁸⁹Ehling P, Meuth P, Eichinger P, *et al*. Human T cells in silico: Modelling their electrophysiological behaviour in health and disease. *J Theor Biol*. 2016;404:236-250.
- ⁹⁰Day JD, Metes DM, Vodovotz Y. Mathematical modeling of early cellular innate and adaptive immune responses to ischemia/reperfusion injury and solid organ allotransplantation. *Front Immunol*. 2015;6:484.
- ⁹¹Bergers LIJC, Reijnders CMA, van den Broek LJ, *et al*. Immune-competent human skin disease models. *Drug Discov Today*. 2016;21(9):1479-1488.
- ⁹²Akhtar AZ, Pippin JJ, Sandusky CB. Animal models in spinal cord injury: A review. *Rev Neurosci*. 2008;19(1):47-60.
- ⁹³Angius D, Wang H, Spinner RJ, Gutierrez-Cotto Y, Yaszemski MJ, Windebank AJ. A systematic review of animal models used to study nerve regeneration in tissue-engineered scaffolds. *Biomaterials*. 2012;33(32):8034-8039.
- ⁹⁴Akhtar AZ, Pippin JJ, Sandusky CB. Animal studies in spinal cord injury: A systematic review of methylprednisolone. *Altern Lab Anim*. 2009;37(1):43-62.
- ⁹⁵Ibid.
- ⁹⁶Kaplan HM, Mishra P, Kohn J. The overwhelming use of rat models in nerve regeneration research may compromise designs of nerve guidance conduits for humans. *J Mater Sci Mater Med*. 2015;26(8):226.
- ⁹⁷Ibid.
- ⁹⁸Mobini S, Song YH, McCrary MW, Schmidt CE. Advances in ex vivo models and lab-on-a-chip devices for neural tissue engineering. *Biomaterials*. 2018; ahead of print.
- ⁹⁹Ibid.
- ¹⁰⁰Zhuang P, Sun AX, An J, Chua CK, Chew SY. 3D neural tissue models: From spheroids to bioprinting. *Biomaterials*. 2018;154:113-133.
- ¹⁰¹Angius *et al*.
- ¹⁰²Shrirao AB, Kung FH, Omelchenko A, *et al*. Microfluidic platforms for the study of neuronal injury in vitro. *Biotechnol Bioeng*. 2018;115(4):815-830.
- ¹⁰³Mobini *et al*.
- ¹⁰⁴Potashkin JA, Blume SR, Runkle NK. Limitations of animal models of Parkinson's disease. *Parkinsons Dis*. 2010;2011:1-7.
- ¹⁰⁵Cummings JL, Morstorf T, Zhong K. Alzheimer's disease drug-development pipeline: Few candidates, frequent failures. *Alzheimer's Res. Ther*. 2014;6(4):1-7.
- ¹⁰⁶Pistollato F, Ohayon EL, Lam A, *et al*. Alzheimer disease research in the 21st century: Past and current failures, new perspectives and funding priorities. *Oncotarget*. 2016;7(26):38999-39016.
- ¹⁰⁷AstraZeneca. Update on Phase III clinical trials of lanabecestat for Alzheimer's disease. <https://www.astrazeneca.com/media-centre/press-releases/2018/update-on-phase-iii-clinical-trials-of-lanabecestat-for-alzheimers-disease-12062018.html>. Published 12 June 2018. Accessed 17 July 2018.
- ¹⁰⁸Cummings *et al*.



- ¹⁰⁹Burns TC, Li MD, Mehta S, Awad AJ, Morgan AA. Mouse models rarely mimic the transcriptome of human neurodegenerative diseases: A systematic bioinformatics-based critique of preclinical models. *Eur J Pharmacol*. 2015;759:101-117.
- ¹¹⁰Lane E, Dunnett S. Animal models of Parkinson's disease and L-dopa induced dyskinesia: How close are we to the clinic? *Psychopharmacology (Berl)*. 2008;199(3):303-312.
- ¹¹¹Ehrnhoefer DE, Butland SL, Pouladi MA, Hayden MR. Mouse models of Huntington disease: Variations on a theme. *Dis Model Mech*. 2009;2(3-4):123-129.
- ¹¹²Ibid.
- ¹¹³Benatar M. Lost in translation: Treatment trials in the SOD1 mouse and in human ALS. *Neurobiol Dis*. 2007;26(1):1-13.
- ¹¹⁴Clerc P, Lipnick S, Willett C. A look into the future of ALS research. *Drug Discov Today*. 2016;21(6):939-949.
- ¹¹⁵Menache A, Beuter A. Commentary: Lessons from the analysis of non-human primates for understanding human aging and neurodegenerative diseases. *Front Hum Neurosci*. 2016;10:33.
- ¹¹⁶Olsson IA, Hansen AK, Sandøe P. Animal welfare and the refinement of neuroscience research methods – a case study of Huntington's disease models. *Lab Anim*. 2008;42(3):277-283.
- ¹¹⁷Ibid.
- ¹¹⁸Pistollato *et al*.
- ¹¹⁹Mirbaha H, Chen D, Morazova OA, *et al*. Inert and seed-competent tau monomers suggest structural origins of aggregation. *Elife*. 2018;7:e36584.
- ¹²⁰Cope TE, Rittman T, Borchert RJ, *et al*. Tau burden and the functional connectome in Alzheimer's disease and progressive supranuclear palsy. *Brain*. 2018;141(2):550-567.
- ¹²¹Habchi J, Chia S, Galvagnion C, *et al*. Cholesterol catalyses A β 42 aggregation through a heterogeneous nucleation pathway in the presence of lipid membranes. *Nat Chem*. 2018;10(6):673-683.
- ¹²²Ochalek A, Mihalik B, Avci HX, *et al*. Neurons derived from sporadic Alzheimer's disease iPSCs reveal elevated TAU hyperphosphorylation, increased amyloid levels, and GSK3B activation. *Alzheimers Res Ther*. 2017;9(1):90.
- ¹²³Berezcki E, Branca RM, Francis PT, *et al*. Synaptic markers of cognitive decline in neurodegenerative diseases: A proteomic approach. *Brain*. 2018;141(2):582-595.
- ¹²⁴Santhanam N, Kumanchik L, Guo X, *et al*. Stem cell derived phenotypic human neuromuscular junction model for dose response evaluation of therapeutics. *Biomaterials*. 2018;166:64-78.
- ¹²⁵Dauth S, Maoz BM, Sheehy SP, *et al*. Neurons derived from different brain regions are inherently different in vitro: A novel multiregional brain-on-a-chip. *J Neurophysiol*. 2017;117(3):1320-1341.
- ¹²⁶Soscia D, Belle A, Fischer N, *et al*. Controlled placement of multiple CNS cell populations to create complex neuronal cultures. *PLoS One*. 2017;12(11):e0188146.
- ¹²⁷Nestler EJ, Hyman SE. Animal models of neuropsychiatric disease. *Nat Neurosci*. 2010;13(10):1161-1169.
- ¹²⁸Molendijk ML, de Kloet ER. Immobility in the forced swim test is adaptive and does not reflect depression. *Psychoneuroendocrinology*. 2015;62:389-391.
- ¹²⁹Schechter MD, Chance WT. Non-specificity of "behavioral despair" as an animal model of depression. *Eur J Pharmacol*. 1979;60(2-3):139-142.
- ¹³⁰Arai I, Tsuyuki Y, Shiimoto H, Satoh M, Otomo S. Decreased body temperature dependent appearance of behavioral despair in the forced swimming test in mice. *Pharmacol Res*. 2000;42(2):171-176.
- ¹³¹Suman PR, Zerbinatti N, Theindl LC, Domingues K, Lino de Oliveira C. Failure to detect the action of antidepressants in the forced swim test in Swiss mice. *Acta Neuropsychiatr*. 2018;30(3):158-167.
- ¹³²De Pablo JM, Parra A, Segovia S, Guillaumon A. Learned immobility explains the behavior of rats in the forced swimming test. *Physiol Behav*. 1989;46(2):229-237.
- ¹³³Jefferys D, Funder J. The effect of water temperature on immobility in the forced swimming test in rats. *Eur J Pharmacol*. 1994;253(1-2):91-94.
- ¹³⁴Lucki I, Dalvi A, Mayorga AJ. Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. *Psychopharmacology (Berl)*. 2001;155(3):315-322.
- ¹³⁵Molendijk, de Kloet.
- ¹³⁶Carvalho C, Vieira Crespo M, Ferreira Bastos L, Knight A, Vicente L. Contribution of animal models to contemporary understanding of attention deficit hyperactivity disorder. *ALTEX*. 2016;33(3):243-249.
- ¹³⁷Kato T, Kasahara T, Kubota-Sakashita M, Kato TM, Nakajima K. Animal models of recurrent or bipolar depression. *Neuroscience*. 2016;321:189-196.
- ¹³⁸Garner JP. The significance of meaning: Why do over 90% of behavioral neuroscience results fail to translate to humans, and what can we do to fix it? *ILAR J*. 2014;55(3):438-456.
- ¹³⁹Jin H, Romano G, Marshall C, Donaldson AE, Suon S, Iacovitti L. Tyrosine hydroxylase gene regulation in human neuronal progenitor cells does not depend on Nurr1 as in the murine and rat systems. *J Cell Physiol*. 2006;207(1):49-57.
- ¹⁴⁰van der Staay FJ, Arndt SS, Nordquist RE. Evaluation of animal models of neurobehavioral disorders. *Behav Brain Funct*. 2009;5:11.
- ¹⁴¹Ibid.
- ¹⁴²Siekmeier PJ. Computational modeling of psychiatric illnesses via well-defined neurophysiological and neurocognitive biomarkers. *Neurosci Biobehav Rev*. 2015;57:365-380.



- ¹⁴³Haggarty SJ, Silva MC, Cross A, Brandon NJ, Perlis RH. Advancing drug discovery for neuropsychiatric disorders using patient-specific stem cell models. *Mol Cell Neurosci*. 2016;73:104-115.
- ¹⁴⁴Adegbola A, Bury LA, Fu C, Zhang M, Wynshaw-Boris A. Concise review: Induced pluripotent stem cell models for neuropsychiatric diseases. *Stem Cells Transl Med*. 2017;6(12):2062-2070.
- ¹⁴⁵McInnis M, Bame M, DeLong C, Williams A, Martinez E, Oshea KS. Stem cell models of bipolar disorder – a developmental perspective. *Eur Neuropsychopharmacol*. 2017;27(S3):S515-S516.
- ¹⁴⁶Biedermann SV, Biedermann DG, Wenzlaff F, et al. An elevated plus-maze in mixed reality for studying human anxiety-related behavior. *BMC Biol*. 2017;15(1):125.
- ¹⁴⁷Scarr E, Udawela M, Dean B. Changed frontal pole gene expression suggest altered interplay between neurotransmitter, developmental, and inflammatory pathways in schizophrenia. *NPJ Schizophr*. 2018;4:4.
- ¹⁴⁸Wang P, Mokhtari R, Pedrosa E, et al. CRISPR/Cas9-mediated heterozygous knockout of the autism gene CHD8 and characterization of its transcriptional networks in cerebral organoids derived from iPSC cells. *Mol Autism*. 2017;8:11.
- ¹⁴⁹Stern S, Santos R, Marchetto MC, et al. Neurons derived from patients with bipolar disorder divide into intrinsically different sub-populations of neurons, predicting the patients' responsiveness to lithium. *Mol Psychiatry*. 2018;23(6):1453-1465.
- ¹⁵⁰Russo FB, Freitas BC, Pignatari GC, et al. Modeling the interplay between neurons and astrocytes in autism using human induced pluripotent stem cells. *Biol Psychiatry*. 2018;83(7):569-578.
- ¹⁵¹Davies A, Green C, Hutton J. Severe sepsis: A European estimate of the burden of disease in ICU. *Intens Care Med*. 2001;27:S284.
- ¹⁵²Verma S. Laboratory animal models to mimic human sepsis: A review. *Research & Reviews: Journal of Zoological Sciences*. 2016;4(2):34-39.
- ¹⁵³Seok J, Warren HS, Cuenca AG, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. *Proc Natl Acad Sci U S A*. 2013;110(9):3507-3512.
- ¹⁵⁴Collins F. Of mice, men, and medicine. NIH. <https://directorsblog.nih.gov/2013/02/19/of-mice-men-and-medicine/>. Published 19 February 2013. Accessed 2 November 2017.
- ¹⁵⁵Ibid.
- ¹⁵⁶Esmon CT. Why do animal models (sometimes) fail to mimic human sepsis? *Crit Care Med*. 2004;32(5):S219-S222.
- ¹⁵⁷Rittirsch D, Hoesel LM, Ward PA. The disconnect between animal models of sepsis and human sepsis. *J Leukoc Biol*. 2007;81(1):137-143.
- ¹⁵⁸Buras JA, Holzmann B, Sitkovsky M. Animal models of sepsis: Setting the stage. *Nat Rev Drug Discov*. 2005;4(10):854-865.
- ¹⁵⁹Nemzek JA, Hugunin KM, Opp MR. Modeling sepsis in the laboratory: Merging sound science with animal well-being. *Comp Med*. 2008;58(2):120-128.
- ¹⁶⁰Ruiz S, Vardon-Bounes F, Merlet-Dupuy V, et al. Sepsis modeling in mice: Ligation length is a major severity factor in cecal ligation and puncture. *Intensive Care Med Exp*. 2016;4(1):22.
- ¹⁶¹Buras et al.
- ¹⁶²Redl H, Bahrami S. Large animal models: Baboons for trauma, shock, and sepsis studies. *Shock*. 2005;24(S1):88-93.
- ¹⁶³Fink MP. Animal models of sepsis. *Virulence*. 2014;5(1):143-153.
- ¹⁶⁴Lilley E, Armstrong R, Clark N, et al. Refinement of animal models of sepsis and septic shock. *Shock*. 2015;43(4):304-316.
- ¹⁶⁵Ibid.
- ¹⁶⁶Sakurai Y, Hardy ET, Ahn B, et al. A microengineered vascularized bleeding model that integrates the principal components of hemostasis. *Nat Commun*. 2018;9:509.
- ¹⁶⁷Cockrell RC, An G. Examining the controllability of sepsis using genetic algorithms on an agent-based model of systemic inflammation. *PLoS Computat Biol*. 2018;14(2):e1005876.
- ¹⁶⁸Allen A, Deshmukh H. All on "CHIP": Using microfluidics to study neutrophil ontogeny. *Transl Res*. 2017;190:1-3.
- ¹⁶⁹Timermans S, Libert C. Learning lessons in sepsis from the children. *Mol Syst Biol*. 2018;14(5):e8335.
- ¹⁷⁰Joachim RB, Altschuler GM, Hutchinson JN, Wong HR, Hide WA, Kobzik L. The relative resistance of children to sepsis mortality: From pathways to drug candidates. *Mol Syst Biol*. 2018;14(5):e7998.
- ¹⁷¹Rahmel T, Schäfer ST, Frey UH, Adamzik M, Peters J. Increased circulating microRNA-122 is a biomarker for discrimination and risk stratification in patients defined by sepsis-3 criteria. *PLoS One*. 2018;13(5):e0197637.
- ¹⁷²Marik PE, Khangoora V, Rivera R, Hooper MH, Catravas J. Hydrocortisone, vitamin C, and thiamine for the treatment of severe sepsis and septic shock: A retrospective before-after study. *Chest*. 2017;151(6):1229-1238.
- ¹⁷³Harris R. Can a cocktail of vitamins and steroids cure a major killer in hospitals? NPR. <https://www.npr.org/sections/health-shots/2018/05/11/609149556/can-a-cocktail-of-vitamins-and-steroids-cure-a-major-killer-in-hospitals>. Published 11 May 2018. Accessed 11 May 2018.
- ¹⁷⁴Ibid.
- ¹⁷⁵Roth S, Liesz A. Stroke research at the crossroads – where are we heading? *Swiss Med Wkly*. 2016;146:w14329.



- ¹⁷⁶Sutherland BA, Minnerup J, Balami JS, Arba F, Buchan AM, Kleinschnitz C. Neuroprotection for ischemic stroke: Translation from the bench to the bedside. *Int J Stroke*. 2012;7(5):407-418.
- ¹⁷⁷Ibid.
- ¹⁷⁸Sommer CJ. Ischemic stroke: Experimental models and reality. *Acta Neuropathol*. 2017;133(2):245-261.
- ¹⁷⁹Ibid.
- ¹⁸⁰Ibid.
- ¹⁸¹Chen Z, Mou R, Feng D, Wang Z, Chen G. The role of nitric oxide in stroke. *Med Gas Res*. 2017;7(3):194-203.
- ¹⁸²Sommer.
- ¹⁸³Lin S, Lin Y, Nery JR, *et al*. Comparison of the transcriptional landscapes between human and mouse tissues. *Proc Natl Acad Sci U S A*. 2014;111(48):17224-17229.
- ¹⁸⁴Kaya AH, Erdogan H, Tasdemiroglu E. Searching evidences of stroke in animal models: A review of discrepancies. *Turk Neurosurg*. 2017;27(2):167-173.
- ¹⁸⁵Sommer.
- ¹⁸⁶Holloway PM, Gavins FN. Modeling ischemic stroke *in vitro*: The status quo and future perspectives. *Stroke*. 2016;47(2):561-569; Werth JL, Park TS, Silbergeld DL, Rothman SM. Excitotoxic swelling occurs in oxygen and glucose deprived human cortical slices. *Brain Res*. 1998;782(1-2):248-254.
- ¹⁸⁷Brown JA, Pensabene V, Markov DA, *et al*. Recreating blood-brain barrier physiology and structure on chip: A novel neurovascular microfluidic bioreactor. *Biomicrofluidics*. 2015;9(5):054124.
- ¹⁸⁸Narsaria R. Nortis awarded \$688K grant from NIH to develop “living” model of blood-brain barrier for research. *Multiple Sclerosis News Today*. <https://multiplesclerosisnewstoday.com/2017/08/23/nortis-awarded-688k-nih-grant-nih-to-develop-living-model-blood-brain-barrier-for-research/>. Published 23 August 2017. Accessed 13 July 2018.
- ¹⁸⁹He Y, Yao Y, Tsirka SE, Cao Y. Cell-culture models of the blood-brain barrier. *Stroke*. 2014;45(8):2514-2526.
- ¹⁹⁰Phan DT, Bender RHF, Andrejcsk JW, *et al*. Blood-brain barrier-on-a-chip: Microphysiological systems that capture the complexity of the blood-central nervous system interface. *Exp Biol Med*. 2017;242(17):1669-1678.
- ¹⁹¹Ibid.
- ¹⁹²Bosetti F, Koenig JI, Ayata C, *et al*. Translational stroke research: Visions and opportunities. *Stroke*. 2017;48(9):2632-2637.
- ¹⁹³Mozaffarian D, Benjamin EJ, Go AS, *et al*. Heart disease and stroke statistics – 2016 update: A report from the American Heart Association. *Circulation*. 2016;133(4):e38-e360.
- ¹⁹⁴Tzschentke TM. Where do we stand in the field of anti-abuse drug discovery? *Expert Opin Drug Dis*. 2014;9(11):1255-1258.
- ¹⁹⁵Stephens DN, Crombag HS, Duka T. The challenge of studying parallel behaviors in humans and animal models. *Curr Top Behav Neurosci*. 2013;13:611-45.
- ¹⁹⁶Green AR, King MV, Shortall SE, Fone KC. Lost in translation: Preclinical studies on 3,4-methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans. *Br J Pharmacol*. 2012;166(5):1523-1536.
- ¹⁹⁷Ibid.
- ¹⁹⁸Ahmed SH. Validation crisis in animal models of drug addiction: Beyond non-disordered drug use toward drug addiction. *Neurosci Biobehav Rev*. 2010;35(2):172-184.
- ¹⁹⁹Ibid.
- ²⁰⁰Ibid.
- ²⁰¹Ibid.
- ²⁰²Ramsden E. Making animals alcoholic: Shifting laboratory models of addiction. *J Hist Behav Sci*. 2015;51(2):164-194.
- ²⁰³Hyman SE, Malenka RC. Addiction and the brain: The neurobiology of compulsion and its persistence. *Nat Rev Neurosci*. 2001;2(10):695-703.
- ²⁰⁴Tzschentke.
- ²⁰⁵Ibid.
- ²⁰⁶Scarnati MS, Halikere A, Pang ZP. Using human stem cells as a model system to understand the neural mechanisms of alcohol use disorders: Current status and outlook. *Alcohol*. 2018, ahead of print.
- ²⁰⁷Lieberman R, Kranzler HR, Levine ES, Covault J. Examining the effects of alcohol on GABA_A receptor mRNA expression and function in neural cultures generated from control and alcohol dependent donor induced pluripotent stem cells. *Alcohol*. 2018;66:45-53.
- ²⁰⁸De Filippis L, Halikere A, McGowan H, *et al*. Ethanol-mediated activation of the NLRP3 inflammasome in iPS cells and iPS cells-derived neural progenitor cells. *Mol Brain*. 2016;9(1):51.
- ²⁰⁹Tian L, Prasad N, Jang YY. In vitro modeling of alcohol-induced liver injury using human-induced pluripotent stem cells. *Methods Mol Biol*. 2016;1353:271-283.
- ²¹⁰Hildebrand F, Andruszkow H, Huber-Lang M, Pape HC, van Griensven M. Combined hemorrhage/trauma models in pigs – current state and future perspectives. *Shock*. 2013;40(4):247-273.
- ²¹¹Ibid.
- ²¹²Staudlbauer KH, Wagner-Berger HG, Raedler C, *et al*. Vasopressin, but not fluid resuscitation, enhances survival in a liver trauma model with uncontrolled and otherwise lethal hemorrhagic shock in pigs. *Anesthesiology*. 2003;98(3):699-704.
- ²¹³Tsukamoto T, Pape HC. Animal models for trauma research: What are the options? *Shock*. 2009;31(1):3-10.
- ²¹⁴Xiong Y, Mahmood A, Chopp M. Animal models of traumatic brain injury. *Nat Rev Neurosci*. 2013;14(2):128-142.



- ²¹⁵Combes RD. A critical review of anaesthetised animal models and alternatives for military research, testing and training, with a focus on blast damage, haemorrhage, and resuscitation. *Altern Lab Anim.* 2013;41(5):385-415.
- ²¹⁶Brown D, Namas RA, Almahmoud K, et al. Trauma in silico: Individual-specific mathematical models and virtual clinical populations. *Sci Transl Med.* 2015;7(285):285ra61.
- ²¹⁷Ziraldó C, Solovyev A, Allegretti A, et al. A computational, tissue-realistic model of pressure ulcer formation in individuals with spinal cord injury. *PLoS Comput Biol.* 2015;11(6):e1004309.
- ²¹⁸Abboud A, Mi Q, Puccio A, et al. Inflammation following traumatic brain injury in humans: Insights from data-driven and mechanistic models into survival and death. *Front Pharmacol.* 2016;7:342.
- ²¹⁹Almahmoud K, Teuben M, Andruszkow H, et al. Trends in intubation rates and durations in ventilated severely injured trauma patients: An analysis from the TraumaRegister DGU®. *Patient Saf Surg.* 2016;10:24.
- ²²⁰Schiller AM, Howard JT, Convertino VA. The physiology of blood loss and shock: New insights from a human laboratory model of hemorrhage. *Exp Biol Med (Maywood).* 2017;242(8):874-883.
- ²²¹Cattaneo C, Maderna E, Rendinelli A, Gibelli D. Animal experimentation in forensic sciences: How far have we come? *Forensic Sci Int.* 2015;254:e29-e35.
- ²²²Knight B. Forensic science and animal rights. *Forensic Sci Int.* 1992;57(1):1-3.
- ²²³Ibid.
- ²²⁴Cattaneo et al.
- ²²⁵Mole CG, Heyns M. Animal models in forensic science research: Justified use or ethical exploitation? *Sci Eng Ethics.* 2018, ahead of print.
- ²²⁶Cattaneo et al.
- ²²⁷Mole, Heyns.
- ²²⁸Cattaneo et al.
- ²²⁹Patronek GJ, Rauch A. Systematic review of comparative studies examining alternatives to the harmful use of animals in biomedical education. *J Am Vet Med Assoc.* 2007;230(1):37-43.
- ²³⁰Goodman JR, Borch CA, Cherry E. Mounting opposition to vivisection. *Contexts.* 2012;11(2):68-69.
- ²³¹Reznick RK, MacRae H. Teaching surgical skills – changes in the wind. *N Engl J Med.* 2006;355(25):2664-2669.
- ²³²Institute of Medicine. *To Err Is Human: Building a Safer Health System.* Washington, DC: The National Academies Press; 2000.
- ²³³Hansen LA. Animal laboratories are not needed to train medical students. *J Surg Educ.* 2014;71(4):454.
- ²³⁴Dua A. Letters to the editor. *Mil Med.* 2014;179(7):vii.
- ²³⁵Grober ED, Hamstra SJ, Wanzel KR, et al. The educational impact of bench model fidelity on the acquisition of technical skill: The use of clinically relevant outcome measures. *Ann Surg.* 2004;240(2):374-381.
- ²³⁶Ghanem AM, Hachach-Haram N, Leung CC, Myers SR. A systematic review of evidence for education and training interventions in microsurgery. *Arch Plast Surg.* 2013;40(4):312-319.
- ²³⁷Hall A, Riojas R, Sharon D. Comparison of self-efficacy and its improvement after artificial simulator or live animal model emergency procedure training. *Mil Med.* 2014;179(3):320-323.
- ²³⁸Hall A. Letters to the editor. *Mil Med.* 2014:179(7).
- ²³⁹Gala SG, Goodman JR, Murphy MP, Balsam MJ. Use of animals by NATO countries in military medical training exercises: An international survey. *Mil Med.* 2012;177(8):907-910.
- ²⁴⁰Seck H. Coast Guard puts permanent end to wounding animals for training. Military.com. <https://www.military.com/daily-news/2018/03/20/coast-guard-puts-permanent-end-wounding-animals-training.html>. Published 20 March 2018. Accessed 16 August 2018.
- ²⁴¹The New York Times Editorial Board. Ban animal use in military medical training. *The New York Times.* <https://www.nytimes.com/2016/06/26/opinion/ban-animal-use-in-military-medical-training.html>. Published 25 June 2016. Accessed 16 August 2018.
- ²⁴²Rep Hank Johnson. Leading medical groups endorse Johnson's military modernization bill. <https://hankjohnson.house.gov/media-center/press-releases/leading-medical-groups-endorse-johnson-s-military-modernization-bill>. Published 27 June 2016. Accessed 16 August 2018.
- ²⁴³Belisomo R. 'TraumaMan' helps doctors save humans, spares animals. Reuters. <https://uk.reuters.com/article/us-health-surgeons-traumaman-idUKKCNORP1O620150925>. Published 25 September 2015. Accessed 16 August 2018.
- ²⁴⁴Robinson MK, Cohen C, de Fraissinette AB, Ponec M, Whittle E, Fentem JH. Non-animal testing strategies for assessment of the skin corrosion and skin irritation potential of ingredients and finished products. *Food Chem Toxicol.* 2002;40(5):573-592.
- ²⁴⁵OECD. New guidance document on an integrated approach on testing and assessment (IATA) for skin corrosion and irritation. Series on Testing and Assessment No 203. [http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono\(2014\)19&doclanguage=en](http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono(2014)19&doclanguage=en). Published 11 July 2014. Accessed 6 May 2020.
- ²⁴⁶De Jong WH, Hoffmann S, Lee M, et al. Round robin study to evaluate the reconstructed human epidermis (RHE) model as an in vitro skin irritation test for detection of irritant activity in medical device extracts. *Toxicol In Vitro.* 2018;50:439-449.
- ²⁴⁷Kandarova H, Willoughby JA, De Jong WH, et al. Pre-validation of an in vitro skin irritation test for medical devices using the reconstructed human tissue model EpiDerm™. *Toxicol In Vitro.* 2018;50:407-417.



- ²⁴⁸OECD. Guidance document on considerations for waiving or bridging of mammalian acute toxicity tests. Series on Testing & Assessment No 237. <http://www.oecd.org/env/ehs/testing/mono%202016%2032.pdf>. Published 2 August 2016. Accessed 6 May 2020.
- ²⁴⁹Luechtefeld T, Maertens A, Russo DP, Rovida C, Zhu H, Hartung T. Analysis of publically available skin sensitization data from REACH registrations 2008–2014. *ALTEX*. 2016;33(2):135-148.
- ²⁵⁰OECD. Guidance document on an integrated approach on testing and assessment (IATA) for serious eye damage and eye irritation. Series on Testing & Assessment No 263. [http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=ENV/JM/MONO\(2017\)15&doclanguage=en](http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=ENV/JM/MONO(2017)15&doclanguage=en). Published 20 July 2017. Accessed 6 May 2020.
- ²⁵¹EPA. Alternate testing framework for classification of eye irritation potential of EPA-regulated pesticide products. 2015. <https://www.epa.gov/pesticide-registration/alternate-testing-framework-classification-eye-irritation-potential-epa>.
- ²⁵²OECD. Guidance document on considerations for waiving or bridging of mammalian acute toxicity tests.
- ²⁵³OECD. The adverse outcome pathway for skin sensitisation initiated by covalent binding to proteins. Series on Testing and Assessment No 168. 4 May 2012. [http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono\(2012\)10/part1&doclanguage=en](http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono(2012)10/part1&doclanguage=en).
- ²⁵⁴Hoffmann S, Kleinstreuer N, Alépée N, et al. Non-animal methods to predict skin sensitization (I): The Cosmetics Europe database. *Crit Rev Toxicol*. 2018;48(5):344-358.
- ²⁵⁵Kleinstreuer NC, Hoffmann S, Alépée N, et al. Non-animal methods to predict skin sensitization (II): An assessment of defined approaches. *Crit Rev Toxicol*. 2018;48(5):359-374.
- ²⁵⁶Wareing B, Urbisch D, Kolle SN, et al. Prediction of skin sensitization potency sub-categories using peptide reactivity data. *Toxicol In Vitro*. 2017;45(Pt 1):134-145.
- ²⁵⁷OECD. Guidance document on the reporting of defined approaches and individual information sources to be used within integrated approaches to testing and assessment (IATA) for skin sensitization. Series on Testing & Assessment No 256. 27 October 2016. [http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono\(2016\)29&doclanguage=en](http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono(2016)29&doclanguage=en).
- ²⁵⁸EPA. Interim science policy: Use of alternative approaches for skin sensitization as a replacement for laboratory animal testing. Draft for public comment. 2018. <https://www.regulations.gov/document?D=EPA-HQ-OPP-2016-0093-0090>.
- ²⁵⁹Health and Safety Executive. Vertebrate testing. <http://www.hse.gov.uk/pesticides/topics/pesticide-approvals/pesticides-registration/applicant-guide/vertebrate-testing.htm>.
- ²⁶⁰Coleman KP, McNamara LR, Grailer TP, et al. Evaluation of an *in vitro* human dermal sensitization test for use with medical device extracts. *Appl In Vitro Toxicol*. 2015;1(2):118-130.
- ²⁶¹OECD. Guidance document on considerations for waiving or bridging of mammalian acute toxicity tests.
- ²⁶²Daneshian M, Akbarsha MA, Blaauboer B, et al. A framework program for the teaching of alternative methods (replacement, reduction, refinement) to animal experimentation. *ALTEX*. 2011;28(4):341-352.
- ²⁶³Hartung T, Borel A, Schmitz G. Detecting the broad spectrum of pyrogens with the human whole-blood monocyte activation test. *Bioprocess Int*. 2016;14(3):38-56.
- ²⁶⁴Anderson RL, Watson WH, Chabot CC. Sublethal behavioral and physiological effects of the biomedical bleeding process on the American horseshoe crab, *Limulus polyphemus*. *Biol Bull*. 2013;225(3):137-151.
- ²⁶⁵EDQM. Monocyte-activation test. *European Pharmacopoeia* 6.7, Chapter 2.6.30. Strasbourg, France: Council of Europe; 2010.
- ²⁶⁶Fennrich S, Hennig U, Toliashvili L, Schlensak C, Wendel HP, Stoppelkamp S. More than 70 years of pyrogen detection: Current state and future perspectives. *Altern Lab Anim*. 2016;44(3):239-253.
- ²⁶⁷Hasiwa N, Daneshian M, Bruegger P, et al. Evidence for the detection of non-endotoxin pyrogens by the whole blood monocyte activation test. *ALTEX*. 2013;30(2):169-208.
- ²⁶⁸US Food and Drug Administration. Guidance for industry. Pyrogen and endotoxins testing: Questions and answers. Washington, DC: FDA; 2012. <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM310098.pdf>.
- ²⁶⁹PETA Science Consortium International e.V. Workshop: Using the monocyte activation test as a standalone release test for medical devices. <https://www.thepsci.eu/our-work/pyrogenicity/>.
- ²⁷⁰EDQM. Monocyte-activation test. *Pharmeuropa*. 2016; 27(4):15-26.
- ²⁷¹EDQM. European Pharmacopoeia Commission adopts revised general chapter on Monocyte-activation test to facilitate reduction in testing on laboratory animals. Strasbourg; 23 June 2016.
- ²⁷²EMA Committee for Medicinal Products for Veterinary Use. Reflection paper providing an overview of the current regulatory testing requirements for veterinary medicinal products and opportunities for implementation of the 3Rs. (Draft) London: EMA; 2016. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/04/WC500205609.pdf.
- ²⁷³Fennrich et al.
- ²⁷⁴Indian Pharmacopoeia Commission. Monocyte activation test. *Indian Pharmacopoeia*. 8th ed. General Chapter Monograph 2.2.25.



- ²⁷⁵SCHEER. Opinion on additives used in tobacco products (Opinion 2). Tobacco additives II. 16 December 2016. https://ec.europa.eu/health/sites/health/files/scientific_committees/scheer/docs/scheer_o_001.pdf.
- ²⁷⁶Brepeols F. Animal tests for the development of tobacco products. European Parliament, parliamentary questions, 16 March 2009.
- ²⁷⁷Parve V. *National Regulations on Ethics and Research in Estonia*. Luxembourg: Office for Official Publications of the European Communities; 2003.
- ²⁷⁸German Animal Welfare Act.
- ²⁷⁹Glasa J. *Slovak Republic – Regulations on Ethics and Research*. Luxembourg: Office for Official Publications of the European Communities; 2003 .
- ²⁸⁰UK Home Office. Guidance on the operation of the Animals (Scientific Procedures) Act 1986, Section 5.18. London: HMSO, 2014.
- ²⁸¹Behrsing H, Raabe H, Manuppello J, *et al.* Assessment of *in vitro* COPD models for tobacco regulatory science: Workshop proceedings, conclusions and paths forward for *in vitro* model use. *Altern Lab Anim.* 2016;44(2):129-166.
- ²⁸²Manuppello JR, Sullivan KM. Toxicity assessment of tobacco products *in vitro*. *Altern Lab Anim.* 2015;43(1):39-67.
- ²⁸³Clippinger A, Allen D, Behrsing H, *et al.* Pathway-based predictive approaches for non-animal assessment of acute inhalation toxicity. *Toxicol In Vitro.* 2018;52:131-145.
- ²⁸⁴Further recent reviews of innovative, non-animal methods for the hazard assessment of tobacco products can be found at http://www.bat-science.com/groupms/sites/BAT_9GVJXS.nsf/vwPagesWebLive/DO9P2BZT.
- ²⁸⁵EURL ECVAM. Strategy to avoid and reduce animal use in genotoxicity testing. 2013. http://publications.jrc.ec.europa.eu/repository/bitstream/111111111/30088/1/jrc_report_en_34844_online.pdf.
- ²⁸⁶*ibid.*; Corvi R, Madia F. *In vitro* genotoxicity testing – can the performance be enhanced? *Food Chem Toxicol.* 2017;106(Pt B):600-608.
- ²⁸⁷SCCS. The SCCS notes of guidance for the testing of cosmetic ingredients and their safety evaluation. 9th revision. 25 April 2016. http://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_190.pdf.
- ²⁸⁸Reisinger K, Blatz V, Brinkmann J, *et al.* Validation of the 3D Skin Comet assay using full thickness skin models: Transferability and reproducibility. *Mutat Res.* 2018;827:27-41.
- ²⁸⁹Kleinstreuer NC, Karmaus AL, Mansouri K, Allen DG, Fitzpatrick JM, Patlewicz G. Predictive models for acute oral systemic toxicity: A workshop to bridge the gap from research to regulation. *Comput Toxicol.* 2018;8:21-24
- ²⁹⁰OECD. Guidance document on considerations for waiving or bridging of mammalian acute toxicity tests.
- ²⁹¹EPA Office of Pesticide Programs. Guidance for waiving or bridging of mammalian acute toxicity tests for pesticides and pesticide products (acute oral, acute dermal, acute inhalation, primary eye, primary dermal, and dermal sensitization). 1 March 2012. <https://www.epa.gov/sites/production/files/documents/acute-data-waiver-guidance.pdf>.
- ²⁹²Kleinstreuer *et al.*
- ²⁹³NICEATM workshop on Predictive Models for Acute Oral Systemic Toxicity, 11–12 April 2018. <https://ntp.niehs.nih.gov/pubhealth/evalatm/test-method-evaluations/acute-systemic-tox/models/index.html>.
- ²⁹⁴European Commission. EURL ECVAM strategy to replace, reduce and refine the use of animals in the assessment of acute mammalian systemic toxicity. 2014.
- ²⁹⁵Hamm J, Sullivan K, Clippinger AJ, *et al.* Alternative approaches for identifying acute systemic toxicity: Moving from research to regulatory testing. *Toxicol In Vitro.* 2017;41:245-259.
- ²⁹⁶Prieto P, Kinsner-Ovaskainen A, Stanzel S, *et al.* The value of selected *in vitro* and *in silico* methods to predict acute oral toxicity in a regulatory context: Results from the European Project ACuteTox. *Toxicol In Vitro.* 2013;27(4):1357-1376.
- ²⁹⁷Prieto P, Graepel R, Gerloff K, *et al.* Investigating cell type specific mechanisms contributing to acute oral toxicity. *ALTEX.* 2018. <https://doi.org/10.14573/altex.1805181>.
- ²⁹⁸Graepel R, Asturiol D, Prieto P, Worth AP. Exploring waiving opportunities for mammalian acute systemic toxicity tests. *Altern Lab Anim.* 2016;44(3):271-279.
- ²⁹⁹ECHA. Guidance on information requirements and chemical safety assessment. Chapter R.7a: Endpoint specific guidance. Version 6.0. July 2017. https://echa.europa.eu/documents/10162/13632/information_requirements_r7a_en.pdf.
- ³⁰⁰Commission Regulation (EU) 2016/863 of 31 May 2016 amending Annexes VII and VIII to Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) as regards skin corrosion/irritation, serious eye damage/eye irritation and acute toxicity. <http://eur-lex.europa.eu/eli/reg/2016/863/oj>.
- ³⁰¹EPA Office of Pesticide Programs. Guidance for waiving acute dermal toxicity tests for pesticide formulations & supporting retrospective analysis. 9 November 2016. https://www.epa.gov/sites/production/files/2016-11/documents/acute-dermal-toxicity-pesticide-formulations_0.pdf.
- ³⁰²Clippinger AJ, Allen D, Behrsing H, *et al.* Nonanimal approaches to assessing the toxicity of inhaled substances: Current progress and future promise. *Appl In Vitro Toxicol.* 2018;4(2):82-88.
- ³⁰³EPA. Meeting materials for the December 4–7, 2018 scientific advisory panel. <https://www.epa.gov/sap/meeting-materials-december-4-7-2018-scientific-advisory-panel-0>.



- ³⁰⁴Clippinger AJ, Allen D, Jarabek AM, *et al.* Alternative approaches for acute inhalation toxicity testing to address global regulatory and non-regulatory data requirements: An international workshop report. *Toxicol In Vitro*. 2018;48:53-70.
- ³⁰⁵Clippinger AJ, Allen D, Behrsing H, *et al.* Pathway-based predictive approaches for non-animal assessment of acute inhalation toxicity. *Toxicol In Vitro*. 2018;52:131-145.
- ³⁰⁶Gottmann E, Kramer S, Pfahringer B, Helma C. Data quality in predictive toxicology: Reproducibility of rodent carcinogenicity experiments. *Environ Health Perspect*. 2001;109(5):509-514.
- ³⁰⁷Boobis AR, Cohen SM, Dellarco VL, *et al.* Classification schemes for carcinogenicity based on hazard-identification have become outmoded and serve neither science nor society. *Regul Toxicol Pharmacol*. 2016;82:158-166.
- ³⁰⁸Grasso P, Crampton RF. The value of the mouse in carcinogenicity testing. *Food Cosmet Toxicol*. 1972;10(3):418-426.
- ³⁰⁹Schach von Wittenau M, Estes PC. The redundancy of mouse carcinogenicity bioassays. *Fundam Appl Toxicol*. 1983;3(6):631-639.
- ³¹⁰Alden CL, Smith PF, Piper CE, Brey L. A critical appraisal of the value of the mouse cancer bioassay in safety assessment. *Toxicol Pathol*. 1996;24(6):722-725.
- ³¹¹Carmichael NG, Enzmann H, Pate I, Waechter F. The significance of mouse liver tumor formation for carcinogenic risk assessment: Results and conclusions from a survey of ten years of testing by the agrochemical industry. *Environ Health Perspect*. 1997;105(11):1196-1203.
- ³¹²Van Oosterhout JP, Van der Laan JW, De Waal EJ, *et al.* The utility of two rodent species in carcinogenic risk assessment of pharmaceuticals in Europe. *Regul Toxicol Pharmacol*. 1997;25(1):6-17.
- ³¹³Cohen SM. Alternative models for carcinogenicity testing: Weight of evidence evaluations across models. *Toxicol Pathol*. 2001;29 Suppl:183-190.
- ³¹⁴Cohen SM, Klaunig J, Meek ME, *et al.* Evaluating the human relevance of chemically induced animal tumors. *Toxicol Sci*. 2004;78(2):181-186.
- ³¹⁵Ward JM. The two-year rodent carcinogenesis bioassay – will it survive? *J Toxicol Pathol*. 2007;20(1):13-19.
- ³¹⁶Billington R, Lewis RW, Mehta JM, Dewhurst I. The mouse carcinogenicity study is no longer a scientifically justifiable core data requirement for the safety assessment of pesticides. *Crit Rev Toxicol*. 2010;40(1):35-49.
- ³¹⁷Reddy MV, Sistare FD, Christensen JS, Deluca JG, Wollenberg GK, DeGeorge JJ. An evaluation of chronic 6- and 12-month rat toxicology studies as predictors of 2-year tumor outcome. *Vet Pathol*. 2010;47(4):614-629.
- ³¹⁸Sistare FD, Morton D, Alden C, *et al.* An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: Support for a proposal to modify current regulatory guidelines. *Toxicol Pathol*. 2011;39(4):716-744.
- ³¹⁹Annys E, Billington R, Clayton R, *et al.* Advancing the 3Rs in regulatory toxicology – carcinogenicity testing: Scope for harmonisation and advancing the 3Rs in regulated sectors of the European Union. *Regul Toxicol Pharmacol*. 2014;69(2):234-242.
- ³²⁰Luijten M, Olthof ED, Hakkert BC, *et al.* An integrative test strategy for cancer hazard identification. *Crit Rev Toxicol*. 2016;46(7):615-639.
- ³²¹Cohen SM. The relevance of experimental carcinogenicity studies to human safety. *Curr Opin Toxicol*. 2017;3:6-11.
- ³²²Wolf DC, Cohen SM, Boobis AR, *et al.* Chemical carcinogenicity revisited 1: A unified theory of carcinogenicity based on contemporary knowledge. *Regul Toxicol Pharmacol*. 2019;103:86-92.
- ³²³Doe JE, Boobis AR, Dellarco V, *et al.* Chemical carcinogenicity revisited 2: Current knowledge of carcinogenesis shows that categorization as a carcinogen or non-carcinogen is not scientifically credible. *Regul Toxicol Pharmacol*. 2019;103:124-129.
- ³²⁴Cohen SM, Boobis AR, Dellarco VL, *et al.* Chemical carcinogenicity revisited 3: Risk assessment of carcinogenic potential based on the current state of knowledge of carcinogenesis in humans. *Regul Toxicol Pharmacol*. 2019;103:100-105.
- ³²⁵Goodman JI. Goodbye to the bioassay. *Toxicol Res*. 2018;7:558-564.
- ³²⁶*Ibid.*
- ³²⁷Billington *et al.*
- ³²⁸Sistare *et al.*
- ³²⁹ICH. *The ICHS1 Regulatory Testing Paradigm of Carcinogenicity in Rats: Status Report*. 2016. https://database.ich.org/sites/default/files/S1%28R1%29_EWG_StatusReport_Mar2016.pdf.
- ³³⁰ICH. *The ICHS1 Regulatory Testing Paradigm of Carcinogenicity in Rats: Status Report*. 2019. https://database.ich.org/sites/default/files/S1_StatusReport_2019_0802.pdf.
- ³³¹EURL ECVAM. EURL ECVAM recommendation on the cell transformation assay based on the Bhas 42 cell line. JRC Reference Report. 2013. <http://dx.doi.org/10.2788/42908>.
- ³³²Stokes W, Jacobs A. Bhas 42 Cell Transformation Assay Validation Study Report. OECD. 2012. http://www.oecd.org/env/ehs/testing/Text_Bhas_Validation_Study_Report.pdf.
- ³³³Sakai A, Sasaki K, Hayashi K, *et al.* An international validation study of a Bhas 42 cell transformation assay for the prediction of chemical carcinogenicity. *Mutat Res*. 2011;725(1-2):57-77.



- ³³⁴Benigni R, Bossa C. Alternative strategies for carcinogenicity assessment: An efficient and simplified approach based on in vitro mutagenicity and cell transformation assays. *Mutagenesis*. 2011;26(3):455-460.
- ³³⁵OECD. Guidance document on the *in vitro* Bhas 42 cell transformation assay. Series on Testing & Assessment No 231. [http://www.oecd.org/env/ehs/testing/ENV_JM_MONO\(2016\)1.pdf](http://www.oecd.org/env/ehs/testing/ENV_JM_MONO(2016)1.pdf).
- ³³⁶OECD. OECD QSAR Toolbox 4.4.1. <https://www.oecd.org/chemicalsafety/oecd-qsar-toolbox.htm>. 2020.
- ³³⁷EPA. OncoLogic™ – a computer system to evaluate the carcinogenic potential of chemicals. <https://www.epa.gov/tsca-screening-tools/oncologictm-computer-system-evaluate-carcinogenic-potential-chemicals>.
- ³³⁸Jacobs MN, Colacci A, Corvi R, et al. Chemical carcinogen safety testing: OECD expert group international consensus on the development of an integrated approach for the testing and assessment of chemical non-genotoxic carcinogens. *Arch Toxicol*. June 2020.
- ³³⁹Browne P, Judson RS, Casey WM, Kleinstreuer NC, Thomas RS. Screening chemicals for estrogen receptor bioactivity using a computational model. *Environ Sci Technol*. 2015;49(14):8804-8814.
- ³⁴⁰EPA. Use of high throughput assays and computational tools in the Endocrine Disruptor Screening Program. <https://www.epa.gov/endocrine-disruption/use-high-throughput-assays-and-computational-tools-endocrine-disruptor>.
- ³⁴¹OECD. New scoping document on *in vitro* and *ex vivo* assays for the identification of modulators of thyroid hormone signaling. Series on Testing and Assessment No 207. 11 July 2014.
- ³⁴²Rovida C, Longo F, Rabbit RR. How are reproductive toxicity and developmental toxicity addressed in REACH dossiers? *ALTEX*. 2011;28(4):273-294.
- ³⁴³Hartung T. Toxicology for the twenty-first century. *Nature*. 2009;460:208-212.
- ³⁴⁴Bouvier d'Yvoire M, Bremer S, Casati S, et al. ECVAM and new technologies for toxicity testing. *Adv Exp Med Biol*. 2012;745:154-180.
- ³⁴⁵Rolaki A, Nepelska M, Bremer S, Graepel R, Price A, Worth A. Reproductive toxicity – effects on fertility and developmental toxicity. In Worth A, Barroso J, Bremer S, et al, eds. *JRC Science and Policy Reports: Alternative Methods for Regulatory Toxicology: A State-of-the-Art Review*. 2014. https://echa.europa.eu/documents/10162/13634/echa_jrc_sla_report_en.pdf.
- ³⁴⁶AOP Wiki. Aromatase (Cyp19a1) reduction leading to impaired fertility in adult female. <https://aopwiki.org/aops/7>. Updated 30 November 2016.
- ³⁴⁷ReProTect. Development of a novel approach in hazard and risk assessment or reproductive toxicity by a combination and application of in vitro, tissue and sensor technologies. 2004–2009. https://cordis.europa.eu/project/rcn/75291_en.html.
- ³⁴⁸van der Burg B, Wedeby EB, Dietrich DR, et al. The ChemScreen project to design a pragmatic alternative approach to predict reproductive toxicity of chemicals. *Reprod Toxicol*. 2015;55:114-123.
- ³⁴⁹EPA. Virtual tissue models: Predicting how chemicals impact development. <https://www.epa.gov/chemical-research/virtual-tissue-models-predicting-how-chemicals-impact-development>.
- ³⁵⁰European Commission. Seventh report on the statistics on the number of animals used for experimental and other scientific purposes in the member states of the European Union. 2013. <https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52013DC0859&from=EN>.
- ³⁵¹OECD. Test No 319A: Determination of *In Vitro* Intrinsic Clearance Using Cryopreserved Rainbow Trout Hepatocytes (RT-HEP). 2018. <https://www.oecd-ilibrary.org/docserver/9789264303218-en.pdf?expires=1534257618&id=id&accname=guest&checksum=0EFBA59C5D35D2862F50B9CF24DE D45C>.
- ³⁵²OECD. Test No 319B: Determination of *In Vitro* Intrinsic Clearance Using Rainbow Trout Liver S9 Sub-Cellular Fraction (RT-S9). 2018. <https://www.oecd-ilibrary.org/docserver/9789264303232-en.pdf?expires=1534257717&id=id&accname=guest&checksum=2077E945948261062F539B14B1720 95F>.
- ³⁵³OECD. Draft guidance document: Determination of *in vitro* intrinsic clearance using cryopreserved hepatocytes (RT-HEP) or liver S9 sub-cellular fractions (RT-S9) from rainbow trout and extrapolation to *in vivo* intrinsic clearance. 2018. <http://www.oecd.org/env/ehs/testing/latestdocuments/3-OECD%20Guidance%20Document%20Draft%20for%20comments.pdf>.
- ³⁵⁴OECD. Test No 305: Bioaccumulation in Fish: Aqueous and Dietary Exposure. 2012. <https://www.oecd-ilibrary.org/docserver/9789264185296-en.pdf?expires=1534257777&id=id&accname=guest&checksum=9AE6102FA262C7A119FC478F6416A 4A8>.
- ³⁵⁵OECD. Test No 236: Fish Embryo Acute Toxicity (FET) Test. 2013. <https://www.oecd-ilibrary.org/docserver/9789264203709-en.pdf?expires=1534257884&id=id&accname=guest&checksum=279D5F896219575ADEC098BD738D 4EB7>.
- ³⁵⁶ECHA. Joint Report ECHA and UBA. Expert workshop on the potential regulatory application of the Fish Embryo Acute Toxicity (FET) Test under REACH, CLP and the BPR. 3–4 May 2017, Helsinki. https://echa.europa.eu/documents/10162/13630/fet_workshop_proceedings_en.pdf/a987ccab-5d4a-a226-2a73-994be484ca8d.



- ³⁵⁷Tanneberger K, Knöbel M, Busser FJM, Sinnige TL, Hermens JLM, Schirmer K. Predicting fish acute toxicity using a fish gill cell line-based toxicity assay. *Environ Sci Technol*. 2013;47(2):1110-1119.
- ³⁵⁸OECD. Test No 203: Fish, Acute Toxicity Test. 1992. <https://www.oecd-ilibrary.org/docserver/9789264069961-en.pdf?expires=1534510163&id=id&accname=guest&checksum=0D2B43A6545188D119BA52AFA660503>.
- ³⁵⁹Fischer M, Belanger SE, Berckmans P, et al. Repeatability and reproducibility of the RTgill-W1 cell line assay for predicting fish acute toxicity. *Toxicol Sci*. 2019;1-12.
- ³⁶⁰ISO 21115:2019: Water quality – determination of acute toxicity of water samples and chemicals to a fish gill cell line (RTgill-W1). <https://www.iso.org/obp/ui/#iso:std:iso:21115:ed-1:v1:en>.
- ³⁶¹Dozier S, Brown J, Currie A. Bridging the gap between validation and implementation of non-animal veterinary vaccine potency testing methods. *Animals*. 2011;1(4):414-432.
- ³⁶²Draayer H. Overview of currently approved veterinary vaccine potency testing methods and methods in development that do not require animal use. *Procedia Vaccinol*. 2011;5:171-174.
- ³⁶³Bristow A, Schulster D, Jeffcoate S. Report of an international workshop on assays, standardization and labelling requirements of somatotropin. *Pharmeuropa*. 1994;6:60-67.
- ³⁶⁴EDQM. Harmonisation with VICH Guidelines 41 and 44 and deletion of the TABST, adopted at the 142nd session of the European Pharmacopoeia Commission. *Pharmeuropa*. 2012;S7.7:1-5.
- ³⁶⁵Unkauf T, Miethe S, Fühner V, Schirrmann T, Frenzel A, Hust M. Generation of recombinant antibodies against toxins and viruses by phage display for diagnostics and therapy. *Adv Exp Med Biol*. 2016;917:55-76.
- ³⁶⁶Dozier et al.
- ³⁶⁷Stokes W, Srinivas G, McFarland R, et al. Report on the international workshop on alternative methods for *Leptospira* vaccine potency testing: State of the science and the way forward. *Biologicals*. 2013;41(5):279-294.
- ³⁶⁸Stokes W, McFarland R, Kulpa-Eddy J, et al. Report on the international workshop on alternative methods for human and veterinary rabies vaccine testing: State of the science and planning the way forward. *Biologicals*. 2012;40(5):369-381.
- ³⁶⁹Veterinary Medicines Directorate. Animal usage in quality control tests for the batch release of Immunological Veterinary Medicinal Products (IVMPs) via the UK from 2007 to 2012. London: VMD; 2016. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/438916/_518852-v8-Animal_Usage_for_QC_Batch_Release_of_IVMPs_2007-2012.pdf.
- ³⁷⁰Jungbäck C, ed. *Potency Testing for Veterinary Vaccines for Animals: The Way From In Vivo to In Vitro*. Langen, Germany: International Alliance for Biological Standardization; 2012. <http://www.epsjv.fiocruz.br/upload/d/silviovalle/VaccineforAnimals.pdf>.
- ³⁷¹De Mattia F, Chapsal JM, Descamps J, et al. The consistency approach for quality control of vaccines – a strategy to improve quality control and implement 3Rs. *Biologicals*. 2011;39(1):59-65.
- ³⁷²De Mattia F, Hendriksen C, Buchheit KH, et al. The vaccines consistency approach project: An EPAA initiative. *Pharmeur Bio Sci Notes*. 2015;2015:30-56.
- ³⁷³Groff K, Brown J, Clippinger AJ. Modern affinity reagents: Recombinant antibodies and aptamers. *Biotechnol Adv*. 2015;33(8):1787-1798.
- ³⁷⁴Bradbury A, Plückthun A. Reproducibility: Standardize antibodies used in research. *Nature*. 2015;518(7537):27-29.
- ³⁷⁵Baker M. Reproducibility crisis: Blame it on the antibodies. *Nature*. 2015;521(7552):274-276.
- ³⁷⁶Bradbury ARM, Trinklein ND, Thie H, et al. When monoclonal antibodies are not monospecific: Hybridomas frequently express additional functional variable regions. *MAbs*. 2018;10(4):539-546.
- ³⁷⁷Bradbury, Plückthun.
- ³⁷⁸Ibid.
- ³⁷⁹Groff et al.
- ³⁸⁰Gray AC, Sidhu SS, Chandrasekera PC, Hendriksen CFM, Borrebaeck CAK. Animal-friendly affinity reagents: Replacing the needless in the haystack. *Trends Biotechnol*. 2016;34(12):960-969.
- ³⁸¹Ibid.; Groff et al.
- ³⁸²Barroso J. Scientific validity of replacements for animal-derived antibodies. *Sci Adv Comm Altern Toxicol Methods Meet*. 2019. https://ntp.niehs.nih.gov/ntp/about_ntp/sacatm/2019/september/presentations/1-4-barroso-508.pdf.
- ³⁸³Groff K, Allen D, Casey W, Clippinger A. Increasing the use of animal-free recombinant antibodies. *ALTEX*. 2020; 37(2);309-311.
- ³⁸⁴Marx U, Embleton MJ, Fischer R, et al. Monoclonal antibody production – the report and recommendations of ECVAM Workshop 23. *Altern Lab Anim*. 1997;25(2):121-137.
- ³⁸⁵Brindley DA, Davie NL, Culme-Seymour EJ, Mason C, Smith DW, Rowley JA. Peak serum: Implications of serum supply for cell therapy manufacturing. *Regen Med*. 2012;7(1):7-13.
- ³⁸⁶van der Valk J, Mellor D, Brands R, et al. The humane collection of fetal bovine serum and possibilities for serum-free cell and tissue culture. *Toxicol In Vitro*. 2004;18(1):1-12.
- ³⁸⁷van der Valk J, Brunner D, De Smet K, et al. Optimization of chemically defined cell culture media – replacing fetal bovine serum in mammalian *in vitro* methods. *Toxicol In Vitro*. 2010;24(4):1053-1063.
- ³⁸⁸van der Valk J, Bieback K, Buta C, et al. Fetal bovine serum (FBS): Past – present – future. *ALTEX*. 2018;35(1): 99-118.





Postbus 2570
1000 CN Amsterdam
020 369 9733
Info@peta.nl
PETA.nl